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Background: Rates of hypertensive disorders and other chronic conditions in pregnancy 
are increasing among childbearing women in the United States. This study examined the 
relation of maternal hypertensive disorders and other chronic and pregnancy-associated 
conditions with severe maternal morbidity (SMM) at delivery and postpartum 
rehospitalization. 
Methods: Birth certificates and fetal death records (BCFD) were linked to delivery-
related hospital discharge (HDD) records in Massachusetts from 2000-2012, using the 
Pregnancy to Early Life Longitudinal (PELL) data system (n=960,982). Non-injury 
emergency department (ED), observational stay (OS) and non-delivery hospital discharge 
(HD) records in the first year postpartum also were linked to corresponding BCFD and 
HDD deliveries from 2002-2011 (n=735,576); a subset of deliveries to women without 
chronic medical conditions were also examined (n=685,228). Multivariate logistic 
regression models estimated the odds of SMM at delivery, multivariate log-binomial and 
Poisson models estimated the risk of rehospitalization within six weeks and one year 
postpartum; analyses used a generalized estimating equations approach to account for 
correlation due to repeat births of women and adjusted for social and biological 
characteristics. Analyses also examined whether SMM modified the relation between 
hypertensive disorders and rehospitalization. 
Results: Between 2000-2012, maternal hypertensive disorders were documented in 8.7% 
of deliveries and the SMM rate was 101.9 per 10,000 deliveries; 5.2% of deliveries from 
2002-2011 had at least one rehospitalization within six weeks and 19.9% within one year 
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postpartum. Hypertensive disorders and other chronic conditions increased the odds of 
SMM and the risk of rehospitalization up to one year postpartum; this risk varied by type 
of hypertensive disorder. SMM at delivery independently increased rehospitalization risk 
in the first six weeks and year postpartum and slightly moderated the relation between 
hypertensive disorders and rehospitalization. 
Conclusions: Maternal hypertensive disorders and other chronic conditions were 
associated with adverse maternal health outcomes at and after delivery and SMM at 
delivery was associated with increased risk of rehospitalization within one year 
postpartum. Our study highlights the need to prevent and manage hypertensive disorders 
and other chronic and pregnancy-associated conditions before, during, and after 
pregnancy as well as the need to address preventable SMM and mitigate its impacts after 
delivery. 
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There are nearly four million births each year in the United States (1). With the 
vast majority of these births in hospitals, childbirth is the most frequent reason for 
hospital admission of females (2). Recent estimates suggest 600-800 women die from 
pregnancy and childbirth each year and another 65,000 experience severe morbidity (3, 4). 
Changing demographic characteristics of the childbearing population in the US suggest 
there are increasing proportions of women with high-risk pregnancies, including those of 
advanced maternal age and with chronic medical conditions such as hypertension, 
diabetes and asthma (1, 5).   
Maternal health and chronic conditions represent research areas that are in 
alignment with Healthy People 2020 (HP2020) objectives related to reducing maternal 
mortality (MICH-5) and maternal illness and complications due to pregnancy (MICH-6) 
(6). Recent national research efforts to assess maternal health and wellbeing include 
defining and evaluating the prevalence of severe maternal morbidity (SMM) among US 
women at delivery; SMM in particular captures indications of organ-system failure 
indicative of severe events (3, 7). Yet there remain few national benchmark measures of 
maternal wellbeing after delivery. Surveillance of maternal health and morbidity before 
and after delivery is critical to improving women’s health, particularly among women at 
risk. 
In 2015, the Maternal and Child Health Bureau (MCHB) at the Health Resources 
and Services Administration (HRSA) announced the Maternal Health Initiative (MHI), a 
public-private partnership, with the overarching goal “to reduce maternal morbidity and 
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mortality by improving women’s health across the life course, and by assuring the quality 
and safety of maternity care” (8). Of the five main areas proposed to improve maternal 
health in the US, one was improving surveillance and research, which included both 
determining the risk of severe morbidity and monitoring the impact of adverse outcomes 
on long-term maternal health (8). In addition, national efforts by the Centers for Disease 
Control and Prevention (CDC) and the American College of Obstetricians and 
Gynecologists recently called for routine standardized identification and evaluation of 
SMM cases by every birthing center in the US. (9-11). Understanding the causes and 
consequences of SMM is an emergent national research priority. 
The primary goal of this dissertation is to examine how underlying maternal 
health status relates to morbidity both at delivery and into the first year postpartum. We 
used the Massachusetts Pregnancy to Early Life Longitudinal (PELL) data system from 
2000-2012, which links vital records to hospitalization data, to examine the relation 
between maternal hypertensive disorders and other chronic and pregnancy-associated 
conditions and maternal morbidity both at delivery and within the first year postpartum. 
The three specific aims of this dissertation were to: 
Aim 1: Evaluate the relation of maternal hypertensive disorders and other chronic 
and pregnancy-associated conditions in pregnancy with severe maternal morbidity 
at delivery; 
Aim 2: Evaluate the relation between severe maternal morbidity at delivery and 
postpartum maternal rehospitalization in the year following delivery among 
women without chronic medical diseases; and  
4 
 
Aim 3: Evaluate the relation between maternal hypertensive disorders and other 
chronic and pregnancy-associated conditions in pregnancy with postpartum 
maternal rehospitalization in the year following delivery independent of severe 
maternal morbidity at delivery. 
Background 
 
Rates of chronic conditions, including hypertensive disorders, are increasing 
among women giving birth in the United States. The prevalence of hypertensive disorders 
at delivery hospitalization among US women increased from 6.7% in 1998 to 8.3% in 
2006 (12). In addition to hypertensive disorders, increasing trends were noted from 1999 
to 2005 among California women presenting at childbirth with both preexisting and 
pregnancy-related comorbidities, including pre-existing and gestational diabetes, 
substance use, mental health conditions, and inflammatory conditions such as asthma, 
and thyroid disorders (13). The magnitude and increasing trend of maternal hypertensive 
disorders in pregnancy and other chronic and pregnancy-associated conditions warrant 
further understanding of their immediate sequelae at birth and in the postpartum.  
The CDC estimated the rate of SMM to be 162.8 per 10,000 delivery 
hospitalizations during 2010-2011, an increase of 120% from 1998-1999, based on data 
from the Nationwide Inpatient Sample (14). Research studies of maternal morbidity at the 
national and state level have also examined the CDC classification and categorization of 
SMM (3, 15, 16). The economic burden of SMM is high; in an analysis of New York 
City deliveries from 2008-2012, SMM deliveries cost on average $15,714 compared to 
$9,357 for non-SMM deliveries (17). The impact of SMM after delivery into the first 
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year postpartum is unknown. The small, yet growing, burden of SMM in the US demands 
research both into its risk factors and consequences. 
A better understanding of the relation between maternal hypertensive disorders 
and morbidity at delivery and in the postpartum is needed, especially in the context of 
national initiatives to improve maternal health. Limited research has examined more 
immediate adverse postpartum maternal outcomes of women; the rarity of clinical events 
related to SMM makes it difficult to obtain adequate data for research. Previous studies 
of postpartum maternal outcomes both in the US and globally also have faced limitations 
in their ability to control for important confounding variables such as behaviors like 
smoking (18-20), have not considered the impact of pre-existing conditions on outcomes 
(21, 22) and have focused on subpopulations that are not generalizable to the larger 
population (23, 24). A more in-depth look at hypertensive disorders and morbidity is 
needed at a population-based level with a greater ability to control for potentially 
confounding variables. This study investigated the relation between maternal health and 
morbidity before pregnancy, at delivery, and beyond the traditional postpartum period at 
a population-level. 
 The study results may inform prevention and management strategies at the state, 
facility and provider levels. At the state level, this research will inform the Massachusetts 
Perinatal Quality Collaborative (MPQC), which aims to improve maternal health 
outcomes through continuous quality improvement projects and the implementation of 
the maternal safety bundles (25, 26). This study may also provide a context for 
encouraging facilities to engage in the review of SMM cases, as called for by national 
organizations (10, 27). Further, this study also may reinforce the evidence-based 
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literature about the need of providers to address prevention and management strategies 
for hypertensive disorders to improve patient health before, during and after pregnancy. 
Beyond the implications of this particular research, the study highlights the usage of 
linked data systems to inform maternal health research at and after delivery. 
Dissertation Overview 
 
 The dissertation is presented in five chapters. This chapter discussed the 
background for the study aims. The second chapter presents a literature review and a 
study rationale, followed by the conceptual framework that guided the research. The third 
chapter presents the methodological approach of this research, including the study design, 
data sources, dependent and independent variables, and analytic plan. Chapter four 
presents the results of the data analysis, including descriptions of univariate, bivariate, 
and multivariate results as well as sensitivity analyses. Chapter five concludes this 
dissertation, with a discussion of the main findings of each aim, the strengths and 
limitations of this research, followed by the public health implications and conclusions. 
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This chapter provides a review of the literature on maternal hypertensive 
disorders in pregnancy and maternal morbidity. The definition and classification of 
maternal hypertensive disorders are first reviewed, followed by their etiology, risk factors 
and recent trends. Other maternal chronic and pregnancy-associated conditions are briefly 
discussed, including a review of trend data. Next, the international context of maternal 
morbidity is presented along with a definition of severe maternal morbidity in the United 
States, followed by current trend information. Research on hypertensive disorders, 
maternal morbidity at delivery and postpartum maternal morbidity is discussed. The 
chapter presents a rationale for this research, including a review of limitations faced by 
previous studies, and concludes with a conceptual framework guiding the research. 
Maternal hypertensive disorders 
Definitions and classification 
Maternal hypertensive disorders during pregnancy are classified by timing, onset 
and severity. Hypertension is defined as either systolic blood pressure (BP) of 140mm Hg 
or greater, a diastolic BP of 90 mm Hg or greater, or both (1). During pregnancy, chronic 
hypertension is defined as high blood pressure prior to conception or before twenty 
weeks gestation. Gestational hypertension is new onset high BP after twenty weeks 
gestation. Hypertension may also be stratified into mild and severe categories, with mild 
hypertension defined as systolic between 140-159mm Hg and/or diastolic 90-109mm Hg 
and severe as systolic greater or equal to 160mm Hg and/or diastolic greater or equal to 
110mm Hg. 
Preeclampsia is the most common form of high blood pressure that complicates 
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pregnancy. It is generally defined as the occurrence of new-onset hypertension and new-
onset proteinuria (protein to creatinine ratio measures or exceeds 3.0 mg/dL) or other 
multi-systemic signs after twenty weeks gestation (1). In the absence of proteinuria, 
preeclampsia can be classified by the presence of hypertension with end organ 
complications characterized by one or more of the following: thrombocyptopenia, 
impaired liver function, renal insufficiency, pulmonary edema, or cerebral or visual 
disturbances (1). Superimposed preeclampsia is the new-onset of proteinuria or organ 
dysfunction after twenty weeks among women with chronic hypertension. Preeclampsia 
may be considered mild or severe in accordance with the blood pressure measurement. In 
addition, preeclampsia is often categorized as early-onset, occurring earlier than 34 
weeks gestation or late onset, after 34 weeks gestation. 
Etiology and risk factors 
While the pathways that lead to preeclampsia and eclampsia are unknown, current 
hypotheses suggest that the disorder is the result of disturbed placental function early in 
pregnancy. There may be poor uterine vasculature, reducing placental perfusion, which in 
turn may lead to unbalanced transfer of nutrients and oxygen to the fetus and carbon 
dioxide and waste to the maternal blood supply (2). Resulting placental hypoxia is 
hypothesized to trigger the placenta to release proinflammatory cytokines into circulation 
that damage the endothelium, a thin membrane lining the inside of heart and blood 
vessels, and ultimately result in manifestation of the maternal syndrome of preeclampsia 
(2-4).  
It is hypothesized that early onset preeclampsia, which compromises 5-20% of 
preeclampsia cases and occurs before 34 weeks gestation, has a different etiology than 
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later onset preeclampsia (4). In addition to different pathologies of early and late onset 
preeclampsia, the National Institute of Child Health and Human Development (NICHD) 
workshop on preeclampsia in 2006 suggested that pathologies associated with 
preeclampsia differed for nulliparous and parous women (2). The NICHD workshop 
acknowledged the “complex and multifactorial nature” of preeclampsia and suggested 
that it is a condition of excessive systemic inflammation (2). 
The theory of excessive systemic inflammation in the manifestation of 
preeclampsia also raises the potential role of other inflammatory chronic conditions 
during pregnancy on maternal morbidity, including asthma and autoimmune diseases. In 
a recent meta-analysis, mothers with asthma had an increased risk of preeclampsia 
compared to mothers without asthma (Relative Risk: 1.54) (5). One mechanism proposes 
that acute asthma exacerbations cause maternal hypoxemia, low oxygen in the maternal 
blood, leading to fetal hypoxia; with limited blood flow to the fetus, fetal growth 
restriction or uteroplacental insufficiency may result (6). Autoimmune diseases, such as 
lupus erythematosus and multiple sclerosis, also involve chronic inflammatory states. 
Preeclampsia may complicate 13-35% of pregnancies to women with systemic lupus 
erythematosus (7). For pregnant women with either multiple sclerosis or systemic lupus 
erythematosus, there are increased serum levels of proinflammatory cytokines in 
comparison to women without the disease (8, 9). The origins and pathways of other 
systemic inflammatory responses in chronic conditions similar to hypertensive disorders 
in pregnancy are also important to explore.  
Researchers have identified some factors associated with a higher risk of 
developing preeclampsia and eclampsia. The American College of Obstetrics and 
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Gynecology (ACOG) in its most recent report on Hypertension in Pregnancy lists the 
following risk factors for preeclampsia: primiparity, previous preeclamptic pregnancy, 
chronic hypertension or chronic renal disease, history of thrombophilia, multifetal 
pregnancy, in vitro fertilization, family history of preeclampsia, type 1 or type 2 diabetes, 
obesity, systemic lupus erythematosus, and advanced maternal age greater than 40 years 
(1). A systematic review by Duckitt et al. (2005) showed the strongest risk factors for 
preeclampsia to be among women with: antiphospholipid syndrome (RR 9.72), previous 
history of preeclampsia (RR 7.19), and type 1 diabetes (RR 3.56) along with multiple 
pregnancy, family history, high body mass index, and maternal age (10).  
Racial, ethnic, and socioeconomic differences have also been reported for 
hypertensive disorders during pregnancy in the US. Results of a population-based study 
in California using linked vital statistics and hospital discharge data showed Hispanic and 
non-Hispanic black women had slightly higher odds of gestational hypertension and 
chronic hypertension than non-Hispanic white women after adjustment for age, parity, 
education, insurance status, prenatal care adequacy, and route of delivery (11). Other 
studies in New York State showed that rates of all hypertensive disorders during 
pregnancy were highest among non-Hispanic black women across all regions and poverty 
levels (12, 13). Tanaka et al. (2007) observed increasing racial and ethnic disparities in 
hypertension rates even after stratification by socioeconomic status and other risk factors 
over a 10-year population-based study of merged hospital discharge and census data in 
New York State (12). In a population-based study of singleton live birth deliveries using 
linked hospital discharge and birth certificate data over 10 years in New York State, 
Savitz et al. (2014) found black women had higher odds of all hypertensive disorders, 
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after adjusting for year, age, insurance, and urban/rural county.  
A European population-based prospective cohort study suggested women with 
low education had almost five times the odds of preeclampsia than women with high 
education, adjusted for: age, gravidity, multiple pregnancy, financial difficulties, smoking 
in pregnancy, working conditions, body mass index and blood pressure at enrollment (14). 
These disparate rates of hypertensive disorders during pregnancy by race and ethnicity 
and socioeconomic status suggest the need to account for these variables in research on 
the relation of hypertensive disorders with severe maternal morbidity. 
Prevalence and trends 
Rates of hypertensive disorders during pregnancy appear to be rising in the US. 
The prevalence of hypertensive disorders in delivery hospitalizations (inclusive of 
chronic and gestational hypertension, and mild and severe preeclampsia/eclampsia) 
increased from 6.7% in 1998 to 8.3% in 2006 in the US; all subtypes showed increasing 
trends except mild preeclampsia (15). In Massachusetts, data from 1998-2007 suggested 
7.0% of women giving birth had pregnancy-related hypertension, defined as gestational 
hypertension, preeclampsia, or eclampsia (16).  
Other national data from 2001-2005 suggest the most common obstetric 
complication was preeclampsia/eclampsia, which affected 3.4% of deliveries, an 11% 
increase from 1993-97 to 2001-05 (17). Massachusetts data from 1998-2007 indicated a 
similar overall preeclampsia prevalence of 3.3%, with 0.6% of preeclampsia cases 
occurring prior to 34 weeks (16).  
There also appear to have been increases in gestational and chronic hypertension. 
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National data indicate an increase in gestational hypertension among delivery 
hospitalizations from 2.1% in 1993-97 to 3.1% in 2001-05 (17). An increase was also 
noted based on linked birth certificate and hospital discharge data in California from 
4.4% to 4.9% between 1999 and 2005, figures higher than national data (11). Chronic 
hypertension varied from less than 1% to almost 2% in recent studies; a 2014 New York 
State study estimated chronic hypertension prevalence to be 0.83% (13) while research 
using the National Inpatient Database reported a prevalence of 1.8% in 2007-08, an 80% 
increase over the 14-year study period (18). Data from the National Hospital Discharge 
Survey corroborate this finding, reporting that chronic hypertension affected 1.9% of 
delivery hospitalizations and was 24% higher in 2001-05 than in 1993-97 (17). Data from 
California documented a 47.5% increase in chronic hypertension from 0.63% to 0.93% 
between 1999 and 2005 (11). Super-imposed preeclampsia is the rarest of all 
hypertensive disorders in pregnancy: researchers examining data from New York State 
recently estimated it to impact 0.23% of pregnant women (13).  
Some of the increasing rates of hypertensive disorders may be reflective of 
changing trends in the childbearing population as women are presenting at childbirth with 
an increasing number of both preexisting and pregnancy-related comorbidities. Over the 
past two decades, birth rates in the US decreased for women aged 15-29 years and 
increased for older women aged 35-44 years, especially for women 40 years and older 
(from 1.2% of all births in 1990 to 2.9% in 2010) (19). Maternal chronic conditions 
increase with age: researchers showed increased odds of both chronic hypertension and 
superimposed preeclampsia among women 35 years and older during delivery 
hospitalization in New York compared to women 25-29 years (13). Additionally, pre-
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pregnancy obesity has risen in the past two decades (20, 21). Among nine states with 
available data, there was a 69% increase in pre-pregnancy obesity from 13% in 1993 to 
22% in 2002 (21). Even though adjusted analyses suggest increases in hypertensive 
disorders independent of maternal risk factors (11), better ascertainment of disease may 
also be reflected in this increase. 
Other maternal chronic and pregnancy-associated conditions 
Prevalence and trends 
Rates of other chronic and pregnancy-associated conditions also appear to be 
increasing among pregnant women in the US. In the National Discharge Survey, the rate 
of asthma during hospital delivery almost doubled from 0.7% during the period 1993-
1997 to 1.3% during the period 2001-2005 (17). In the National Inpatient Sample, the 
rate of depression at hospital delivery increased from 0.3% to 1.4% from 1998 to 2005 
(22). In California, chronic disease rates increased significantly from 1999-2005, 
including: asthma (1.0% to 1.8%), substance abuse (1.7% to 2.9%), mental health 
conditions, including depression (1.0% to 1.2%), pre-existing diabetes (0.7% to 0.8%), 
and gestational diabetes (4.0% to 5.7%) (11).  
Severe maternal morbidity at delivery 
International context 
Maternal morbidity and mortality can be considered on a continuum with major 
categories ranging from normal/healthy pregnancy, morbidity, severe morbidity, near 
miss, to death (23). In 2011, the World Health Organization (WHO) adopted the 
definition of maternal “near miss” as “a woman who nearly died but survived a 
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complication that occurred during pregnancy, childbirth or within 42 days of termination 
of pregnancy” and established standard criteria to examine quality of obstetric care (24). 
In 2010-2011, the WHO Multi-country Survey on Maternal and Newborn Health project 
included over 314,000 women and their infants in 29 countries to assess the management 
of severe maternal complications and the prevalence of maternal near miss, which was 
estimated to be 0.8% (25). This project also developed the maternal severity index (MSI), 
which estimates the probability of death in women with complications related to 
pregnancy. In 2016, the WHO Maternal Morbidity Working Group defined maternal 
morbidity and associated disability as “any health condition attributed to and/or 
complicating pregnancy and childbirth that has a negative impact on the woman’s 
wellbeing and/or functioning” and proposed a standard matrix of 121 conditions for 
measurement (26). In part, this shift represents the recognition that the term “near miss” 
can be ambiguous because by definition it is a facility-based measure, not a population-
based one (27).  
US definition, classification and validation 
The CDC defines maternal morbidity as encompassing “physical and psychologic 
conditions that result from or are aggravated by pregnancy and have an adverse effect on 
a woman’s health” (28). Building on frameworks of antenatal hospitalizations (29, 30), 
complications during delivery hospitalization (31, 32) and international guidelines (24), 
the CDC developed an identification system to define severe maternal morbidity (SMM) 
based on the International Classification of Disease, 9
th
 Revision, Clinical Modification 
(ICD-9-CM) diagnosis and procedure codes (33). This system of measuring SMM was 
updated and refined in 2012 to include a total of twenty-five specific ICD-9-CM codes 
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that capture indications of organ-system failure indicative of severe events (33, 34) 
(Table 2.1). Kuklina et al. (2009) refined the Callaghan et al. (2008) definition of SMM 
to classify the presence of SMM only among deliveries with a length of stay ≥90
th
 
percentile for mode of delivery; reclassification did not apply to procedure-based codes 
(35).  
Table 2.1 Severe Maternal Morbidity Indicators 





1. Acute myocardial infarction x 
 2. Acute renal failure x 
 3. Adult respiratory distress syndrome x 
 4. Amniotic fluid embolism x 
 5. Aneurysm x 
 6. Cardiac arrest/ventricular fibrillation x 
 7. Disseminated intravascular coagulation x 
 8. Eclampsia x 
 9. Heart failure during procedure or surgery x 
 10. Internal injuries of thorax, abdomen, and pelvis x 
 11. Intracranial injuries x 
 12. Puerperal cerebrovascular disorders x 
 13. Pulmonary edema x 
 14. Severe anesthesia complications x 
 15. Sepsis x 
 16. Shock x 
 17. Sickle cell anemia with crisis x 
 18. Thrombotic embolism x 
 19. Blood transfusion 
 
x 











23. Operations on heart and pericardium 
 
x 







In 2016, the CDC SMM ICD-9-CM criteria were validated with chart reviews and 
found to have reasonably high sensitivity (0.77) and a positive predictive value (PPV) of 
0.44 with a C-statistic of 0.87; researchers found the sole indicator of blood transfusion to 
be the most important source of false-positives. Main et al. (2016) concluded these 
criteria “can serve as a reasonable administrative metric for measuring severe maternal 
morbidity at population levels” but cautioned against the use of the criteria at individual 
hospitals because case-mix effects were strong (36). Another study analyzing the validity 
of SMM discharge billing codes found a range of PPVs for SMM categories, with an 
overall PPV of 89% (99% CI: 82%-93%) when length of stay was restricted to greater or 
equal to 3 days; researchers found “codes demonstrated a high PPV when supporting 
medical information contained objective data, such as laboratory values, pathology 
results, or procedure documentation” (37).  
Prevalence and trends 
The rate of SMM in the US was estimated to be 163 per 10,000 delivery 
hospitalizations in 2010-2011, an increase of 120% from 1998-1999 based on data from 
the Nationwide Inpatient Sample, the largest all-payer hospital inpatient care database in 
the US (38). Some researchers examining SMM at the national and state level have 
started to use the CDC classification and categorization while others have relied on other 
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markers of morbidity at delivery, including: admission to the ICU or blood transfusion 
greater than or equal to four units or prolonged postpartum length of stay (39). Findings 
from research into other risk factors for morbidity among US women at delivery show 
increased risk among women older than 35 years, of non-white race/ethnicity, with 
multiple gestations, and with a prior cesarean delivery (40-44). Recent research has also 
suggested women with singleton pregnancies conceived through assisted reproductive 
technology are at increased risk of SMM at delivery (45, 46). 
Hypertensive disorders and maternal morbidity at delivery 
Hypertensive disorders during pregnancy are associated with adverse maternal 
outcomes at delivery, although definitions of morbidity vary in these studies (15, 40, 41, 
47-49). In a study of morbidity measured by obstetric-related ICU admissions, the 
leading diagnosis associated with admission was pregnancy-related hypertensive disease, 
present in 29.9% of admissions (49). Researchers using data from the Nationwide 
Inpatient Sample of the Healthcare Cost and Utilization Project found women with 
hypertensive disorders had increased risk of adverse outcomes including acute renal 
failure, pulmonary edema, adult respiratory disease syndrome, puerperal cerebrovascular 
disorder, disseminated intravascular coagulation syndrome, and ventilation (15); these 
specific outcomes represent some conditions and procedures included in the SMM 
definition. In an NICHD study of 25 Maternal-Fetal Medicine Unit Networks, women 
with any hypertension diagnosis had a greater than 3-fold increase in severe maternal 
morbidity, defined as a score-based system of ICU admissions, intubation greater than 12 
hours, organ failure, surgical intervention, or blood transfusion greater than 3 units (40). 
Previous studies of hypertensive disorders have not specifically considered the CDC 
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definition of SMM as an outcome, and others have not adequately controlled for 
important confounding variables, especially other chronic comorbidities, limiting the 
validity of their inferences. 
Conditions and procedures in the CDC classification system of SMM related to 
cardiovascular illness represent a plausible pathway of the manifestation of hypertensive 
disorders due to damage to the endothelium, the linings of the heart and blood vessels (2, 
3). Plausible pathways are also suggested for a relation of hypertensive disorders with 
SMM for other conditions and procedures included in the measure. For example, 
considering women with preeclampsia, clinical decisions to deliver before full gestation 
increase the likelihood of cesarean delivery and may, in turn, increase the risk of sepsis or 
of anesthetic complications (50, 51). Additionally, preeclampsia may lead to increased 
risk of hemorrhage requiring transfusions, another qualifying procedure for SMM, due to 
decreased blood flow to organs other than the placenta (52). Another indicator of SMM is 
amniotic fluid embolism, which is hypothesized to be related to placental abnormalities 
(53).  
Other chronic conditions also are associated with morbidity at delivery. A review 
of women with asthma found those with severe or poorly controlled asthma have an 
increased risk of spontaneous abortion, intrauterine growth restriction, preterm delivery, 
postpartum hemorrhage and cesarean delivery (6). In a retrospective cohort study of a 
over 280,000 pregnancies from a primary care database of women in England and Wales, 
women with asthma were at increased odds of postpartum hemorrhage, anemia and 
cesarean delivery after adjustment of maternal age, smoking habit, and body mass index 
(54). In a review of autoimmune conditions, among women with systemic lupus 
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erythematosus, there was a two- to four-fold higher rate of pregnancy complications, 
including preterm labor and cesarean delivery; among women with rheumatoid arthritis, 
there was an increased frequency of cesarean delivery (7). In a large population-based 
study in Sweden, women with type 1 diabetes had increased odds of cesarean delivery 
and very preterm birth, after controlling for maternal age, parity, body mass index, 
chronic hypertensive disease, smoking habits and ethnicity (55). In a systematic review 
and meta-analysis including 30 studies, maternal depression during pregnancy was 
associated with increased odds of premature delivery (56). And in a linked population-
level administrative database study, women with illicit drug use in pregnancy, including 
opioids, stimulants, and cannabis, were more likely to deliver preterm after adjustment of 
maternal age, smoking, other drug use, ethnicity, and insurance status (57). Most of these 
studies assessed outcomes in the newborn, and few have specifically addressed maternal 
morbidity. The lack of research on maternal morbidity for these conditions is an 
important gap in the literature addressed by our study. 
Maternal morbidity in the postpartum period 
Traditionally, the first six weeks after delivery are considered the postpartum 
period. The American College of Obstetricians and Gynecologists recommends all 
women have a comprehensive postpartum visit within the first six weeks after birth (58). 
Complications occurring during this time are generally considered to be related to events 
during pregnancy or delivery (59). National surveys such as the National Inpatient 
Sample or the National Discharge Survey have attempted to capture postpartum maternal 
health through examining specific hospitalization inpatient codes, but these data are 
dependent on a postpartum hospitalization diagnosis coding (34, 35). While they can be 
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used to estimate maternal morbidity rates during the postpartum hospitalization, they are 
not linked to hospital delivery discharge data for individual women. On a population 
level, linkage of the birth certificate, hospital discharge delivery records, and prospective 
hospital utilization data after delivery to assess maternal health is undertaken at the state 
level (60-62). Massachusetts is one state in which this linkage has been undertaken. 
An increased research focus on the impact of delivery hospitalization for both the 
mother and infant ensued when Health Maintenance Organizations and third party payers 
started to encourage shorter delivery stays in the 1990s (63). In general, a short stay for a 
vaginal delivery is considered less than 48 hours and less than 96 hours for a cesarean 
delivery (63). More recently, with the increased rate of cesarean deliveries in the US, 
researchers have investigated the impacts of short lengths of stay by method of delivery 
through maternal rehospitalization, generally defined as an admission to a hospital within 
a specified time of a discharge from the same or another hospital (62, 64, 65).  
Liu et al. (2002) examined length of stay and maternal rehospitalization within 60 
days among Canadian women, finding an increased risk of readmissions with short length 
of stay among women with cesarean deliveries; the most frequent risk factors and causes 
of readmission were postpartum hemorrhage, major puerperal infection and some 
hypertensive disorders (64). In a case control study, Sharvit et al. (2014) found increased 
risk of rehospitalization within 14 days associated with emergency cesarean delivery; the 
most common indication of rehospitalization was infection (65). The length of stay 
concept also led to research focused on discharge readiness, which addresses a more 
individualized approach taking into consideration the opinions of the mother, pediatrician 
and obstetrician for the timing of discharge; researchers found increased health care use 
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and poorer health outcomes 2-4 weeks post-delivery among mother-infant dyads when 
there was discordance in provider and patient opinions about discharge readiness (66). 
Some researchers also have focused on specific populations to examine 
postpartum maternal health. Among a hospital network in the US, Clark et al. (2010) 
found that 4.8% of women who deliver were seen in the Emergency Department within 
42 days of delivery (67). The results of a study of women delivering low birth weight 
(LBW) or preterm infants showed that almost 60% were rehospitalized within five years 
(68). Among women with a cesarean delivery, researchers found the most common major 
complication after delivery to be maternal infection, with infections in 29% of women 
during delivery hospitalization and 8% after primary hospital discharge (69). 
Other studies of postpartum morbidity combine both pregnant women and 
postpartum women (<42 days post-delivery) to examine hospitalizations (34, 70). In a 
review of studies, pregnant and postpartum women accounted for 0.4-16% of all 
Intensive Care Unit admissions. Hypertensive disorders were the most prevalent 
indication for admissions (70). 
Hypertensive disorders and postpartum morbidity 
Preeclampsia is associated with poor long-term outcomes in women. In particular, 
meta-analyses have identified preeclampsia as a risk factor for later stage cardiovascular 
disease. McDonald et al. (2008) found women with preeclampsia/eclampsia had more 
than double the risk of subsequent cardiac disease, cerebrovascular disease, and 
cardiovascular mortality in a meta-analysis of fifteen studies, ten of which focused on 
women less than 56 years of age (71). Bellamy et al. (2007) found preeclampsia to be 
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related to increases in the risk of future hypertension, ischemic heart disease, venous 
thromboembolism, and death from any cause, with weighted mean follow-up for 
outcomes ranging from 4.7-14.5 years (72). This research supports a common cause of 
preeclampsia and cardiovascular disease, specific vascular damage due to preeclampsia, 
or both (72). Research into subclinical outcomes also indicate increased odds of higher 
blood pressure and being on blood pressure medication among women with a history of 
hypertensive disorders during pregnancy, with a mean follow-up time of 16.5 years (73). 
In 2011, the American Heart Association updated their clinical guidelines to include a 
history of preeclampsia or pregnancy-induced hypertension as risk factors for 
cardiovascular disease in women (74). 
Some US studies examining associations between maternal hypertensive disorders 
during pregnancy and post-delivery maternal outcomes focused on specific vulnerable 
populations. Hamilton et al. (2002) examined postpartum hospitalization among women 
with high-risk pregnancies, a group including women diagnosed with chronic 
hypertension; they found that one in six women required one or more rehospitalization 
and almost one in five required an acute care visit within one year postpartum (75). 
Another study of only women with insurance found that those with hypertensive 
disorders during pregnancy were more likely than women without complications to 
attend primary care visits in the year after delivery; however, the rates of primary care 
utilization were still below what was recommended (76).  
Other US studies face some methodological limitations. One large population-
based study in the Washington State from 1998-2000 examined varying severity of 
hypertension during pregnancy and cardiovascular and thrombolytic events (60). A 
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greater than 2-fold risk for cardiovascular events was noted among women with 
gestational hypertension, and mild and severe preeclampsia. While the researchers 
combined records from birth certificate and hospital discharge data, and followed women 
for a median length of 8 years, they excluded chronic hypertension as an exposure. 
Another study found increased risk of prehypertension and hypertension in the early 
years after delivery among women who developed gestational hypertension; however, 
they only focused on women who had prenatal care and delivered live singleton neonates 
at one US medical center and did not have data about pre-existing hypertension (77). 
Another study examined the relation between preeclampsia and ischemic stroke among 
US women 15-44 years of age in a case control study but relied on self-reports by women 
of a physician diagnosis of preeclampsia (78). 
One recent US study in New York City, using linked birth certificate data and 
hospital discharge data, examined more immediate clinical events among women with 
gestational hypertension and preeclampsia in the year following delivery (61). The 
researchers found increased odds of heart failure among women who had gestational 
hypertension during pregnancy and increased odds of heart failure, intracranial 
hemorrhage, stroke/transient ischemic attack, coronary heart disease, deep vein 
thrombosis, and type 2 diabetes among those with preeclampsia (61). Although Savitz et 
al. (2014) used hospital discharge data linked to birth certificate data, they did not also 
use the birth certificate to ascertain conditions during pregnancy, with the exception of 
gestational diabetes (61). Using both the birth certificate and hospital discharge data 
improves the ascertainment of conditions compared to using only one data source (79, 




A life course perspective addressing pre-pregnancy conditions is important in 
understanding the impact of hypertensive disorders and other chronic and pregnancy-
associated conditions. Previous research on the relation between hypertensive disorders 
and maternal morbidity has generally excluded women with pre-existing conditions, 
specifically chronic hypertension, limiting the generalizability of the research to women 
with underlying chronic conditions (60, 61). Some studies aggregated all pre-existing 
conditions, including hypertension, into one category, limiting the ability to understand 
the role of chronic hypertension specifically (42). The current study examined women 
with underlying chronic conditions that included maternal hypertensive disorders and 
other common chronic conditions such as pre-existing diabetes, asthma, autoimmune 
conditions, depression, and substance use disorders as well as pregnancy-associated 
conditions such as gestational diabetes.  
In addition to examining chronic conditions prior to pregnancy, other indicators, 
considered as confounders, captured the context of a woman’s social and biological 
environment. Prior birth outcomes as well as household and family characteristics may be 
critical in the relation between hypertensive disorders in pregnancy and maternal 
morbidity at and after delivery. Previous research has been limited by failure to adjust for 
the timing of delivery and socio-demographic variables, such as race/ethnicity and 
smoking (15). It also has been limited by data available largely for delivery events, and 
not for the women themselves (15, 33, 47, 81). This study examined deliveries to women 
from delivery through one year postpartum and linked repeat births as well as accounted 
for a range of social and biological variables obtained from multiple sources.  
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Research on maternal health in the US has been limited, in general, and studies 
following women after delivery are particularly sparse in number. Previous studies have 
not captured postpartum maternal health, with the exception of some case control studies 
within single institutions and studies of short time periods after delivery or among 
specific populations (75, 76). To address the limitation of short follow-up in previous 
research, this study examined postpartum maternal rehospitalization within six weeks and 
up to one year post-delivery to align with standard maternal and pregnancy-related 
mortality measures in the US (82). The ability to link surveillance systems from delivery 
into the postpartum period in Massachusetts offered avenues to explore these pathways 
more comprehensively, including three different measures of postpartum maternal 
morbidity: emergency department admissions, observational stays, and hospital discharge 
rehospitalizations.  
The recent national efforts to define and explore SMM at delivery offered new 
opportunities to explore maternal health prior to and after delivery. It is unknown if 
hypertensive disorders in pregnancy or SMM at delivery are associated with maternal 
morbidity in the postpartum. Some studies have examined type of delivery and 
readmission rates but have not accounted for pre-existing or pregnancy-related conditions 
or the severity of maternal conditions at birth beyond type of delivery (62). Moreover, 
other studies that examined the relation between hypertensive disorders during pregnancy 
and postpartum maternal health did not take into account chronic maternal conditions 
preceding birth (61). This study investigated the relation between maternal health and 
morbidity before pregnancy, at delivery, and beyond the traditional postpartum period at 




Based on the review of literature, the framework informing this study suggests the 
need for an integrative approach to examine women’s health. The conceptual framework 
attempts to integrate biological, social, and biosocial pathways in understanding the 
relation between hypertensive disorders during pregnancy and morbidity at birth and in 
the postpartum. The conceptual framework adapts both a life course and an integrated 
perinatal health approach, centered on the premise that pregnancy is a critical period in a 
woman’s life, affecting her future health. It acknowledges factors present prior to 
pregnancy, especially risk factors that may be shared among hypertensive disorders and 
cardiovascular disease (83). The model provides the basis for the methodological 
approach in this study. 
Ben-Shlomo and Kuh (2002) define a life course approach to chronic disease 
epidemiology as “the study of long-term effects on chronic disease risk of physical and 
social exposures during gestation, childhood, adolescence, young adulthood and later 
adult life” (84). The approach posits factors that either raise disease risk or promote good 
health accumulate gradually over the life course although there are critical periods where 
“an exposure can have adverse or protective effects on development and subsequent 
disease outcome.” Pregnancy is considered a critical period of development for the fetus, 
but to a lesser extent, for the mother. Our work highlights the need to extend the model to 
women’s health before, during and following pregnancy. Thus, we adapt the life course 
model to consider the impact of hypertensive disorders during pregnancy on SMM at the 
time of delivery as well on the subsequent health of the mother as measured by maternal 
hospitalization in the year postpartum.  
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The integrated perinatal health framework proposed by Misra, Guyer and Allston 
(2003) also recognizes the social, psychological, behavioral, environmental and 
biological influences prior to pregnancy that impact outcomes in addition to the changing 
demography of pregnancy with more women delaying their first birth (85). The 
conceptual framework is also informed by research suggesting women at high risk for 
cardiovascular disease may be identified during the reproductive years. Research has 
shown increased risk of cardiovascular disease among women with hypertensive 
disorders during pregnancy although the mechanisms linking pregnancy events to later 
life disease are not well understood (86-88).  
Applying a women’s health life course-based framework centered on the 
reproductive years, the conceptual model adapts the framework of Misra, Guyer and 
Allston (2003) to examine the health trajectories of women at birth and in the year 
following delivery in the context of distal and proximate determinants. Also informed by 
Ben-Sholmo and Kuh (2002), this conceptual model adapts their ideas to consider an 
integration of social and biological factors both prior to and during pregnancy for the 
mother (Figure 2.1). 
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Figure 2.1 Conceptual Framework 
 
 
In this framework, distal and proximate factors influence a woman’s health before, 
during and after pregnancy. Distal factors consider genetic factors, and the physical and 
social environment. While it was not possible to consider genetic factors in the current 
study, the social environment includes individual characteristics, such as socioeconomic 
status and race, as well as partner, family, and neighborhood characteristics. Proximal 
risk factors acknowledge the interplay between biomedical responses, including chronic 
conditions, with behavioral responses, such as smoking. Distal and proximal factors 
influence a woman’s health prior to conception, through pregnancy, birth and post-
delivery. Short-term maternal disease and complications represent maternal morbidities at 









& Complications  
Long-term 
Maternal Disease 


















birth, while long-term maternal disease and complications may include rehospitalizations 
within the first year postpartum.  
The framework also includes health care as a modifying characteristic that may 
impact a variety of relations in the framework, from primary prevention activities to 
medical interventions. There are potential unknown factors in this conceptual model that 
require acknowledgement, as the etiology of hypertensive disorders during pregnancy is 
unknown. This study cannot evaluate all dimensions of framework described here but 
focuses on the periods during and after pregnancy, informed by prior and current 
biological and behavioral responses as well as health care and sociodemographic 
characteristics. Most importantly, the framework focuses on the health of the mother, not 
the fetus or newborn; it has generally not been considered in this context. 
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 This chapter describes the study methods to evaluate the relation between 
maternal hypertensive disorders and severe maternal morbidity at delivery and the impact 
of each on maternal morbidity in the first year postpartum. This chapter begins with the 
study aims and hypotheses, followed by the study design and data sources. Descriptions 
are then presented for the dependent and independent variables. The final section presents 
the analytic plan for each of the study aims, including statistical models. 
Study Aims and Hypotheses 
Based on the population of deliveries to women residing in Massachusetts using 
maternal hospital delivery discharge records from January 1, 2000-December 31, 2012 
linked with birth certificate and fetal death record data, the following aims and 
hypotheses were evaluated:  
Aim 1 
Evaluate the relation between maternal hypertensive disorders and other chronic 
and pregnancy-associated conditions in pregnancy with severe maternal morbidity 
at delivery.  
1) H0(null): There is no association between maternal hypertensive 
disorders in pregnancy and severe maternal morbidity at delivery.  
2) H0(null): There is no association between chronic and pregnancy-
associated conditions in pregnancy and severe maternal morbidity at 
delivery.  
 
Aim 2  
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Evaluate the relation between severe maternal morbidity at delivery and 
postpartum maternal rehospitalization in the year following delivery among 
women without chronic medical diseases. 
1) H0(null): There is no association between severe maternal morbidity at 
delivery and rehospitalization in the year following delivery among 
women without chronic medical conditions. 
 
Aim 3 
Evaluate the relation between maternal hypertensive disorders and other chronic 
and pregnancy-associated conditions in pregnancy with postpartum maternal 
rehospitalization in the year following delivery independent of severe maternal 
morbidity at delivery. 
1) H0(null): There is no association between maternal hypertensive 
disorders in pregnancy and rehospitalization in the year following 
delivery, independent of severe maternal morbidity at delivery  
2) H0(null):: There is no association between chronic and pregnancy-
associated conditions and rehospitalization in the year following delivery, 
independent of severe maternal morbidity at delivery  
3) H0(null): The relation of maternal hypertensive disorders and other 
chronic and pregnancy-associated conditions does not differ for deliveries 




Null hypotheses were included due to lack of prior studies to indicate which hypertensive 
disorders or other chronic or pregnancy-associated conditions may be related to severe 
maternal morbidity and the relation between severe maternal morbidity and subsequent 
rehospitalization outcomes. 
Study Design 
 In Aim 1, the study design was a retrospective cohort design based on deliveries 
among resident women in Massachusetts from 2000-2012; the exposure of maternal 
hypertensive disorders and other chronic and pregnancy-associated conditions before and 
during pregnancy were documented on vital records and hospital delivery discharge 
records and severe maternal morbidity (SMM) at delivery was assessed based on hospital 
delivery discharge records. For Aim 2, the study was a retrospective cohort study of 
deliveries among resident women in Massachusetts without chronic medical conditions 
from 2002-2011, with the exposure of SMM collected at the time of delivery on hospital 
delivery discharge records and the outcome collected within the first year postpartum 
using non-delivery hospital discharge, observational stay, and emergency department 
records. For Aim 3, a retrospective cohort design examined all deliveries among resident 
women in Massachusetts from 2002-2011, with the exposure of hypertensive disorders 
and other chronic and pregnancy-associated conditions before and during pregnancy 
documented on vital records and hospital delivery discharge records and the outcome 
collected for the first year postpartum on hospital discharge, observational stay, and 
emergency department records. Across all aims, multiple deliveries to the same woman 
were included and analytic methods were used to adjust for these multiple deliveries over 




Data were obtained from the Pregnancy to Early Life Longitudinal (PELL) data 
system, a population-based data system housed at the Massachusetts Department of 
Public Health (MDPH). The PELL data system is a longitudinally linked database of 
Massachusetts mothers and their children, which includes vital statistics records, hospital 
discharge records, and public health program participation data.  
Vital statistics and hospital utilization data were used for this study. Birth 
certificate data and hospital discharge data are mandated by law to be reported to the 
Massachusetts Department of Public Health (M.G.L. c.111§24B and M.G.L. c.12C§8). 
Birth certificate data includes information on the place of birth, date, name, race/ethnicity 
and sex of child, as well as demographic information about the mother and father and the 
mother’s birth history. The birth certificate also includes information about maternal risk 
factors of pregnancy as well as labor and delivery complications. Birth certificates are 
filed by city or town clerks and forwarded electronically to the state Department of Public 
Health. In 2011, the Massachusetts Department of Pubic Heath initiated the Vitals 
Information Partnership, an electronic birth registration interactive module, and updated 
the birth certificate to the 2003 US Standard Certificate of Live Birth. Massachusetts 
requires fetal death reporting if a fetus is of at least twenty weeks gestation or at least 
350g (M.G.L. c.111§202). Massachusetts law also requires death certificates to report 
information including: date of death, age of decedent and disease or cause of death 
(M.G.L. c.46§1). 
Hospital discharge data include the maternal hospital discharge for the delivery 
hospitalization as well as non-delivery hospitalizations, observational stays, and 
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emergency department visit records. These data systems contain some limited 
demographic information about the patient as well as principal diagnoses related to the 
admission, procedures completed, length of stay, costs, and sources of payment. Both 
diagnoses and procedures are coded using the International Classification of Disease 
Manual, 9
th
 revision, Clinical Modification edition. There are up to fifteen potential 
diagnosis and procedure coding fields for hospital discharge, and six each for 
observational stay and emergency department records. As an administrative database, 
hospital discharge records are generally filed to procure payment; coding may more 
accurately reflect medical-surgical conditions that affect reimbursement rather than 
obstetric diagnoses (1). Hospital discharge data also provide a population-based means to 
conduct public health surveillance. Importantly, births that happen outside of a hospital 
setting are captured through the birth certificate but not through hospital discharge 
records. 
Both deterministic and probabilistic methods are used to link records from the 
various datasets to the PELL data system using LinkPro software (InfoSoft, Inc.; 
Winnipeg, Manitoba, Canada). Selected linkage variables include facility code, medical 
record number, date of birth/date of delivery, sex, zip code, and birth weight. Previous 
studies using the PELL data system have reported the linkage rate of deliveries to 
maternal hospital discharge records to be 99.2% (2). For Aim 1, PELL data were 
obtained for maternal hospital delivery discharge data from January 1, 2000-December 




For Aims 2 and 3, the matched data from Aim 1 were used for 2002-2011 and 
linked to prospective maternal non-delivery hospital discharges, observational stays, 
emergency department admissions and death data from 2002-2012 through a unique 
maternal identifier to capture rehospitalization in the first year postpartum. Emergency 
department data first became available for analysis in 2002 and the most recently linked 
data available from PELL are for 2012. 
Massachusetts adopted the 2003 U.S. Standard Certificate of Live Birth starting in 
2011. New variables of note on the 2003 revision included maternal height and pre-
pregnancy weight to determine body mass index and a new categorization of maternal 
smoking before and during pregnancy. For all analyses, birth certificate data were coded 
to match 2000-2010 variable data with 2011-2012 variables.  
Data access was authorized by the Massachusetts Department of Public Health in 
accordance with M.G.L c.111 §24A and the Massachusetts Center for Health Information 
and Analysis. The Institutional Review Board at Johns Hopkins Bloomberg School of 
Public Health determined this study to be exempt under 45 CFR 46.101(b), Category (4) 
due to the use of existing de-identified data in a limited use dataset.  
Study Population 
For Aim 1, the study population included deliveries to Massachusetts resident 
women with a Massachusetts occurent hospital delivery discharge record for either a live 
birth or fetal death from January 1, 2000-December 31, 2012. There were 988,285 
deliveries of births and 5,047 deliveries of fetal deaths from 2000-2012, of which 
970,353 were unique maternal deliveries that included 22,968 deliveries with plurality 
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greater than one (21,532 twin, 700 triplets, and 26 quadruplet or greater records). There 
were 986,745 hospital delivery discharge records from the same period. Data were 
merged by unique maternal identifier, providing 960,982 matched birth/fetal death and 
hospital delivery discharge records; 9,371 birth/fetal death records did not merge, of 
which a majority were births at home, birthing centers, or military centers, and did not 
have a hospital delivery discharge record. There also were 25,763 hospital delivery 
discharge records that did not merge, likely explained by the fact that the birth 
certificate/fetal death certificate files do not capture non-residents births or births to MA 
residents out of state. The matched 960,982 records represent deliveries to 643,874 
unique women; 60.8% (n=390,684) had one delivery 30.8% (n=197,762) had two 
deliveries, and 8.4% (55,425) had three or more deliveries during the study period. 
For Aims 2 and 3, the study population was drawn from deliveries to women from 
January 1, 2002-December 31, 2011 to allow for one year of postpartum follow-up 
through the end of 2012 as well as uniform linkage with hospital utilization data; 
emergency department records data became available statewide in 2002. For Aim 2, it 
was narrowed to deliveries to women without chronic medical conditions; 735,576 
deliveries to women in Massachusetts from 2002-2011 were initially identified from 
hospital delivery discharge records linked to birth certificate and fetal death records that 
informed Aim 1. Women with pre-existing chronic conditions of asthma, autoimmune 
conditions, pre-existing diabetes, chronic hypertension and superimposed preeclampsia 
were excluded to examine the relation between events at delivery and morbidity 
postpartum. These conditions were identified from the birth certificate and fetal death 
records and the hospital delivery discharge records based on the results of Aim 1. A total 
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of 50,348 linked birth certificate, fetal death, and hospital delivery discharge records 
were excluded from analysis for these conditions. The final study sample for Aim 2 was 
685,228 deliveries to women. 
For Aim 3, all deliveries to Massachusetts resident women with a Massachusetts 
occurent hospital delivery discharge record for either a live birth or fetal death from 
January 1, 2002-December 31, 2011 were included. There were 735,576 such deliveries 
in Massachusetts from 2002-2011 identified from hospital delivery discharge records 
linked to birth certificate and fetal death records. Non-delivery hospital discharge, 
observational stay, and emergency department admission records from 2002 through the 
end of 2012 were linked with these data through a unique maternal identifier to capture 
one year postpartum follow-up. 
Dependent Variables 
Aim 1 
The main dependent variable for Aim 1 was severe maternal morbidity (SMM) at 
delivery, defined by the methods of Callaghan et al. (2008) and Kuklina et al. (2009), and 
updated by Callaghan et al. (2012) (3-6). SMM is based on the presence or absence of 
twenty-five conditions a woman may experience at delivery (Table 3.1). Although a 
woman may have multiple indicators of SMM, this variable was dichotomous, consistent 
with previous research. Twenty-five ICD-9-CM diagnosis and procedure codes from any 
of the fifteen diagnosis and fifteen procedure code fields in the hospital delivery 
discharge record were first used to identify SMM; these criteria have reasonably high 
sensitivity (0.77) and a positive predictive value of 0.44 (6). SMM-indicated deliveries 
with short lengths of stay, defined as ≤90
th
 percentile for method of delivery (calculated 
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separately for vaginal, primary cesarean, repeat cesarean), were reclassified as 
hospitalization without SMM. Based on previous methods, the severity recalculation was 
not applied to transfers, deaths, or procedure-based codes, such as ventilation or 
hysterectomy. Table 3.1 shows the 25 diagnosis and procedure categories that are 
included in the overall measure of SMM. Eclampsia, although a category of hypertensive 
disorders during pregnancy as recognized by ACOG, was considered an outcome of 
SMM at birth in this analysis as defined by Callaghan et al. (2008) (4). 
The ICD-9-CM code for one indicator of SMM, blood transfusion, does not 
include information about the number of units transfused and may inflate the rate of 
SMM for women with only that indication; sensitivity analyses were conducted for SMM 
with and without blood transfusion (7). Further, a dichotomous variable defined by at 
least one cardiac-related SMM indicator was identified based on hypothesized relations 
with hypertension, as noted in previous research. It was examined as another outcome in 
Aim 1, both with and without the shock indication (See Table 3.1 for the cardiac-related 
SMM indicators) (8).   
Table 3.1 Severe Maternal Morbidity Indications and Corresponding ICD-9-CM 
Coding 




1. Acute myocardial infarction 410.xx x 
2. Acute renal failure 584.x, 669.3x  
3. Adult respiratory distress syndrome 518.5, 518.81, 518.82, 518.84,799.1  
4. Amniotic fluid embolism 673.1x  
5. Aneurysm 441.xx  
6. Cardiac arrest/ventricular fibrillation 427.41, 427.42, 427.5 x 
7. Disseminated intravascular coagulation 286.6, 286.9, 666.3x  
8. Eclampsia 642.6x  
9. Heart failure during procedure or surgery 669.4x, 997.1 x 




11. Intracranial injuries 800.xx, 801.xx, 803.xx, 804.xx, 851.xx-
854.xx 
 
12. Puerperal cerebrovascular disorders 430, 431, 432.x, 433.xx, 434.xx, 436, 
437.x, 671.5x, 674.0x, 997.2, 999.2 
 
13. Pulmonary edema 428.1, 518.4  
14. Severe anesthesia complications 668.0x, 668.1x, 668.2x  
15. Sepsis 038.xx, 995.91, 995.92  
16. Shock 669.1x, 785.5x, 995.0, 995.4, 998.0 x
1 
17. Sickle cell anemia with crisis 282.62, 282.64, 282.69  
18. Thrombotic embolism 415.1x, 673.0x, 673.2x, 673.3x, 673.8x  
19. Blood transfusion 99.0x  
20. Cardio monitoring 89.6x x 
21. Conversion of cardiac rhythm 99.6x x 
22. Hysterectomy 68.3x-68.9  
23. Operations on heart and pericardium 35.xx, 36.xx, 37.xx, 39.xx x 
24. Temporary tracheostomy 31.1  
25. Ventilation 93.90, 96.01-96.05, 96.7x  
1
The cardiac-related SMM indicator was considered both with and without shock 
Aims 2 and 3 
For Aims 2 and 3, the dependent variable was at least one non-injury, non-
antenatal-related hospital encounter within the first year after delivery; it was considered 
separately by type: hospital discharge, observational stay, or emergency department visit. 
Analyses also examined hospital encounters within six weeks postpartum, to align with 
the standard definitions of pregnancy-related mortality in the United States (9, 10). 
For each type of hospital encounter, all diagnosis code fields in the record were 
first scanned for injury-related ICD-9-CM codes, using methods from previous studies 
(Table 3.2) (11). The number of diagnosis code fields varied by type of hospital 
encounter: non-delivery hospital discharge records had fifteen fields and observational 
stay and emergency department records each had six fields. Diagnosis code fields were 
also scanned for antenatal-related conditions based on previously published methods 
(Table 3.2) (12). Hospitals encounters indicated for injury-related or antenatal- diagnosis 
51 
 
codes were excluded from analyses. The death file from 2002-2012 was also linked to 
identify maternal deaths within the first year postpartum (N=160). Maternal deaths were 
described by timing and hospital encounter. Based on preliminary analysis and low 
numbers, women who died within the first year after delivery remained in the analysis; 
sensitivity analyses were conducted with and without maternal deaths. 
Table 3.2 Injury- and Antenatal-related ICD-9-CM Coding 
Group ICD-9-CM Coding 
Injury-related 800-999.99 with excluded codes for late effects of injuries, adverse 
drug effects and medical care-related injuries: E849, E870-E876, 
E878-879, E929, E930-E949, E959, E969, E977, E989, E999 
Antenatal-related  Fifth digit of 3 in ICD-9-CM codes for primary or secondary 




 This section first discusses the main independent variables by study aim, followed 
by other social and biological independent covariates, which were also examined across 
all aims. 
Aim 1 
The main independent variable in Aim 1 was maternal hypertensive disorders in 
pregnancy. In addition, other prevalent maternal chronic and pregnancy-associated 
conditions of asthma, autoimmune conditions, depression, gestational diabetes, pre-
existing diabetes, and substance use disorders were examined as key variables, as well as 
their relation to hypertensive disorders.  
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Hypertensive disorders in pregnancy 
To expand approaches used in previous research, this study examined 
subcategories of hypertensive disorders: chronic hypertension, gestational hypertension, 
mild and severe preeclampsia, and super-imposed preeclampsia. Both birth certificate and 
maternal hospital discharge at delivery data were used to ascertain chronic hypertension 
and gestational hypertension (Table 3.3) (13, 14). In the maternal hospital delivery 
discharge data, the 15 diagnosis codes fields were scanned to identify maternal 
hypertensive disorders using the International Classification of Disease, 9
th
 revision, 
Clinical Modification (ICD-9-CM). The ability to use multiple databases, including 
hospital administrative databases and vital statistics, presented an opportunity to improve 
ascertainment of these variables. Previous research indicates that combining hospital 
discharge record and birth certificate data improves ascertainment of hypertension than 
either record alone (15, 16). One recent US study validated the medical record against the 
hospital discharge record, birth certificate data, and the data combined for classifying 
hypertensive disorders (15). Findings showed underestimation of chronic hypertension 
and gestational hypertension by the birth certificate or hospital discharge data alone; 
combining the two data sources provided more complete identification of chronic and 
gestational hypertension than the birth certificate data alone, as assessed by true positive 
fractions (15).  
Classification of hypertensive disorders during pregnancy was hierarchical and 
mutually exclusive, identifying in order: superimposed preeclampsia, severe 
preeclampsia, mild preeclampsia, chronic hypertension, gestational hypertension, and no 
hypertension. If there were conflicting reports on the vital records and hospital discharge 
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data, the more severe code was used. In the hospital discharge record diagnosis coding 
fields, the International Classification of Disease, 9
th
 revision, Clinical Modification 
(ICD-9-CM) manual lists outdated terms of essential and transient hypertension; 
therefore, as in previous studies, essential and pre-existing hypertension codes identified 
chronic hypertension and gestational hypertension included the transient hypertension 
codes (Table 3.3) (17, 18). Unspecified hypertension, a condition listed in the ICD-9-CM 
manual, was not used to inform hypertensive categories as previous research varies on its 
interpretation (17, 19). 
For chronic hypertension, 41.4% (n=6,246) of cases were identified by both 
sources, 31.8% (n=4,791) were identified only on the hospital delivery discharge record, 
and 26.8% (n=4,040) were identified only on the birth certificate/fetal death record. For 
gestational hypertension, 39.8% (n=14,199) of cases were identified by both sources, 
41.0% (n=14,634) only on the hospital delivery discharge record, and 19.2% (n=6,863) 
only on the birth certificate/fetal death record. In cases of multiple gestations, any 
indication of gestational or chronic hypertension on any one birth certificate or fetal death 
record indicated presence of the condition for that delivery. 
Asthma, Autoimmune conditions, Depression, Gestational diabetes, Pre-existing 
diabetes, Substance use disorders 
Based on previous research, other common chronic and pregnancy-associated 
conditions among pregnant women include diabetes (pre-existing and gestational), 
asthma, substance use disorders, depression and autoimmune conditions (20). ICD-9-CM 
codes, informed from previous studies and national definitions, were scanned in each 
diagnostic field of the maternal delivery discharge record for these chronic conditions 
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(21, 22) (See Table 3.3). With the exception of pre-existing and gestational diabetes, as 
noted below, any classification of chronic conditions in any of the 15 diagnosis codes on 
the maternal hospital delivery discharge record indicated the presence of a chronic 
condition. If an ICD-9-CM code was not listed in any field, these conditions were coded 
as not present to create dichotomous variables, indicating the presence or absence of the 
condition. The sensitivities for coding chronic conditions on the hospital discharge data 
are found to be low; in a recent systematic review, Lain et al. (2012) found the sensitivity 
for asthma to range between 12.3-42.0% (16). The specificity of asthma, however, was 
high ranging from 98.9-99.4. Caution is made in interpreting the coefficients of these 
variables with low sensitivity in the analyses.  
Birth certificate data supplemented ICD-9-CM diagnosis codes on the maternal 
hospital delivery discharge record for exposure ascertainment for pre-existing and 
gestational diabetes (14). A mutually exclusive hierarchical categorization was 
implemented; if data sources conflicted, pre-existing diabetes took precedence. For pre-
existing diabetes, 24.0% (n=3,888) of cases were identified by both sources, 21.8% 
(n=2,384) were identified only on the hospital delivery discharge record, and 42.7% 
(n=4,677) only on the birth certificate/fetal death record. For gestational diabetes, 61.1% 
(n=30,098) of cases were identified by both sources, 26.5% (n=13,039) only on the 
hospital delivery discharge record, and 12.4% (n=6,123) only on the birth certificate/fetal 
death record. Similar to the hypertensive variables, when records were aggregated by 
delivery in the case of multiple gestations, any indication of pre-existing or gestational 
diabetes on any birth certificate or fetal death record indicated presence of the condition.   
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Table 3.3 Preexisting and Pregnancy-associated Conditions, Data Sources and 
Coding 
 
Aim Variable Source Numeric/Categorical Response Categories  
1,2,3 Superimposed preeclampsia HDD 1: ICD-9-CM codes: 642.7x;  
Otherwise, scan for other hypertensive codes 
1,2,3 Severe preeclampsia HDD 2: ICD-9-CM codes: 642.5x;  
Otherwise, scan for other hypertensive codes 
1,2,3 Mild preeclampsia HDD 3: ICD-9-CM codes: 642.4x;  
Otherwise, scan for other hypertensive codes 
1,2,3 Chronic hypertension BC, FD, 
HDD 
4: BC or  ICD-9-CM codes: 642.0x, 642.1x, 
642.2x, 401.x, 405.x, 416.0x 459.3x;  
Otherwise, scan for other hypertensive codes 
1,2,3 Gestational hypertension BC, FD, 
HDD 
5: BC or ICD-9-CM codes: 642.3x; 
0: Otherwise, none (reference) 
1,2,3 Pre-existing diabetes BC, FD, 
HDD 
1: BC  or ICD-9-CM codes: 250, 249, 362.01-
362.06, 366.41, 357.2, 648.0;  
Otherwise, Scan for gestational diabetes 
1,2,3 Gestational diabetes BC, FD, 
HDD 
2: BC or ICD-9-CM codes: 648.8;  
0: Otherwise, none (reference) 
1,2,3 Asthma (CMS) HDD 1: ICD-9-CM codes: 493; 
0: Otherwise, No (reference) 
1,2,3 Autoimmune conditions (21) HDD 1: ICD-9-CM codes: 130.3, 136.1, 242.0, 283.0, 
340, 357.0, 358.0, 358.1, 379.4, 390-398, 422, 
429.0, 446.0-446.2, 446.4, 446.7, 516.3, 517.0, 
547.2, 555, 556, 579.0, 580, 581.3, 581.9, 582, 
583.0-583.4, 694.0, 694.2-694.6, 696.0, 696.1, 
701.0, 710.1, 710.0, 710.3, 710.4, 714.0-714.3, 
720.0, 851.1;  
0: Otherwise, No (reference)  
1,2,3 Depression (CMS OASH) HDD 1: ICD-9-CM codes: 296.2, 296.3, 296.5, 296.6, 
296.89, 298, 300.4, 309.1, 311;  
0: Otherwise, No (reference) 
1,2,3 Substance use disorders (23) HDD 1: ICD-9-CM codes: 291, 292, 303, 304, 305.0, 
305.2-305.7, 305.9;  
0: Otherwise, No (reference) 
 
Aim 2  
Severe Maternal Morbidity at Delivery 
The main independent variable in Aim 2 was SMM at delivery, as described 
above as the dependent variable in Aim 1. SMM was considered both with and without 
the blood transfusion indicator in all analyses. In addition, the number of SMM indicators 
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was examined as a sensitivity analysis on a scale of 0, 1, or 2+ indicators to further 
understand the relation between SMM at delivery hospitalization and postpartum hospital 
encounters.  
Aim 3  
Maternal Hypertensive Disorders and other Chronic and Pregnancy-associated 
Conditions at Delivery 
 In Aim 3, the main independent variable was maternal hypertensive disorders in 
pregnancy. In addition, other prevalent maternal chronic and pregnancy-associated 
conditions of asthma, autoimmune conditions, depression, gestational diabetes, pre-
existing diabetes, and substance use disorders were also examined as key variables, 
particularly in their relation to hypertensive disorders. These variables were described in 
more detail in Aim 1. 
Severe Maternal Morbidity at Delivery 
Another key variable in Aim 3 was SMM at delivery, as described above as the 
main dependent variable in Aim 1 and the main independent variable in Aim 2. Similar to 
Aim 2, SMM was considered both with and without the blood transfusion indicator in all 
analyses. In addition, the number of SMM indicators was examined as a sensitivity 
analysis on a scale of 0, 1, or 2+ indicators to further understand the relation between 
SMM at delivery hospitalization and postpartum hospital encounters. 
Other Covariates 
Main covariates, including social and biological variables, were informed by the 
conceptual model available on either vital records or hospital discharge data: mother’s 
age, race/ethnicity, maternal education, insurance delivery payer, calendar time, hospital 
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level, prenatal care initiation, parity, plurality, current low birth weight delivery, 
smoking, method of delivery, marital status, and congenital cardiac disease (Table 3.4). 
These covariates were ascertained from the birth certificate and, if available, also from 
the hospital discharge delivery record. For Aims 2 and 3, an additional covariate of length 
of stay of delivery hospitalization was included. Description of covariates was based on 
data for Aim 1 for deliveries from 2000-2012, which was inclusive of the data for Aims 2 
and 3. 
Year of delivery was based on the birth certificate and fetal death records to represent the 
calendar year of delivery. The largest number of births occurred in 2000 and the least in 
2012, with an overall decrease by 11.1% over the time period, reflecting overall declines 
in birth rates. 
Hospital level was based on the facility of birth information on the birth certificate and 
fetal death records. MDPH staff in the Office of Data Translation in the Bureau of Family 
Health and Nutrition have aligned facilities with hospital designations from 2000-2012.  
Level I facilities are those providing basic care; Level 2 represents facilities with 
specialty care; and Level III, facilities with subspecialty care (24). Information on 
hospital level was either missing (0.05%) or other (0.15%) in 0.20% of records. 
Race/ethnicity was obtained from the birth and fetal death records and defined by five 
categories: 1) Hispanic; 2) non-Hispanic white; 3) non-Hispanic black; 4) Asian/Pacific 




Maternal age at delivery was obtained from the birth and fetal death records as a 
continuous variable. The mean age of women in the study was 29.7 years with a standard 
deviation of 6.06 and ranges from 10-61 years. There was 0.00001% missing data for this 
variable. For analytic purposes and to align with previous studies, maternal age was 
defined as five dichotomous variables based on six groups: <20 years, 20-24 years, 25-29 
years, 30-34 years, 35-39 years, and 40+ years, with the reference group of 25-29 years. 
Maternal education was obtained from birth certificate and fetal death records. Data was 
collected differently for 2000-2010 and 2011-2012 due to the adoption of the 2003 US 
Standard Certificate of Live Birth in 2011. This variable was defined by four categories: 
college or more, some college, high school graduate, or less than high school. College or 
more was derived from “Bachelor’s” or “Post-Graduate” coding for the 2000-2010 
maternal degree variable and “Bachelor’s Degree,” “Master’s Degree,” or “Doctorate or 
Professional Degree” in the 2011-2012 data. Some college was defined based on 
“Associate” or “Certificate/other” coding in the 2000-2010 maternal degree data and 
“Some college credit but no degree,” and “Certificate,” or “Associate Degree” in the 
2011-2012 data. High school graduation was “High school” or “GED,” in maternal 
diploma coding or “12 years of education” in the years of maternal education variable 
from the 2000-2010 records and the “High school graduate or GED completed” maternal 
education variable in 2011-2012. Less than high school was defined by “No high school” 
in the maternal diploma category in 2000-2010 data and “8
th





grade, no diploma” in the 2011-2012 data. If there was no information, the variable was 




Payer source was informed by both the hospital delivery discharge record and the birth 
certificate and fetal death records to capture the insurance payer source at delivery. Payer 
source was a categorical variable with four categories: private, public, self-pay, and free 
care. When both sources agreed on delivery payer (86.2% of deliveries), then the payer 
source was so assigned. If they did not agree, payer source was defined hierarchically, 
first by any indication in either source of public, then self-pay, then free care, then 
private. If there was no information in either data source, the variable was then 
categorized as missing (0.00004%). Private insurance at delivery was the most common 
type and assigned as the reference category. 
Cigarettes during pregnancy information was obtained from birth certificate and fetal 
death records, were assessed differently assessments in 2000-2010 and 2011-2012. In 
2000-2010, tobacco use during pregnancy was measured by the number of cigarettes per 
day in the year prior to pregnancy and during pregnancy. In 2011-2012, the question 
asked about smoking by trimester, including the three months prior to pregnancy. To 
ensure comparability across years, smoking was measured as a dichotomous variable to 
capture any smoking during pregnancy. From 2000-2010, any non-zero value indicated 
smoking during pregnancy as did any non-zero value in any trimester from 2011-2012. 
There was 0.18% missing data for this variable. No smoking during pregnancy was 
assigned as the reference category. 
Marital status was obtained from birth certificate and fetal death records to indicate status 
at delivery. Marital status had three categories: married, not married, or previously 
married within 300 days of birth. To align with previous research, this variable was 
defined as a dichotomous, married and not married; the latter included the previously 
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married category. Not married was the reference category and there was 0.02% missing 
data. 
Parity was obtained from birth certificate and fetal death records to include previous 
pregnancies carried to a viable gestational age. It is calculated from the number of 
previous live births and previous fetal deaths plus one. The mean parity was 1.9 with a 
standard deviation of 1.1. For analytic purposes this variable was defined by three 
categories, parities one, two, and three or more, with primiparity as the reference group. 
There was 0.49% missing data for this variable.  
Prenatal care was obtained from birth certificate and fetal death records from the variable 
assessing the month prenatal care began. The mean month of prenatal care initiation was 
2.9 months with a standard deviation of 1.3. To align with previous studies, this variable 




  and 3
rd
  trimester  initiation. There was 1.26% 
missing data for this variable. Prenatal care initiation in the 1
st
 trimester of pregnancy was 
the reference group. 
Plurality was obtained from birth certificate and fetal death records to capture the number 
of fetuses in the pregnancy. The mean was 1.02 with a standard deviation of 0.16 and 
range of 1-5 gestations. This variable was defined by three categories: singleton delivery, 
twin delivery, triplet delivery or greater. There were no missing data for this variable. 
The reference category was a singleton delivery. 
Maternal cardiac disease was obtained from both birth certificate and fetal death records 
and the hospital delivery discharge ICD-9-CM diagnosis coding. If cardiac disease was 
indicated on the birth certificate or fetal death record or any ICD-9-CM codes were listed 
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in the fifteen potential hospital delivery discharge record (Codes: 746.84, 746.86, 746.89, 
746.9, V13.65), then maternal cardiac disease was defined as present; if no indication, it 
was considered to be absent; as a result, there was no missing data for this indicator. No 
cardiac disease was the reference group for this variable. 
Low birth weight delivery was based on the birthweight at time of delivery reported on 
birth certificate and fetal death records. Low birthweight (LBW) was defined as any 
delivery less than 2500 grams. In cases of multiple deliveries, any LBW delivery was 
coded as a LBW. There was 0.43% missing data for this variable. The reference category 
was a non-LBW delivery. 
Method of Delivery was obtained from both the hospital delivery discharge record and 
the birth certificate and fetal death records and defined by four categories: vaginal, 
vaginal birth after cesarean (VBAC), cesarean, and repeat cesarean delivery. Data from 
both sources agreed in 83.48% of deliveries. Data was available from only one data 
source in 13.24% of deliveries. In the remaining deliveries with discordant information, 
data from the hospital discharge record was used. There was 0.07% missing records for 
this variable. Vaginal deliveries were used as the reference group. 
Length of stay at delivery hospitalization was obtained from the hospital delivery 
discharge record. Stays between 1-2 days were the referent category. Table 3.4 shows 





Table 3.4 Covariates, Data Sources and Coding 
Proximate and distal factors 
Aim Variable Source Numeric/Categorical Response Categories  
1,2,3 Year of delivery Linkage Aim 1:  
1: 2000-2002 (reference) 
2: 2003-2006,  
3: 2007-2009,  
4: 2010-2012,  
Aims 2-3:  
1: 2002-2003 (reference),  
2: 2004-2005,  
3: 2006-2007,  
4: 2008-2009,  
5: 2010-2011 
1,2,3 Hospital Level BC, FD, 
HDD 
1: Level I,  
2: Level II,  
3: Level III (reference),  
1,2,3 Race/ethnicity BC, FD 1: Hispanic,  
2: non-Hispanic white (reference), 
3: non-Hispanic black,  
4: Asian/Pacific Islander,  
5: Native American or Other 
1,2,3 Maternal age at delivery 
(years) 
BC, FD 1: <20,  
2: 20-24, 
3: 25-29 (reference)  
4: 30-34,  
5: 35-39,  
6: 40+ 
1,2,3 Maternal education BC,FD 1: None,  
2: HS or GED (reference),  
3: Some college, 
4: College or above 




1: Private (reference),  
2: Public,   
3: Self-pay,  
4: Free care 
1,2,3 Cigarettes daily during 
pregnancy 
BC FD 0: None (reference),  
1: Any 
1,2,3 Marital status BC,FD 0: Unmarried (reference),  
1: Married 
1,2,3 Parity  1: 1 (reference),  
2: 2,  
3: 3+ 
1,2,3 Trimester of prenatal care 
initiation 
BC,FD 0: None 
1: 1
st







1,2,3 Plurality BC,FD 1: Singletons (reference),  
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2: Twins,  
3: Triplets or more 
1,3 Cardiac disease BC, FD, 
HDD 
1: BC flag or ICD-9 code for congenital cardiac 
disease: 746.84, 746.86, 746.89, 746.9, V13.65; 
0: Otherwise, no (reference) 
Morbidity at delivery 
1,2,3 Low Birthweight delivery 
(grams) 
BC, FD 0:  ≥2500g (reference) 
1: <2500 grams, 
1,2,3 Method of Delivery BC, FD, 
HDD 
1: Vaginal (reference) 
2: Vaginal Birth After Cesarean,  
3: Primary cesarean,  
4: Repeat cesarean 
1,2,3 Severe maternal morbidity HDD See Table 3. for full ICD-9-CM coding  
1,2,3 Length of stay at delivery HDD 1: 1-2 days (reference),  
2: 3-4 days,  
3: 5+ days 
2,3 Type of stay HD, ED, OS HD: 1: HD flag, 0: Otherwise 
OS: 1: OS flag; 0: Otherwise 
ED: 1: ED flag; 0: Otherwise 
2,3 Principal condition present HD, ED, OS ICD-9-CM coding to inform other variables 
2,3 Principal diagnosis code HD, ED, OS ICD-9-CM coding to inform other variables 
2,3 Principal procedure code HD ICD-9-CM coding to inform other variables 
2,3 Diagnosis codes HD, OS, ED ICD-9-CM coding (15 fields HD; 6 fields OS; 6 
fields ED) 
2,3  Procedure codes HD, OS, ED ICD-9-CM coding (15 fields HD; 6 fields OS; 6 
fields ED) 
2,3 Admission date HDD, HD, 
OS, ED 
Date 
2,3 Discharge date HDD, HD, 
OS, ED 
Date 
2,3 Date of death Death Date 
 
Data Evaluation 
The Massachusetts birth certificate prior to 2011 did not include a field for 
maternal weight or height; therefore, the only consistent source for obesity data was the 
ICD-9-CM coding on the delivery hospitalization for the entire study period. If obesity 
was listed as an ICD-9–CM code during the delivery hospitalization, the variable was 
coded as dichotomous, obese versus non-obese. Analyses were conducted with post-2011 
data to examine obesity from data on the birth certificate for the maternal height and 
weight variables compared to obesity codes captured in the hospital discharge data. This 
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analysis revealed limited validity of the obesity data on the hospital delivery discharge 
record. Comparisons of information from ICD-9-CM coding in the hospital delivery 
discharge record and birth certificate data in 2011-2012 were inconsistent with only a 
16.6% match of ICD-9-CM obesity coding in 2011-2012 to the obesity measure derived 
from the height and weight data in the birth certificate records; therefore, obesity was not 
included in analyses.  
Missing data was also evaluated for the variables when possible. For variables 
informed only by ICD-9-CM diagnosis or procedure codes, investigations into 
missingness were not feasible; if a code was not present on any of the diagnosis and/or 
procedure codes, it was considered absent, not missing. Variables from the birth 
certificate, with the exception of prenatal care initiation, had missing values for less than 
one percent of records; missingness ranged from 0.00001% (maternal age) to 1.26% 
(prenatal care trimester of initiation). Due to the low prevalence of missingness across the 
data, multiple imputation was not considered (25), and deliveries with missing data were 
excluded in multivariate analyses. For multivariate analyses, in Aim 1, 97.8% of 
observations were used (n=940,982); in Aim 2, 99.0% of observations were used 
(n=678,677); and in Aim 3, 98.3% of all observations were used (n=723,061). 
Statistical Methods 
Aim 1 
The analysis of data involved several steps, the first of which was descriptive. 
Frequencies of each category of hypertension and chronic conditions were estimated by 
delivery hospitalization and examined for trends over the study period. Similarly, the 
criteria defining SMM based on ICD-9-CM codes were applied and frequencies of the 
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contributing diagnoses and procedures to SMM were estimated and examined over the 
study period. The prevalence of subcategories of hypertensive disorders in pregnancy and 
the rate of SMM for each was then estimated. Metric covariates, such as maternal age, 
were categorized based on clinically meaningful and interpretable cut points informed by 
previous research. The prevalence of hypertensive disorders in pregnancy was then 
described by social and biological characteristics. 
Bivariate relations between maternal hypertensive disorders in pregnancy and 
SMM with the social and biological covariates were examined using Wald 𝜒2 tests. 
Significant changes in trends over time were assessed through Cochrane-Armitage tests. 
For all analyses, statistical significance was assessed at p ≤ 0.05. A priori confounders 
from the conceptual model included were: maternal age, race/ethnicity, maternal 
education, insurance delivery payer, calendar time, hospital size, prenatal care initiation, 
parity, plurality, current LBW weight delivery, smoking during pregnancy, cardiac 
disease, and marital status. Of particular interest was the relation between chronic 
conditions, hypertensive disorders, and severe maternal morbidity. Additional variables 
that were significant in Wald tests were included initially in the multivariable analyses.  
Logistic multivariable regression models of SMM with and without blood 
transfusion used a generalized estimating equations (GEE) approach to account for 
multiple deliveries by the same woman over the study period. The GEE approach is an 
alternative to maximum likelihood (ML) estimation that allows for analyzing correlated 
responses by incorporating the covariance matrix of the vector of responses (26). 
Adjusted odds ratios of SMM for hypertensive disorders in pregnancy as well as other 
chronic conditions were estimated along with 95% confidence intervals. A second model 
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examined the outcome of cardiac-specific SMM, using the same methods as described 
above. A priori interaction terms were proposed to examine relations between 
hypertensive disorders with other chronic and pregnancy-associated conditions, age, and 
race/ethnicity.  
Model fit was assessed using quasi-likelihood scores and multicollinearity by 
variance inflation factors on a linear multivariable regression model (27, 28). The 
correlation of outcomes among women with multiple deliveries over the study period was 
examined through matrices. Exchangeable (𝑟𝑖𝑗,𝑖𝑗′ = 𝑝, 𝑗 ≠ 𝑗
′), autoregressive (𝑟𝑖𝑗,𝑖𝑗′ =
𝑝|𝑡𝑖𝑗−𝑡𝑖𝑗′|), and unstructured (𝑟𝑖𝑗,𝑖𝑗′ = 𝜌𝑗𝑗′) matrices were explored to model within 
subject correlation. All analyses were performed sequentially using SAS 9.3 (Cary, NC).  
An example of a model estimated for Aim 1 is shown below.  
Example: Logistic Regression Model with GEE Approach of Severe Maternal Morbidity 
(SMM) with chronic hypertension as a predictor of interest  
Let 𝑌𝑖𝑗 = 1 if the 𝑗
𝑡ℎ delivery had severe maternal morbidity in the 𝑖𝑡ℎ woman, and 




} =  𝛽0 +  𝛽1𝐶ℎ𝑟𝑜𝑛𝑖𝑐𝐻𝑇𝑁𝑖𝑗 +  𝛽2𝐺𝑒𝑠𝑡𝐻𝑇𝑁𝑖𝑗 + 𝛽3𝑀𝑃𝐸𝑖𝑗 + 𝛽4𝑆𝑃𝐸𝑖𝑗 +





} = average log odds of SMM at delivery across women;  
𝛽0 = log odds of SMM at delivery for women without a diagnosis of hypertension in 
pregnancy (coded as 0) and with all other variables in the referent category;  
𝛽1 = difference in log odds of SMM at delivery for women with chronic hypertension 
(coded as 1) versus women without chronic hypertension (coded as 0), adjusting for all 
other variables in the equation; and 
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Ɛ𝑖𝑗  ~ 𝑁(0, 𝜎
2). 
The odds ratio of SMM at delivery for women with chronic hypertension versus those 
without chronic hypertension adjusting for all other variables in the equation was 
calculated through 𝑒𝛽1 . 
 
Aim 2 
In Aim 2, the population was restricted to women without chronic medical 
conditions, specifically asthma, autoimmune conditions, chronic hypertension and pre-
exiting diabetes, based on results from Aim 1. Exploratory data analyses were first 
conducted to understand the relation between SMM at delivery and hospitalization in the 
year postpartum. Analyses first described all one year and six week postpartum hospital 
encounters by visit and by delivery over the study period. Injury- and antenatal-related 
encounters were described and then excluded from further analysis. Exploratory analyses 
also examined deliveries to women who died during the first year post-delivery and when 
they died; sensitivity analyses considered exclusion of maternal death. Analyses 
described the type of postpartum hospital encounter by number, postpartum timing, and 
primary diagnoses. The first three digits of the ICD-9-CM principal diagnosis codes were 
extracted for each type of encounter to describe the main causes of hospital utilization. 
Next, analyses assessed each type of encounter within six weeks and one year by SMM. 
Bivariate relations between SMM and at least one hospital encounter with the social and 
biological variables were examined through Wald χ
2
 tests. Trends over time were 
assessed through Cochrane-Armitage tests. All analyses used significance p ≤ 0.05. 
Log-binomial multivariable regression models of the relation of SMM with 
hospital encounters were estimated using a GEE approach to account for multiple 
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deliveries by the same woman over the study period. These models were adjusted for a 
priori and statistically significant confounders from the bivariate analyses. The log link 
required for log-binomial regression initially did not converge in multivariable regression 
models, as the link does not ensure that predicted probabilities are mapped to the [0,1] 
range that is required for probabilities; to assure convergence of the multivariable log-
binomial regression models, a negative intercept of 4 was used to start estimation as 
suggested in previous research (29).  
Model fit and selection was informed through quasi-likelihood statistics (QIC), 
which is analogous to Akaike Information Criterion (AIC) statistics when using a 
generalized estimating equations (GEE) approach (28). Multicollinearity was assessed 
through variance inflation factors (VIF) on a linear regression scale; variables were 
considered for exclusion from the model if the mean VIF was greater than 10 (27). 
Previous analyses informed within-subject correlation of outcomes over the study period 
through correlation matrices. Sensitivity analyses examined SMM with and without 
blood transfusion as well as SMM categorized by total number of indicators (0, 1, 2+). 
Example: Log Binomial Regression Model with GEE Approach of Hospital Readmission 
within Six Weeks with Severe Maternal Morbidity (SMM) as a predictor of interest  
Let 𝑌𝑖𝑗 = 1 if the 𝑗
𝑡ℎ delivery had a hospital readmission within six weeks postpartum in 
the 𝑖𝑡ℎ woman, and 𝑌𝑖𝑗 = 0 otherwise.  
𝐿𝑜𝑔(Pr (𝑌𝑖𝑗 = 1|𝑏𝑖1, 𝑏𝑖2)) =  𝛽0 +  𝛽1𝑆𝑀𝑀𝑖𝑗 +  𝛽2𝐴𝑔𝑒𝑖𝑗 +  𝛽3𝑅𝑎𝑐𝑒𝑖 … + 𝛽𝑝𝑋𝑝𝑖𝑗 +  Ɛ𝑖𝑗  
where: 
𝐿𝑜𝑔(Pr (𝑌𝑖𝑗 = 1|𝑏𝑖1, 𝑏𝑖2)) = average log risk of hospital discharge record within six 
weeks postpartum across women;  
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𝛽0 = log relative risk of hospital readmission within six weeks postpartum without SMM 
(coded as 0) and with all other variables in the referent category;  
𝛽1 = difference in log risks of hospital readmission within six weeks postpartum for 
women with SMM at delivery (coded as 1) versus women without SMM at delivery 
(coded as 0), adjusting for all other variables in the model; and 
Ɛ𝑖𝑗  ~ 𝑁(0, 𝜎
2). 
The relative risk of hospital readmission within six weeks postpartum for women with 
SMM at delivery versus women without SMM at delivery adjusting for all other variables 
in the model was calculated through 𝑒𝛽1 . 
 
Aim 3 
For Aim 3, women with chronic medical conditions were included in the study 
population to capture all deliveries to MA resident women from 2002-2011 and capture 
all non-injury and non-antenatal-related postpartum rehospitalizations within one year. 
As described in Aim 2, preliminary analyses described the overall rate of hospitalization 
for each type of encounter within six weeks and one year by delivery. The prevalence of 
each type of rehospitalization within the first six weeks and one year post-delivery was 
then described by maternal hypertensive disorders and SMM at delivery. Measures of 
SMM and hospital encounters were compared by a priori confounders from the 
conceptual model in bivariate analyses through chi-square tests; they included social and 
biological confounders listed in previous aims. Variables that were significant in Wald 
tests (p<0.05) were included initially in the multivariable analyses.  
Modified Poisson regression models were used for multivariable analyses with a 
generalized estimating equations approach, after initial log-binomial regression models 
failed to converge (30). The main exposures were hypertensive disorders and other 
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chronic and pregnancy-associated conditions as in Aim 1 as well as SMM as in Aim 2. 
The main dependent variable was hospitalization by type (hospital discharge, 
observational stay, emergency department) within both six weeks and one year 
postpartum. Interactions were evaluated to determine if SMM at delivery modified the 
relation between maternal hypertensive disorders, as categorized in Aim 1, and 
postpartum hospital utilization, with significance assessed at p <0.05. Stratified analyses 
by SMM examined if there were differences in the risk of rehospitalization on maternal 
hypertensive disorder subtypes. 
Sensitivity analyses examined SMM with and without blood transfusion as well 
as SMM categorized by total number of indicators (0, 1, 2+). Sensitivity analyses also 
examined whether SMM mediated the relation between maternal hypertensive disorders 
and rehospitalization. These regression models provided adjusted relative risks for 
hospital encounters within six weeks and one year postpartum with 95% confidence 
intervals estimated for exposures of interests. 
Example: Poisson Regression Model with GEE Approach of Hospital Readmission 
within Six Weeks with chronic hypertension as a predictor of interest  
Let 𝑌𝑖𝑗 = 1 if the 𝑗
𝑡ℎ delivery had a hospital readmission within six weeks postpartum in 
the 𝑖𝑡ℎ woman and 𝑌𝑖𝑗 = 0 otherwise.  
𝐿𝑜𝑔 (Pr (𝑌𝑖𝑗 = 1|𝑏𝑖1, 𝑏𝑖2))  =  𝛽0 +  𝛽1𝐶ℎ𝑟𝑜𝑛𝑖𝑐𝐻𝑇𝑁𝑖𝑗 +  𝛽2𝐺𝑒𝑠𝑡𝐻𝑇𝑁𝑖𝑗 + 𝛽3𝑀𝑃𝐸𝑖𝑗 +
𝛽4𝑆𝑃𝐸𝑖𝑗 + 𝛽5𝑆𝐼𝑃𝐸𝑖𝑗 + 𝛽6𝑅𝑎𝑐𝑒𝑖 +  𝛽7𝐴𝑔𝑒𝑖𝑗 … +  𝛽𝑝𝑋𝑝𝑖𝑗 +  Ɛ𝑖𝑗  
where: 
𝐿𝑜𝑔 (Pr (𝑌𝑖𝑗 = 1|𝑏𝑖1, 𝑏𝑖2)) = average log risk of hospital readmission within six weeks 
postpartum across women;  
𝛽0 = log relative risk of hospital readmission within six weeks postpartum without 
chronic hypertension (coded as 0) and with all other variables in the referent category;  
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𝛽1 = difference in log risks of hospital readmission within six weeks postpartum for 
women with chronic hypertension (coded as 1) versus women without chronic 
hypertension (coded as 0), adjusting for all other variables in the model; and 
Ɛ𝑖𝑗  ~ 𝑁(0, 𝜎
2). 
The relative risk of hospital readmission within six weeks postpartum for women with 
chronic hypertension versus women without chronic hypertension adjusting for all other 
variables in the model was calculated through 𝑒𝛽1 . 
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This chapter describes the findings for each study aim: 1) Evaluate the relation of 
maternal hypertensive disorders and other chronic and pregnancy-associated conditions 
in pregnancy with severe maternal morbidity at delivery; 2) Evaluate the relation between 
severe maternal morbidity at delivery and postpartum maternal rehospitalization in the 
year following delivery among deliveries to women without chronic medical diseases; 
and 3) Evaluate the relation between maternal hypertensive disorders and other chronic 
and pregnancy-associated conditions in pregnancy with postpartum maternal 
rehospitalization in the year following delivery, independent of severe maternal 
morbidity at delivery. 
 This chapter begins with a description of the study populations for the three aims, 
followed by a description of the main dependent variables in these analyses, severe 
maternal morbidity (SMM) at delivery and hospital utilization in the first six weeks and 
year postpartum. Next, for each study aim, the bivariate and confounder analyses will be 




During 2000-2012, there were 980,962 deliveries to resident women in 
Massachusetts with linked birth certificate/fetal death records and hospital delivery 
discharge records. Deliveries decreased 11.1% over the study period, from 78,171 in 
2000 to 69,493 in 2012 (Figure 4.1). These linked deliveries represented 99.0% of 
resident deliveries in the state. The 980,962 deliveries were to 642,874 unique women; 
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60.8% of these women had one delivery over the study period and 39.2% had two or 
more deliveries.  
Figure 4.1 Linked Deliveries by Year, MA women 2000-2012 
 
The characteristics of the study sample for all aims are shown in Table 4.1. The 
majority of deliveries across all aims were to women 25-34 years of age (56%), non-
Hispanic white women (68%), with at least a high school education (89%), who were 
privately insured (60%) and who were married (68%). Just under half of deliveries were 
to primiparous women (45%) and almost all were singleton deliveries (98%). Most 
deliveries occurred to women who received prenatal care in the first trimester (83%) and 
did not smoke cigarettes during pregnancy (92-93%). More than four in ten deliveries 




























Table 4.1 Descriptive Characteristics in Study Populations by Aim 









Overall %, N 
(N=960,982) 
Overall %, N 
(N=685,228) 
Overall %, N 
(N=735,576) 
Maternal age (years)    
     <20  6.0 (57,791) 6.0 (41,138) 6.0 (44,281) 
     20-24 15.7 (150,521) 15.9 (107,760) 15.8 (116,500) 
     25-29 24.1 (231,915) 24.2 (166,122) 24.1 (177,262) 
     30-34 31.8 (305,971) 31.6 (216,818) 31.5 (231,794) 
     35-39 18.2 (174,438) 18.1 (124,066) 18.2 (134,147) 
     40+ 4.2 (40,332) 4.1 (28,312) 4.3 (31,579) 
Race/ethnicity    
     Hispanic 14.1 (135,354) 14.0 (96,025) 14.2 (104,231) 
     NH White 68.2 (654,112) 68.0 (465,374) 67.8 (497,867) 
     NH Black  8.4 (80,992) 8.2 (56,105) 8.6 (62,854) 
     Asian/PI 7.4 (70,618) 7.8 (53,078) 7.5 (54,984) 
     Am. Indian/Other 1.9 (18,054) 2.0 (13,614) 2.0 (14,532) 
PNC month initiation    
     No PNC 0.3 (3011) 0.3 (2,199) 0.3 (2,355) 
     1st trimester 83.0 (787,587) 82.8 (561,014) 82.9 (602,801) 
     2nd trimester 13.9 (131,968) 14.1 (95,215) 14.0 (101,780) 
     3rd trimester 2.8 (26,270) 2.8 (19,072) 2.8 (20,233) 
Parity    
     1 45.2 (432,364) 45.4 (309,709) 45.3 (331,982) 
     2 35.3 (327,524) 34.5 (235,409) 34.3 (251,482) 
     3+ 20.5 (196,386) 20.1 (137,098) 20.3 (148,900) 
Plurality    
     Singleton 97.7 (938,830) 97.7 (669,570) 97.7 (718,355) 
     Twins 2.2 (21,430) 2.2 (15,168) 2.3 (16,680) 
     Triplets + 0.1 (722) 0.1 (490) 0.1 (541) 
Education    
     <HS 10.8 (103,727) 10.7 (73,430) 10.8 (79,236) 
     HS/GED 36.3 (347,955) 36.8 (251,618) 37.0 (271,803) 
     Some college 11.2 (107,352) 10.0 (68,007) 10.1 (73,783) 
     Bachelors + 41.7 (399,306) 42.5 (290,664) 42.1 (309,108) 
Cigarette Use during 
Pregnancy 
   
     No 92.3 (885,223) 92.8 (634,555) 92.6 (680,114) 
     Yes 7.7 (74,051) 7.2 (49,551) 7.4 (54,268) 
Hospital Level    
     Level 1 19.4 (185,804) 19.9 (135,866) 19.5 (142,905) 
     Level 2 37.7 (361,866) 38.0 (259,904) 37.2 (272,734) 
     Level 3 42.9 (411,491) 42.1 (288,111) 43.4 (318,530) 
Method of Delivery    
     Vaginal 67.5 (647,996) 67.3 (461,001) 66.6 (489,698) 
     VBAC 2.4 (22,684) 2.1 (14,499) 2.1 (15,516) 
     Primary C-section 18.0 (173,106) 18.3 (124,987) 18.7 (137,193) 
     Repeat C-section 12.1 (116,492) 12.3 (84,077) 12.6 (92,481) 
Marital Status    
     Married at delivery 68.3 (656,183) 68.2 (466,875) 67.7 (497,673) 
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     Not married  31.7 (304,617) 31.9 (218,210) 32.3 (237,747) 
Insurance Delivery Payer    
     Private 60.2 (578,765) 60.1 (411,556) 59.7 (439,103) 
     Public 37.7 (361,800) 38.1 (264,280) 38.5 (283,008) 
     Free care 1.1 (10,341) 1.0 (6,776) 1.0 (7,372) 
     Self-pay 1.0 (10,037) 0.8 (5,584) 0.8 (6060) 
Low birth weight    
     No 93.2 (891,939) 93.4 (637,625) 93.1 (681,673) 
     Yes 6.8 (64,929) 6.6 (44,736) 6.9 (50,703) 
Diabetes    
     Pre-existing diabetes 1.1 (10,951) -- 1.2 (8,747) 
     Gestational diabetes 5.1 (49,259) 5.0 (34,436) 5.2 (37,989) 
     None 93.7 (900,772) 95.0 (650,792) 93.7 (688,840) 
Asthma 3.4 (32,678) -- 3.5 (25,392) 
Depression 2.6 (24,949) 2.5 (16,892) 2.8 (20,475) 
Substance use 1.4 (13,250) 1.3 (9,170) 1.4 (10,437) 
Autoimmune conditions 0.7 (6,714) -- 0.7 (5,237) 
Congenital cardiac 
disease 
0.8 (7,194)  0.7 (5184) 
 
During the study period for Aim 1, 8.7% of deliveries had a reported diagnosis of 
a maternal hypertensive disorder. Gestational hypertension was the most common form 
of hypertensive disorder (3.7%), followed by mild preeclampsia (2.0%), chronic 
hypertension (1.6%), severe preeclampsia (1.1%), and superimposed preeclampsia 
(0.3%). All maternal hypertensive disorders, with the exception of mild preeclampsia, 
increased during the study period (p <0.0001 for trend) (Figure 4.2). Overall, any 
maternal hypertensive disorders increased among deliveries from 7.7% in 2000 to 10.0% 
in 2012. 
The most common maternal chronic conditions among deliveries were asthma 
(3.4%) and depression (2.6%), followed by substance use disorders (1.4%), pre-existing 
diabetes (1.2%) and autoimmune conditions (0.7%). Gestational diabetes (5.1%) was the 
most common pregnancy-associated condition. All chronic conditions and pregnancy-









































































Aim 2  
The population for Aims 2 and 3 was confined to years 2002-2011; 2002 was the 
first year for which all types of postpartum data were available and 2011 was the last year 
for which follow-up for one year postpartum was possible. There were 735,576 deliveries 
with linked hospital delivery and birth certificate/fetal death records to resident women in 
Massachusetts between 2002 and 2011. For Aim 2, deliveries to women with chronic 
medical conditions prior to pregnancy that were associated with SMM at delivery were 
excluded from the study population. Based on Aim 1 results, these conditions included: 
chronic hypertension, superimposed preeclampsia, pre-existing diabetes, autoimmune 
conditions and asthma, (n=50,348) for a final population for this aim of 685,228. The 
final population represents 93.2% of the linked birth certificate/fetal death records with 
hospital delivery discharge data from 2002-2011 and 92.2% of all hospital deliveries. 
Descriptive characteristics for deliveries for Aim 2 mirrored those from Aim 1 
(Table 4.1). The SMM rate was 99 per 10,000 deliveries during the study period; without 
transfusion, the SMM rate was 43 per 10,000. Both SMM rates increased over the study 
period (p<0.0001 for trend). Among deliveries to women with SMM at delivery, 85.4% 
had one SMM indicator, 9.6% had two SMM indicators, and 5.1% had two or more 
SMM indicators.  
Aim 3 
For Aim 3, all deliveries identified in hospital delivery and birth certificate/fetal 
death records from 2002-2011 were included for a study population of 735,576. 
Descriptive characteristics for deliveries for Aim 3 mirrored those from Aim 1 (Table 
4.1). Maternal hypertensive disorders were present in 8.8% of deliveries to women during 
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the study period: 3.8% had gestational hypertension, 2.0% had mild preeclampsia, 1.6% 
had chronic hypertension, 1.1% had severe preeclampsia, and 0.3% had superimposed 
preeclampsia. Among deliveries with reports of other chronic and pregnancy-associated 
conditions, 5.2% had gestational diabetes, 3.5% had asthma, 1.2% had preexisting 
diabetes, and 0.7% had autoimmune conditions.   
 In Aim 3, the rate of SMM at delivery was 106.2 per 10,000 delivery 
hospitalizations; without transfusion, the rate of SMM at delivery hospitalization was 
47.0 per 10,000 delivery hospitalizations.  
 
Aim 1 
Dependent Variable: SMM 
 
The overall rate of SMM was 101.9 per 10,000 deliveries. The rate increased from 
59 per 10,000 in 2000 to 145 per 10,000 in 2012 (Figure 4.4). This rate reflects the 
recalculation of SMM to consider length of stay by method of delivery. Without this 
recalculation, the overall SMM rate of all twenty-five indicators was 125.4 per 10,000 
deliveries. Excluding blood transfusion, the rate of SMM was 46.0 per 10,000 deliveries 
across the study period; it also increased significantly during the study period (p<0.001). 
The rate of increase was greater for SMM including transfusion. Without recalculation 
for length of stay by method of delivery, the SMM rate without blood transfusion was 
71.4 per 10,000 deliveries.  
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Figure 4.4 Rates of Severe Maternal Morbidity with and without Blood Transfusion 
at Delivery by Year, Deliveries to MA Women 2000-2012 
 
SMM25R: SMM with blood transfusion 
SMM24R: SMM without blood transfusion 
 
Table 4.2 shows the percentage of deliveries with each SMM indicator. The most 
common SMM conditions and procedures were blood transfusion (67.5 per 10,000 
deliveries), heart failure (8.6 per 10,000 deliveries), operations on the heart and 
pericardium (8.4 per 10,000 deliveries), and disseminated intravascular coagulation (8.1 
per 10,000 deliveries). The recalculation criteria, which adjusted for length of stay based 
on method of delivery, had the greatest impact on the indicators of severe anesthesia 
complications and heart failure during procedure or surgery.  
Table 4.2 Severe Maternal Morbidity at Delivery Indicators, Deliveries to MA 
Women 2002-2012 
Classification 
% deliveries (n) Severity Recalculated
1 
% deliveries (n) 
1. Acute myocardial infarction 0.00 (26) 0.00 (20) 
2. Acute renal failure 0.05 (478) 0.04 (358) 
3. Adult respiratory distress syndrome 0.03 (331) 0.03 (276) 
4. Amniotic fluid embolism 0.00 (40) 0.00 (30) 
5. Aneurysm 0.00 (19) Suppressed
2 
6. Cardiac arrest/ventricular fibrillation 0.01 (54) 0.00 (44) 
7. Disseminated intravascular coagulation 0.14 (1378) 0.08 (776) 
8. Eclampsia 0.05 (458) 0.03 (283) 
9. Heart failure during procedure or surgery 0.21 (1999) 0.09 (830) 













































12. Puerperal cerebrovascular disorders 0.04 (350) 0.02 (187) 
13. Pulmonary edema 0.01 (138) 0.01 (108) 
14. Severe anesthesia complications 0.02 (224) 0.01 (91) 
15. Sepsis 0.02 (278) 0.02 (247) 
16. Shock 0.03 (243) 0.02 (178) 
17. Sickle cell anemia with crisis 0.01 (79) 0.01 (68) 
18. Thrombotic embolism 0.02 (183) 0.02 (150) 
19. Blood transfusion 0.67 (6,482) -- 
20. Cardio monitoring 0.01 (69) -- 
21. Conversion of cardiac rhythm 0.00 (42) -- 
22. Hysterectomy 0.07 (676) -- 
23. Operations on heart and pericardium 0.08 (807) -- 
24. Temporary tracheostomy 0.00 (12) -- 
25. Ventilation 0.05 (502) -- 
Overall SMM (25 conditions) 1.25 (12,049) -- 
SMM (24 conditions; no blood transfusion) 0.71 (6,860)  
SMM 25 recalculated (based on LOS and MOD)  1.02 (9,793) 
SMM 24 recalculated (based on LOS and MOD)  0.46 (4,420) 
1 Recalculation based on length of stay was not applied to delivery hospitalizations with severe 
complications identified by procedure codes 
2 Cell suppression when <11 
Bivariate Results 
 
The highest rate of SMM among deliveries with hypertensive disorders was 817.8 
per 10,000 deliveries among deliveries to women with severe preeclampsia, followed by 
superimposed preeclampsia (567 per 10,000), mild preeclampsia (284 per 10,000), 
chronic hypertension (196 per 10,000) and gestational hypertension (142 per 10,000). 
Among deliveries to women with other chronic conditions, the rate of SMM was highest 
among those with autoimmune conditions (259.2 per 10,000 deliveries), followed by 
preexisting diabetes, substance use disorders, depression, asthma, and gestational 
diabetes (Figure 4.5). 
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Figure 4.5 Rate of SMM per 10,000 deliveries by Maternal Hypertensive Disorders 
and Chronic Conditions before and during Pregnancy, Deliveries to MA Women 
2000-2012 
 
Other social and biological characteristics were also associated with SMM at 
delivery, with all significant in Wald χ
2
 statistical tests (p<0.0001) (Table 4.3). Rates of 
SMM at delivery were elevated for deliveries to women older than 40 years of age (170.3 
per 10,000 deliveries), non-Hispanic black women (178.8 per 10,000), and women with 
less than high school education (125.5 per 10,000), and who were publicly insured (124.7 
per 10,000). 
Table 4.3 Severe Maternal Morbidity Rate by Social and Biological Characteristics, 
Deliveries to MA Women 2000-2012 
Characteristic SMM25 rate per 10,000 
deliveries 
 Overall 101.7 
Maternal age(years)  


































     20-24 96.8 
     25-29 93.4 
     30-34 90.4 
     35-39 118.0 
     40+ 170.3 
Race/ethnicity  
     Hispanic 126.3 
     Non-Hispanic White 86.0 
     Non-Hispanic Black  178.8 
     Asian/Pacific Islander 108.5 
     American Indian/Other 95.3 
PNC month initiation  
     No PNC 302.2 
     1st trimester 97.3 
     2nd trimester 109.8 
     3rd trimester 109.6 
Parity  
     1 108.5 
     2 82.8 
     3+ 116.5 
Plurality  
     Singleton 94.6 
     Twins 389.6 
     Triplets + 720.2 
Education  
     <High School 125.5 
     High School/GED 106.1 
     Some college 108.9 
     Bachelors + 87.9 
Cigarette Use   
     No  102.5 
     Yes 87.0 
Hospital Level  
     Level 1 82.9 
     Level 2 73.0 
     Level 3 134.5 
Method of Delivery  
     Vaginal 55.8 
     VBAC 96.1 
     Primary C-section 225.8 
     Repeat C-section 172.8 
Marital Status  
     Married at delivery 93.1 
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     Not married  119.6 
Insurance Delivery Payer  
     Private 86.9 
     Public 124.7 
     Free care 111.6 




Table 4.4 shows variation in maternal hypertensive disorders by social and 
biological characteristics as well as other chronic and pregnancy-associated conditions. 
With a sample of almost one million deliveries, all Wald χ
2
 analyses were significant 
(p<0.0001). Maternal age, education, race/ethnicity, prenatal care initiation, parity, 
plurality, cigarette use during pregnancy, hospital level, insurance payer, method of 
delivery, low birth weight delivery, marital status and all chronic and pregnancy-related 
chronic conditions were significantly associated with maternal hypertensive disorders. 
 
Table 4.4 Prevalence of Maternal Hypertensive Disorders by Social and Biological 
























Overall % (n=960,982) 91.3  0.3 1.1 2.0 1.6 3.7 
Maternal age (years)             
     <20  92.1 0.1 1.4 2.8 0.4 3.3 
     20-24 92.4 0.2 1.1 2.2 0.7 3.4 
     25-29 91.6 0.3 1.0 2.1 1.3 3.9 
     30-34 91.5 0.3 1.0 1.8 1.6 3.8 
     35-39 90.6 0.5 1.1 1.9 2.4 3.7 
     40+ 86.6 0.9 1.6 2.4 4.1 4.4 
Race/ethnicity             
     Hispanic 92.3 0.3 1.3 2.3 1.2 2.5 
     Non-Hispanic White 91.1 0.3 0.9 2.0 1.5 4.2 
     Non-Hispanic Black  87.8 0.8 1.9 2.5 3.3 3.7 
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     Asian/PI 95.3 0.2 0.7 1.2 0.7 1.9 
     Am. Indian/Other 91.7 0.3 1.3 2.3 1.3 3.1 
PNC month initiation             
     No PNC 90.9 0.7 2.2 2.1 1.9 2.3 
     1st trimester 91.2 0.3 1.0 2.0 1.6 3.8 
     2nd trimester 92.1 0.3 1.0 2.0 1.4 3.2 
     3rd trimester 93.1 0.3 0.9 1.7 1.3 2.8 
Parity             
     1 89.1 0.3 1.5 2.9 1.4 4.7 
     2 93.3 0.3 0.7 1.3 1.5 2.9 
     3+ 92.8 0.4 0.7 1.3 2.0 2.9 
Plurality             
     Singleton 91.9 0.3 1.0 1.9 1.6 3.7 
     Twins 78.4 0.8 5.0 7.9 2.0 5.9 
     Triplets + 68.8 0.8 9.6 12.9 2.2 5.7 
Education             
     <High School 92.7 0.3 1.1 2.0 1.1 2.9 
     HS/GED 91.1 0.4 1.1 2.2 1.6 3.7 
     Some college 89.9 0.4 1.1 2.2 2.1 4.2 
     Bachelors + 91.6 0.3 1.0 1.8 1.5 3.9 
Cigarette Use 93.3 0.2 0.6 1.5 1.3 3.0 
Hospital Level             
     Level 1 92.9 0.2 0.5 1.7 1.3 3.5 
     Level 2 92.6 0.2 0.7 1.7 1.2 3.7 
     Level 3 89.5 0.5 1.7 2.5 2.0 3.9 
Method of Delivery             
     Vaginal 92.9 0.2 0.6 1.7 1.3 3.4 
     VBAC 95.1 0.2 0.3 0.9 1.4 2.2 
     Primary C-section 84.8 0.7 3.0 3.9 2.2 5.5 
     Repeat C-section 91.6 0.5 1.0 1.4 2.5 3.0 
Marital Status             
     Married at delivery 91.4 0.3 1.0 1.9 1.6 3.8 
     Not married  91.2 0.3 1.2 2.3 1.5 3.5 
Insurance Delivery Payer             
     Private 91.1 0.3 1.0 2.0 1.6 4.1 
     Public 91.8 0.4 1.2 2.1 1.5 3.1 
     Free care 89.2 0.6 1.4 2.5 2.2 4.2 
     Self-pay 89.7 0.5 1.3 2.3 2.4 3.7 
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Low birth weight 77.4 1.9 8.4 5.3 2.7 4.4 
Gestational diabetes 77.4 1.9 8.4 5.3 2.7 4.4 
Asthma 84.4 0.9 1.8 3.4 3.8 5.7 
Depression 87.2 0.7 1.8 2.7 2.8 4.8 
Substance use 88.5 0.7 1.7 2.5 2.5 4.1 
Preexisting diabetes 92.0 0.5 1.1 1.7 1.7 3.0 
Autoimmune conditions 72.7 2.7 3.8 5.4 9.3 6.1 
Congenital cardiac disease 86.0 1.0 2.3 2.4 3.5 4.8 
1




The results of multivariable logistic regression analysis are presented in Table 
4.5. Adjusting for confounders and other chronic conditions, the odds of SMM were 4.08 
(95% CI: 3.71-4.48) for deliveries to women with severe preeclampsia, 2.65 (95% CI: 
2.23-3.15) for superimposed preeclampsia, 2.30 (95% CI: 2.09-2.53) for mild 
preeclampsia, 1.60 (95% CI: 1.46-1.75) for gestational hypertension and 1.50 (95% CI: 
1.32-1.70) for chronic hypertension compared to deliveries to women without 
hypertension. Excluding blood transfusion, the adjusted odds of SMM did not change 
markedly by type of hypertensive disorder; however there were differences in the 
magnitude of point estimates. When SMM was considered without blood transfusion, 
odds estimates were either the same or lower for all maternal hypertensive disorders, with 
the exception of superimposed preeclampsia, which was higher (from 2.65 to 3.34). 
Deliveries to women with autoimmune conditions showed the highest odds of 
SMM (aOR: 1.81; 95% CI: 1.54-2.14) among other chronic conditions (Table 4.5). 
Depression also was associated with increased odds of SMM (aOR 1.24; 95% CI: 1.11-
1.38). Pre-existing diabetes, asthma and substance use disorders were associated with 
slightly increased odds of SMM (p<0.05). The odds of SMM were not increased for 
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gestational diabetes. When transfusion was excluded, the odds of SMM remained 
significant only for autoimmune conditions, asthma and pre-existing diabetes. 
Table 4.5 Unadjusted and Adjusted Odds of Severe Maternal Morbidity at Delivery, 
Deliveries to MA Women, 2000-2012 
 Unadjusted OR of 
SMM 
(95% CI) 










Hypertensive disorders (Reference= 
None) 
   
     Superimposed PE 7.04 (6.02-8.22) 2.65 (2.23-3.15) 3.34 (2.72-4.10) 
     Severe preeclampsia 10.42 (9.66-11.23) 4.08 (3.71-4.48) 3.96 (3.48-4.50) 
     Mild preeclampsia 3.43 (3.14-3.74) 2.30 (2.09-2.53) 2.12 (1.84-2.45) 
     Chronic hypertension 2.37 (2.10-2.66) 1.50 (1.32-1.70) 1.50 (1.26-1.79) 
     Gestational hypertension 1.82 (1.67-1.99) 1.60 (1.46-1.75) 1.60 (1.40-1.83) 
Other chronic conditions 
(Reference=None) 
   
     Gestational diabetes 1.33 (1.23-1.44) 0.94 (0.86-1.03) 0.98 (0.87-1.11) 
     Asthma 1.55 (1.42-1.70) 1.12 (1.01-1.23) 1.18 (1.02-1.36) 
     Depression 1.67 (1.51-1.84) 1.24 (1.11-1.38) 1.12 (0.95-1.32) 
     Substance use disorder 1.74 (1.53-1.99) 1.20 (1.03-1.40) 1.23 (0.97-1.54) 
     Preexisting diabetes 2.52 (2.23-2.85) 1.17 (1.03-1.34) 1.27 (1.07-1.51) 
     Autoimmune conditions 2.61 (2.24-3.04) 1.81 (1.54-2.14) 2.13 (1.72-2.64) 
1
Adjusted for: race/ethnicity, education, age, hospital level, parity, plurality, prenatal care, cigarette use, 
method of delivery, insurance status, year, low birth weight, congenital cardiac conditions 
Bold indicates p<0.05. 
 
 Social and biological characteristics were also associated with increased odds of 
SMM (Table 4.6). Deliveries to women aged greater than thirty-five years had increased 
odds of SMM compared to deliveries to women aged 25-29 years. Deliveries to Hispanic 
and non-Hispanic black women also had increased odds of SMM compared to those for 
non-Hispanic white women. Deliveries to women with a bachelor’s degree or greater had 
decreased odds of SMM compared to those to women with a high school education. 
Deliveries to women on public insurance had increased odds of SMM at delivery 
compared to those on private insurance. The odds of SMM were greater among deliveries 
to women with no prenatal care compared to receipt of care in the first trimester. 
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Smoking during pregnancy was associated with decreased odds of SMM at delivery. 
Deliveries to women with higher-order multiples or LBW infants had a greater odds of 
SMM, while deliveries at lower level hospitals had decreased odds of SMM at delivery. 
Table 4.6 Unadjusted and Adjusted Logistic Regression Models of Severe Maternal 
Morbidity at Delivery, by Social and Biological Characteristics, Deliveries to MA 
Women 2000-2012 
 
Unadjusted OR of 
SMM25 
(95% CI) 





Maternal age (years)   
     <20  1.17 (1.07-1.28) 1.03 (0.93-1.14) 
     20-24 1.03 (0.97-1.11) 0.96 (0.89-1.03) 
     25-29 Ref Ref 
     30-34 0.97 (0.92-1.03) 1.02 (0.96-1.08) 
     35-39 1.27 (1.19-1.35) 1.20 (1.12-1.28) 
     40+ 1.84 (1.19-1.35) 1.44 (1.31-1.58) 
Race/ethnicity   
     Hispanic 1.48 (1.40-1.56) 1.24 (1.17-1.33) 
     Non-Hispanic White Ref Ref 
     Non-Hispanic Black  2.10 (1.98-2.22) 1.45 (1.35-1.55) 
     Asian/Pacific Islander 1.26 (1.17-1.36) 1.34 (1.24-1.45) 
     American Indian/Other 1.10 (0.95-1.28) 0.96 (0.81-1.12) 
PNC month initiation   
     No PNC 3.15 (2.54-3.89) 1.97 (1.52-2.56) 
     1st trimester Ref Ref 
     2nd trimester 1.12 (1.06-1.19) 1.05 (0.99-1.11) 
     3rd trimester 1.13 (1.00-1.27) 1.04 (0.92-1.17) 
Parity   
     1 Ref Ref 
     2 0.76 (0.83-0.80) 0.78 (0.73-0.83) 
     3+ 1.08 (1.03-1.13) 0.97 (0.91-1.04) 
Plurality   
     Singleton Ref Ref 
     Twins 4.22 (3.92-4.53) 1.76 (1.61-1.94) 
     Triplets + 8.08 (6.09-10.72) 2.05 (1.53-2.79) 
Education   
     <High School 1.18 (1.11-1.26) 1.09 (1.01-1.17) 
     High School /GED Ref Ref 
     Some college 1.03 (0.96-1.10) 0.96 (0.90-1.03) 
     Bachelors + 0.83 (0.79-0.87) 0.88 (0.83-0.93) 
Cigarette Use   
     No Ref Ref 
     Yes 0.84 (0.78-0.91) 0.80 (0.73-0.88) 
Hospital Level   
     Level 1 0.61 (0.58-0.65) 0.86 (0.81-0.92) 
     Level 2 0.54 (0.51-0.56) 0.68 (0.65-0.72) 
     Level 3 Ref Ref 
Method of Delivery   
     Vaginal Ref Ref 
     VBAC 1.73 (1.50-1.98) 1.83 (1.58-2.11) 
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     Primary C-section 4.09 (3.91-4.29) 3.08 (2.92-3.26) 
     Repeat C-section 3.13 (2.96-3.30) 3.08 (2.90-3.28) 
Insurance Delivery Payer   
     Private Ref Ref 
     Public 1.44 (1.38-1.50) 1.27 (1.20-1.34) 
     Free care 1.30 (1.08-1.56) 0.99 (0.81-1.21) 
     Self-pay 1.32 (1.10-1.58) 0.80 (0.66-0.98) 
Low birth weight delivery   
     No Ref Ref 
     Yes 3.94 (3.75-4.14) 1.79 (1.67-1.92) 
Maternal congenital cardiac 
disease 
  
     No Ref Ref 
     Yes 3.78 (3.33-4.28) 2.67 (2.33-3.04) 
1 
Adjusted model also controls for maternal hypertensive disorders and other chronic conditions of: 
gestational diabetes, asthma, depression, substance use, preexisting diabetes, autoimmune conditions as 
reported in Table 4.5. 
Bold indicates p<0.05 
 
Results with Interaction Terms 
 
A priori interaction terms for hypertensive disorders with chronic conditions, 
advanced maternal age, and non-Hispanic black race were examined. Simple logistic 
regression models examined the odds of SMM for deliveries to women with only 
hypertensive disorders, then only the hypothesized interaction group (chronic condition, 
age and race), and then both together. These analyses revealed some combinations of 
hypertensive disorders and chronic conditions, race, and age with significantly increased 
odds of SMM compared to either individual group; they were examined in multivariable 
regression models (Table 4.7). Black race was examined across all types of maternal 
hypertensive disorders due to a priori assumptions. Two interaction terms were 
marginally significant in multivariable models, pre-existing diabetes and superimposed 
preeclampsia (p=0.061) and black race and severe preeclampsia (p=0.095), but were not 
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Preexisting diabetes 1.52 (1.39-1.67) 1.58 (1.32-1.89) 3.22 (2.09-4.98) 0.294 













































Black race 9.34 (8.61-
10.14) 























Model Fit Diagnostics 
 
An exchangeable correlation structure provided the best fit and the most 
parsimonious final model. Different correlation structures were also hypothesized. Both 
exchangeable and unstructured correlations were examined with an exchangeable 
correlation structure, providing a lower QIC score and more parsimonious model, with no 
changes in associations. The exchangeable working correlation in the final model was 
0.0297, with a minimum cluster size of zero and maximum cluster size of nine. 
Quasi-likelihood (QIC) scores also informed model selection, with preference 
given to lower scores (Table 4.8). Marital status, an initial variable for inclusion based on 
bivariate analyses, was excluded in the final multivariable regression model based on 
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QIC scores; the model without marital status was more parsimonious and had a lower 
QIC score. Variance inflation factors were also analyzed in the final model in a linear 
regression model to assess multicollinearity among variables. Variance inflation for 
variables ranged from 1.00-1.90, with a mean VIF of 1.19; there was no evidence of 
multicollinearity. 
Table 4.8 Aim 1 Regression Model Correlation Structures and Fit Statistics 
 
Description Correlation Structure QIC 
Model 0 HTN only Exchangeable 106053.8 
Model 1 Model 0 + chronic conditions Exchangeable 105556.8 
Model 2 Model 1 + pre-pregnancy conditions Exchangeable 100748.4 
Model 3 Model 2 + delivery conditions Exchangeable 95093.66 
Model 4 Model 3 - marriage Exchangeable 95092.81 
Model 5 Model 4 + interactions Exchangeable 95103.33 




 Regression models examined SMM both with and without the blood transfusion 
indicator (Table 4.5); no differences were found in the association between maternal 
hypertensive disorders and SMM, whether SMM was considered with or without blood 
transfusion. To further understand the association between maternal hypertensive 
disorders and cardiac-related morbidity, two indicators of cardiac-related SMM, one with 
shock and one without, were examined (Table 4.9). All types of hypertensive disorders, 
with the exception of gestational hypertension, were associated with increased odds of 
cardiac-related SMM in both of the models (aOR range: 1.26-1.81). 
 
Table 4.9 Aim 1 Sensitivity Analysis: Multivariable Logistic Regression Models of 
Cardiac-related Severe Morbidity at Delivery, Deliveries to MA Women 2000-2012 
 Adjusted OR of  Cardiac-
related SMM25 (no shock)
1 
Adjusted OR of Cardiac-
related SMM25
1
 (with shock) 
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(95% CI) (95% CI) 
Hypertensive disorders   
     Superimposed PE 1.68 (1.18-2.39) 1.63 (1.16-2.29) 
     Severe preeclampsia 1.81 (1.47-2.23) 1.72 (1.40-2.11) 
     Mild preeclampsia 1.26 (1.03-1.55) 1.28 (1.05-1.56) 
     Chronic hypertension 1.45 (1.18-1.79) 1.38 (1.12-1.70) 
     Gestational hypertension 1.13 (0.95-1.35) 1.13 (0.95-1.34) 
Other chronic conditions   
     Gestational diabetes 1.03 (0.89-1.18) 1.01 (0.88-1.16) 
     Asthma 1.02 (0.84-1.23) 1.06 (0.89-1.28) 
     Depression 1.35 (1.11-1.63) 1.30 (1.07-1.57) 
     Substance use 0.95 (1 0.69-1.33) 0.92 (0.67-1.27) 
     Preexisting diabetes 0.79 (0.60-1.04) 0.82 (0.63-1.06) 
     Autoimmune conditions 2.04 (1.56-2.67) 2.18 (1.69-2.82) 
1
Adjusted for: race/ethnicity, education, age, hospital level, parity, plurality, prenatal care, cigarette use, 
method of delivery, insurance status, year, low birth weight, congenital cardiac conditions 
Bold indicates statistical significant p<0.05 
Aim 2 and Aim 3 
Dependent Variable: Rehospitalization within 6 weeks and 1 year postpartum 
 
For Aims 2 and 3, the dependent variable was rehospitalization within six weeks 
and one year postpartum. In Aim 2, the population was restricted to deliveries to women 
without chronic medical conditions; in Aim 3, all deliveries to women were considered. 
Before the Aim 2 analyses are presented, an overview is given of the dependent variable 
for the entire population of deliveries to women in Massachusetts from 2002-2011. 
Deliveries to Women in MA, 2002-2011 
 
Over the study period, there were 351,410 hospital rehospitalizations within the 
first year postpartum to deliveries of resident MA women in the study population. Of 
these rehospitalizations, 75.2% (n=264,526) were non-injury non-antenatal hospital 
rehospitalizations within one year postpartum. The proportion of all non-injury-related 
and non-pregnancy-related rehospitalizations varied by type of rehospitalization: 83.4% 
for hospital discharge (HD), 74.5% for emergency department (ED), and 73.3% for 
observational stay (OS) records. Figure 4.6 shows the step-wise application of exclusion 
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criteria for each type of rehospitalization record within one year postpartum and the final 
aggregation of rehospitalizations by delivery for the entire study population. 
Figure 4.6 Hospital Rehospitalization Selection and Exclusion Criteria, Deliveries to 
MA Women 2002-2011 
  
After applying the exclusion criteria, the majority of all hospital rehospitalizations 
were ED admissions (87.1%) compared to HD (9.7%) and OS rehospitalizations (3.2%).  
For the first six weeks postpartum, the majority was still from the ED (73.9%) but there 
was a greater proportion of both HD (20.2%) and OS rehospitalizations (5.9%).  
Types of rehospitalizations were then aggregated by delivery; 5.2% of all 
deliveries to women had at least one hospital rehospitalization (ED, OS, or HD) within 
the first six weeks postpartum and 19.9% within the first year. Stratifying by 
rehospitalization types within the first six weeks postpartum, 1.2% of all deliveries to 
women in the study had at least one HD rehospitalization, 0.4% had at least one OS 
rehospitalization and 4.0% had at least one ED admission. During the first year 
Hospital rehospitalizations aggregated by delivery within 6 weeks 
HD: 8,888 OS: 2,706 ED: 29,240 
Hospital rehospitalizations aggregated by delivery within 1 year 
HD: 21,693 OS: 8,107 ED: 131,289 
Total non-injury, non-antenatal-related hospital rehospitalizations within 1 year 
HD: 25,655 OS: 8,591 ED: 230,280 
Exclude antenatal-related  rehospitalizations 
HD: 1,222 OS: 2,541 ED: 11,049 
Exclude injury-related rehospitalizations  
HD: 2,889 OS: 587 ED: 67,608 
Exclude HD rehospitalizations same day as delivery discharge 
HD: 988 
Total postpartum hospital rehospitalizations < 1 year, deliveries to MA women 2002-2011 
HD: 30,754 OS: 11,719 ED: 308,937 
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postpartum, 3.0% of all had at least one HD rehospitalization, 1.1%, at least one OS 
rehospitalization, and 17.9% had at least one ED admission (Figure 4.7).  
Figure 4.7 Postpartum Rehospitalization by Type and Timing, Deliveries to MA 
Women 2002-2011 
 
HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
 
In the first six-week postpartum period, 5.2% of deliveries to women in the study 
period had at least one rehospitalization; this percentage rose from 4.6% for deliveries in 
2002 to 5.5% in 2011 (p<0.0001 for trend). More than one quarter (26.1%) of all 
postpartum rehospitalizations occurred within 42 days postpartum, but this figure varied 
by type of rehospitalization. Across the first year postpartum, 41.0% of all HD 
rehospitalizations, 33.4% of all OS rehospitalizations, and 22.3% of all ED admissions 
occurred in the first six weeks postpartum (Figure 4.8). For HD rehospitalizations within 
the first year, 10.2% occurred within the first seven days postpartum and for OS 
































































Figure 4.8 Percent of First Year Postpartum Hospital Rehospitalizations by 
Postpartum Days, Deliveries to MA Women 2002-2012 
 
HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
 
Of all deliveries to women with at least one rehospitalization within the first year 
postpartum, the majority (63.6%) had only one rehospitalization, 19.5% had two 
rehospitalizations and 16.9% had three or more rehospitalizations. Stratified by type, the 
majority of deliveries with HD, OS or ED records had only one rehospitalization, 
although there was a greater percentage of repeat ED visits than for either HD or OS 


















































Figure 4.9 Percent Deliveries with Postpartum Hospital Rehospitalizations within 
One Year by Type and Frequency, Deliveries to MA Women 2002-2011 
 
HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
 
Over the study period, the percentage of women with any type of hospital 
rehospitalization in the first year postpartum rose from 18.0% in 2002 to 20.3% in 2011 
(p<0.0001 for trend). ED admissions rose over the time period from 15.9% to 18.4% 
(p<0.0001). HD rehospitalizations also rose from 2.87 to 3.02% (p<0.001), while OS 
rehospitalizations showed little change. Similar trends were seen in the first six weeks; 
the percentage ED admissions and HD rehospitalizations increased over the study period 
(p<0.0001 and p=0.0002, respectively); no trends were identified with OS 
rehospitalizations.  
The five most common primary diagnoses for rehospitalization varied both by 
timing (<6 weeks vs. <1 year) and type (ED, OS, HD) (Table 4.10 & Table 4.11). Non-
specific codes were common across all types of rehospitalization. Among specific codes 


































































common diagnosis for both OS and HD records at both 6 weeks and within 1 year. 
Postpartum hemorrhage also was a common cause for all types of first rehospitalizations 
in the first 6 weeks postpartum.   
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Table 4.10 Top Primary Diagnoses Among Postpartum Women with Hospital Discharge, Observational Stay, and Emergency 
Department Records within Six Weeks, Deliveries to MA Women 2002-2011 
 Hospital Discharge Record Observational Stay Record Emergency Department 
Rank % women with 




% women with 
OS record <6 
weeks 
Primary Diagnosis (ICD-9-CM 
code) 
% women with ED 
record <6 weeks 
Primary Diagnosis 
(ICD-9-CM code) 
1 20.4 Other and unspecified 
complications of the 
puerperium not elsewhere 
classified 
19.3 Hypertension complicating 
pregnancy childbirth and the 
puerperium 
9.8 Other and 
unspecified 
complications of 
the puerperium not 
elsewhere 
classified 
2 16.3 Hypertension complicating 
pregnancy childbirth and 
the puerperium 
14.9 Other and unspecified 
complications of the 
puerperium not elsewhere 
classified 
7.9 Other symptoms 
involving abdomen 
and pelvis 
3 13.9 Major puerperal infection 11.9 Postpartum hemorrhage 5.3 Other current 





childbirth or the 
puerperium 
4 8.0 Other current conditions in 
the mother classifiable 
elsewhere but complicating 
pregnancy childbirth or the 
puerperium 
10.6 Other current conditions in the 
mother classifiable elsewhere 
but complicating pregnancy 
childbirth or the puerperium 
4.3 Postpartum 
hemorrhage 
5 6.8 Postpartum hemorrhage 4.8 Other complications of 







HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
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Table 4.11 Top Primary Diagnoses Among Postpartum Women with Hospital Discharge and Observational Stay Records 
within One Year, MA Women with Deliveries 2002-2011 
 Hospital Discharge Record Observational Stay Record  Emergency Department 






% women with 
ED record <1 
year 
Primary Diagnosis (ICD-9-CM 
code) 
% women with ED 
record <1 year 
Primary Diagnosis 
(ICD-9-CM code) 
1 9.5 Cholelithiasis 9.7 Cholelithiasis 9.5 Other symptoms 
involving abdomen 
and pelvis 
2 9.0 Other and unspecified 
complications of the 
puerperium not elsewhere 
classified 
6.5 Hypertension complicating 





and other chest 
symptoms 
3 6.7 Hypertension complicating 
pregnancy childbirth and 
the puerperium 
6.4 Other symptoms involving 
abdomen and pelvis 
3.7 Acute pharyngitis 
4 5.8 Major puerperal infection 5.4 Other and unspecified 
complications of the 
puerperium not elsewhere 
classified 
3.7 Symptoms 
involving head and 
neck 
5 4.1 Episodic mood disorders 4.9 Symptoms involving respiratory 
system and other chest 
symptoms 
3.5 General symptoms 




Deliveries to Women without Chronic Medical Conditions in MA, 2002-2011 
 
When limited to women without chronic conditions, rehospitalizations patterns 
were similar to those for the entire population but the rates were attenuated: 1.1% of 
deliveries to women had HD rehospitalizations within six weeks and 2.8% within one 
year; 0.3% had OS rehospitalizations within six weeks and 1.0% within one year; and 
3.9% had ED admissions within six weeks and 17.3% within one year (Figure 4.10). 
Figure 4.10 Percent Postpartum Hospital Rehospitalization by Type and Timing, 
Deliveries to MA Women without Chronic Medical Conditions 2002-2011 
 
HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
 
Aim 2  
Bivariate Results 
 
Almost three in ten deliveries with SMM (28.3%) to women without chronic 
medical conditions had at least one rehospitalization within the first year postpartum 
compared to two in ten (19.2%) without SMM. In the first six weeks postpartum, 11.3% 
of deliveries to women with SMM at delivery had a rehospitalization compared to 4.9% 






















































Figure 4.12). Among deliveries to women with SMM, 4.5% had an HD rehospitalization 
within six weeks compared to 1.1% without SMM; within one year, the respective figures 
were 7.7% and 2.7 %. Within six weeks, 1.2% of deliveries to women with SMM at 
delivery had an OS rehospitalization compared to 0.3% without and within one year, 
2.2% with SMM had at least one OS rehospitalization compared to 1.0% without. Within 
six weeks, 7.0% of deliveries to women with SMM had an ED admission at six weeks 
compared to 3.8% without SMM and 23.2% had an ED admission within one year 
compared to 17.3% without SMM. All bivariate comparisons were significant at 
p<0.0001.   
 SMM was stratified by specific indicators of severe morbidity and compared by 
type and timing of hospital rehospitalization (Table 4.12). For deliveries to women with 
renal failure, 6.6% had an HD rehospitalization within the first six weeks and 10.0% 
within the first year. For deliveries to women with puerperal cerebrovascular disorders, 
11.9% had an ED admission within the first six weeks and 34.1% within the first year. 
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Figure 4.11 Severe Maternal Morbidity at Delivery and Hospital Rehospitalizations 
within 6 weeks postpartum, Deliveries to MA Women without Chronic Medical 
Conditions 2002-2012 
 
HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
 
Figure 4.12 Severe Maternal Morbidity at Delivery and Hospital Rehospitalizations 
within 1 year postpartum, Deliveries to MA Women without Chronic Medical 
Conditions 2002-2011 
 
































































































































Table 4.12 Severe Maternal Morbidity Indicators and Hospital Rehospitalizations by Type and Timing, deliveries to MA 
Women without Chronic Medical Conditions 2002-2012 
Classification HD  
6 weeks 
% (N)   
(1.13) 
OS  
6 weeks  






















1. Acute myocardial 
infarction 
-- -- -- -- -- -- -- 
2. Acute renal failure 6.64 (14) -- 8.53 (18) 9.95 (21) -- 18.96 (40) 0.03 (211) 
3. Adult respiratory distress 
syndrome 
-- -- 10.24 (17) 10.24 (17) -- 29.52 (49) 0.02 (166) 
4. Amniotic fluid embolism -- -- -- -- -- -- 0.00 (22) 
5. Aneurysm -- -- -- -- -- -- -- 
6. Cardiac arrest/ventricular 
fibrillation 
-- -- -- -- -- -- 0.00 (30) 
7. Disseminated 
intravascular coagulation 
4.77 (25) -- 5.34 (28) 6.68 (35) 2.10 (11) 15.65 (82) 0.08 (524) 
8. Eclampsia -- -- 10.89 (22) 5.94 (12) -- 28.22 (57) 0.03 (202)  
9. Heart failure during 
procedure or surgery 
5.43 (31) -- 8.06 (46) 9.81 (56) 2.63 (15) 23.12 (132) 0.08 (571) 
10. Internal injuries of 
thorax, abdomen, and pelvis 
-- -- -- -- -- -- 0 (33) 
11. Intracranial injuries -- -- -- -- -- -- -- 
12. Puerperal 
cerebrovascular disorders 
-- -- 11.90 (15) 14.29 (18) -- 34.13 (43) 0.02 (126) 
13. Pulmonary edema -- -- -- -- -- 21.88 (14) 0.01 (64) 
14. Severe anesthesia 
complications 
-- -- -- -- -- 20.75 (11) 0.01 (53) 
15. Sepsis -- -- -- 11.27 (16) -- 26.06 (37) 0.02 (142) 
16. Shock -- -- -- 9.92 (12) -- 23.14 (28) 0.02 (121) 
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17. Sickle cell anemia with 
crisis 
-- -- -- 27.27 (12) -- -- 0.01 (44) 
18. Thrombotic embolism -- -- -- 13.08 (14) -- 31.78 (34) 0.02 (107) 
19. Blood transfusion 4.35 (201) 1.21 (56) 7.03 (325) 7.63 (353) 2.18 (101) 23.72 (1097) 0.67 (4625) 
20. Cardio monitoring -- -- -- -- 2.13(12) -- 0.00 (34) 
21. Conversion of cardiac 
rhythm 
-- -- -- -- -- -- 0.00 (22) 
22. Hysterectomy 3.70 (17) -- 5.66 (26) 6.32 (29) -- 18.52 (85) 0.07 (459) 
23. Operations on heart and 
pericardium 3.37 (19) -- 4.79 (27) 5.50 (31) 2.13 (12) 19.33 (109) 0.08 (564) 
24. Temporary tracheostomy 3.72 (11) -- -- -- -- -- 0.04 (296) 
25. Ventilation 3.72 (11) -- 10.14 (30) 8.45 (25) -- 31.08 (92) 0.04 (296) 
HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 












Other social and biological characteristics were associated with postpartum 
hospital rehospitalizations, all with significant Wald χ
2
 statistical tests (p<0.0001) (Table 
4.13). These characteristics were considered as confounders in the analysis of the relation 
of SMM with rehospitalization. 
 
Table 4.13 Social and Biological Characteristics and Postpartum Hospital 
Rehospitalizations by Type and Timing, Deliveries to MA Women without Chronic 
Medical Conditions 2002-2012 
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Table 4.14 shows the variation in SMM both with and without transfusion by 
social and biological characteristics as well as other pregnancy-associated conditions. 
With a population of about 685,000 women without chronic conditions, all Wald χ
2
 
analyses were significant (p<0.0001). Maternal age, education, race/ethnicity, parity, 
plurality, cigarette use during pregnancy, hospital level, insurance payer, method of 
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delivery, low birth weight delivery, marital status and all chronic and pregnancy-related 
chronic conditions were significantly associated with SMM both with and without 
transfusion. 
 
Table 4.14 Sample Characteristics by Severe Maternal Morbidity at Delivery, 
Deliveries to MA Women without Chronic Medical Conditions 2002-2011 
Characteristic SMM without 
transfusion 
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Low birth weight delivery 
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Main Multivariate Results 
 
Multivariable regression results are presented below for SMM with and without 
transfusion across HD (Table 4.15), OS (Table 4.16), and ED visits (Table 4.17). There 
was increased risk of HD rehospitalization among deliveries to women with SMM 
compared to those without SMM within six weeks (aRR 2.48; 95% CI: 2.20-2.80) and 
one year postpartum (aRR: 2.04; 95% CI: 1.87-2.23) (Table 4.15) after adjustment for 
confounders. The adjusted relative risk of HD rehospitalization at 42-364 days 
postpartum was markedly less than the risk within six weeks (aRR: 1.65; 95% CI: 1.44-
1.89 vs. aRR 2.48; 95% CI: 2.20-2.80).  
SMM was also associated with an increased risk of OS rehospitalization within 
six weeks (aRR 2.47; 95% CI: 1.94-3.14) (Table 4.16). There also appeared to be an 
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increased risk within one year (aRR 1.69; 95% CI: 1.43-2.01); however, there was no 
significant increased risk of OS rehospitalization between 42-364 days for deliveries to 
women with SMM at delivery (aRR: 1.26; 95% CI: 0.99-1.61) after adjustment of 
confounders.  
For ED admissions within six weeks, women with SMM at delivery had an almost 
50% increased risk compared to women without SMM at delivery, after adjustment for 
confounders (aRR: 1.47; 95% CI: 1.34-1.61) (Table 4.17). Within one year, there was 
still an increased risk of ED admissions among deliveries to women who experienced 
SMM at delivery compared to those without (aRR: 1.16; 95% CI: 1.11-1.21), but the risk 
was attenuated from the estimate seen within six weeks. The risk associated with 
deliveries of women with SMM was slightly increased (aRR: 1.08; 95% CI: 1.03-1.14) 
when ED readmission was examined between 42-364 days. 
Across all outcomes and time points, adjusted risk estimates for rehospitalization 
were similar when SMM was defined with and without transfusion; however, there were 
slight differences in the magnitude of some estimates. Compared to SMM without 
transfusion, risk point estimates were higher for SMM with transfusion for six-week HD 




Table 4.15 Relative Risk of Postpartum Hospital Discharges by Timing, Deliveries to MA Women without chronic medical 
conditions 2002-2011 
 <42 days Postpartum 
Rehospitalization 
42-<365 days Postpartum 
Rehospitalization 
<365 days Postpartum Rehospitalization 





 (95% CI) 




 HD  
(95% CI) 




 HD  
(95% CI) 
SMM: no transfusion 4.27 (3.62-5.03) 2.27 (1.91-2.70) 2.08 (1.71-2.53) 1.66 (1.35-2.03) 2.97 (2.63-3.36) 1.96 (2.63-3.36) 
SMM: with transfusion 4.12 (3.68-4.60) 2.48 (2.20-2.80) 1.99 (1.74-2.27) 1.65 (1.44-1.89) 2.85 (2.62-3.10) 2.04 (1.87-2.23) 
1
Adjusted for: age, race/ethnicity, pregnancy-related conditions (preeclampsia, gestational hypertension, gestational diabetes), education, method of delivery, 
insurance status, parity, plurality, length of stay at delivery hospitalization, year, hospital level, marital status, smoking status 
 
Table 4.16 Relative Risk of Postpartum Observation Stays by Timing, Deliveries to MA Women without chronic medical 
conditions 2002-2011 
 <42 days Postpartum 
Rehospitalization 
42-<365 days Postpartum 
Rehospitalization 
<365 days Postpartum Rehospitalization 




 OS  
(95% CI) 




 OS  
(95% CI) 




 OS  
(95% CI) 
SMM: no transfusion 3.12 (2.19-4.44) 2.10 (1.46-3.03) 1.56 (1.10-2.22) 1.25 (0.87-1.81) 2.08 (1.63-2.67) 1.57 (1.21-2.03) 
SMM: with transfusion 3.47 (2.77-4.33) 2.47 (1.94-3.14) 1.52 (1.20-1.92) 1.26 (0.99-1.61) 2.16 (1.84-2.54) 1.69 (1.4-2.01) 
1
Adjusted for: age, race/ethnicity, pregnancy-related conditions (preeclampsia, gestational hypertension, gestational diabetes), education, method of delivery, 
insurance status, parity, plurality, length of stay at delivery hospitalization, year, hospital level, marital status, smoking status 
 
Table 4.17 Relative Risk of Postpartum Emergency Department Visits by Timing, Deliveries to MA Women without chronic 
medical conditions 2002-2011 
 <42 days Postpartum 
Rehospitalization 
42-<365 days Postpartum 
Rehospitalization 
<365 days Postpartum 
Rehospitalization 
















 ED  
(95% CI) 
SMM: no transfusion 1.80 (1.57-2.05) 1.49 (1.30-1.71) 1.13 (1.03-1.23) 1.09 (0.99-1.18) 1.28 (1.19-1.37) 1.17 (1.09-1.25) 
SMM: with transfusion 1.83 (1.67-2.00) 1.47 (1.34-1.61) 1.21 (1.14-1.28) 1.08 (1.03-1.14) 1.35 (1.29-1.41) 1.16 (1.11-1.21) 
1
Adjusted for: age, race/ethnicity, pregnancy-related conditions (preeclampsia, gestational hypertension, gestational diabetes), education, method of delivery, 
insurance status, parity, plurality, length of stay at delivery hospitalization, year, hospital level, marital status, smoking status 
 
Table 4.18 and Table 4.19 show the risk of rehospitalization across the different 
types of hospital encounters by all other variables in the fully adjusted model. There were 
qualitatively different findings across the types of encounters. For example, deliveries 
among older women had an increased risk of HD and OS rehospitalization but a 
decreased risk of ED admission at six weeks and one year. Deliveries to non-Hispanic 
black women had higher risk of HD and OS rehospitalization compared to white women 
but no difference in risk of ED admission within six weeks. The risk of ED admission 
was greater for deliveries paid for by public insurance than for HD rehospitalization. 
Lower level of hospital at delivery was associated with an increased risk of ED admission 
but a decreased risk of HD rehospitalization. 
Table 4.18 Adjusted Relative Risk of 6 week Rehospitalizations by Social and 
Biological Characteristics, Deliveries to MA Women 2002-2011 


















     <20 
     20-24 
     25-29 
     30-34 
     35-39 























     Hispanic 
     Non-Hispanic White 
     Non-Hispanic Black 
     Non-Hispanic Asian 




















     <HS 
     HS/GED 
     Some college 

















     Private 
     Public     
     Self-care 
















Marital Status    
114 
 
     Married 







Cigarette use in pregnancy 
     Yes 











     1 
     2   














     Singletons 
     Twins 













Method of Delivery 
     Vaginal 
     VBAC 
     Primary Cesarean 

















     1 
     2 













Length of Stay at delivery 
     1-2 days 
     3-4 days 














     Yes 











    Yes 











     Yes 











Also adjusted for SMM 
Bold indicates p<0.05 
 
Table 4.19 Adjusted Relative Risk of 1 Year Rehospitalizations by Social and 













     <20 
     20-24 
     25-29 
     30-34 
     35-39 























     Hispanic 
     Non-Hispanic White 
     Non-Hispanic Black 


















     Other 0.92 (0.83-1.01) 0.89 (0.75-1.06) 1.01 (0.98-1.04) 
Education 
     <HS 
     HS/GED 
     Some college 

















     Private 
     Public     
     Self-pay  

















     Married 










Cigarette use in pregnancy 
     Yes 











     1 
     2   














     Singletons 
     Twins 













Method of Delivery 
     Vaginal 
     VBAC 
     Primary Cesarean 

















     1 
     2 













Length of Stay at delivery 
     1-2 days 
     3-4 days 














     Yes 











    Yes 











     Yes 











     2002-2003 
     2004-2005 
     2006-2007 
     2008-2009 




















Also adjusted for SMM 






Based on analyses in Aim 1, an exchangeable correlation structure was used to 
provide the best fit and the most parsimonious final model. The exchangeable working 
correlation in the final model was 0.0297, with a minimum cluster size of zero and 
maximum cluster size of nine. 
Quasi-likelihood (QIC) scores also informed model selection, with preference 
given to lower scores. Variance inflation factors were also analyzed in the final model in 
a linear regression model to assess multicollinearity among variables. Variance inflation 
for variables ranged from 1.01-1.79, with a mean VIF of 1.28; there was no evidence of 
multicollinearity. 
Sensitivity Analyses 
Severe maternal morbidity  
 
 SMM is a composite indicator of 25 ICD-9-CM diagnosis and procedure codes 
and was examined in multiple ways. It was initially analyzed as a dichotomous variable 
(≥1 SMM indicator vs. 0) and examined both with and without the blood transfusion 
indicator. There were no differences in adjusted risks across all outcomes when SMM at 
delivery was considered with or without blood transfusion. In addition, to understand if 
deliveries to women with multiple SMM indicators had an increased risk of 
rehospitalization, a sensitivity analysis was performed with categorization of 0, 1, 2+ 
SMM indicators. In adjusted models, there appeared to be no evidence of increased risk 




Table 4.20 Aim 2 Sensitivity Analysis: Alternative Categorization of Severe 
Maternal Morbidity Indicator as Main Independent Variable 






























No SMM REF REF REF REF REF REF 

























Adjusted for: age, race/ethnicity, pregnancy-related conditions (preeclampsia, gestational hypertension, 
gestational diabetes), education, method of delivery, insurance status, parity, plurality, length of stay at 
delivery hospitalization, year, hospital level, marital status, smoking status 
Bold indicates p<0.05 
 
Mental health indicators 
 
 Mental health indicators of substance use disorders and depression were initially 
not considered in the main multivariable regression model due to null findings from Aim 
1 with SMM without transfusion. Sensitivity analyses of adding these mental health 
indicators in the regression model revealed no difference in the risk of all types of 
postpartum rehospitalization among deliveries to women with SMM from main the 
multivariate results. Models of risk of ED admission within one year with the added 
mental health indicators did not converge with log-binomial regression and were then 
assessed through a Poisson distribution. Additional assessments of potential interaction 
between mental health and SMM at delivery were not statistically significant. In adjusted 
models, risk of rehospitalization across types and time points among deliveries to women 
with depression ranged from 1.30 to 1.63; deliveries to women with substance use 
disorders also had an increased risk of rehospitalization ranging from 1.26 to 1.99 across 




Maternal deaths in the year after delivery 
 
There were 138 maternal deaths after delivery and within the first year postpartum 
in the delivery population during the study period (0.02%). Thirty-one deaths were within 
the first six weeks postpartum (22.5%) and 107 were between six and fifty-two weeks 
(77.5%). Of those who died, 12% had SMM at delivery (N=16) and 11% had either mild 
or severe preeclampsia or gestational hypertension (N=15). Removing maternal deaths 





Maternal hypertensive disorder subtypes were stratified by SMM to examine 
rehospitalization by different types of encounters and timeframes (Figures 4.13-4.18). 
Similar to Aim 1 results, deliveries to women with maternal hypertensive subtypes were 
more likely to be rehospitalized compared to women without any type of hypertension. 
Similar to Aim 2 results, deliveries to women with SMM at delivery were more likely to 
be rehospitalized compared to women without morbidity. In general, the percentage of 
deliveries with rehospitalization was increased among deliveries with SMM for all 
subtypes of maternal hypertensive disorders; however, this relation in some instances was 




Figure 4.13 Six Week Postpartum Hospital Discharge Rehospitalization by 
Hypertensive Status and Severe Maternal Morbidity, Deliveries to MA Women 
2002-2011 
 
G HTN: Gestational hypertension; C HTN: Chronic hypertension; M PE: Mild preeclampsia; S PE: Severe 
preeclampsia; SI PE: Superimposed preeclampsia 
 
Figure 4.14 One Year Postpartum Hospital Discharge Rehospitalization by 
Hypertensive Status and Severe Maternal Morbidity, Deliveries to MA Women 
2002-2011 
 
G HTN: Gestational hypertension; C HTN: Chronic hypertension; M PE: Mild preeclampsia; S PE: Severe 
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Figure 4.15 Six Week Postpartum Observational Stay Rehospitalization by 
Hypertensive Status and Severe Maternal Morbidity, Deliveries to MA Women 
2002-2011 
 
G HTN: Gestational hypertension; C HTN: Chronic hypertension; M PE: Mild preeclampsia; S PE: Severe 
preeclampsia; SI PE: Superimposed preeclampsia 
 
Figure 4.16 One Year Postpartum Observational Stay Rehospitalization by 
Hypertensive Status and Severe Maternal Morbidity, Deliveries to MA Women 
2002-2011
G HTN: Gestational hypertension; C HTN: Chronic hypertension; M PE: Mild preeclampsia; S PE: Severe 
preeclampsia; SI PE: Superimposed preeclampsia 
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Figure 4.17 Six Week Postpartum Emergency Department Admissions by 
Hypertensive Status and Severe Maternal Morbidity, Deliveries to MA Women 
2002-2011 
 
G HTN: Gestational hypertension; C HTN: Chronic hypertension; M PE: Mild preeclampsia; S PE: Severe 
preeclampsia; SI PE: Superimposed preeclampsia 
 
Figure 4.18 One Year Postpartum Emergency Department Admissions by 
Hypertensive Status and Severe Maternal Morbidity, Deliveries to MA Women 
2002-2011 
 
G HTN: Gestational hypertension; C HTN: Chronic hypertension; M PE: Mild preeclampsia; S PE: Severe 
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Main Multivariate Results 
Hospital Discharge Rehospitalization 
 
The magnitude of the adjusted risk of HD rehospitalization in the first six weeks 
was similar among deliveries with SMM and among those with maternal hypertensive 
disorders. Among those with SMM, the risk of rehospitalization was 2.27 (95% CI: 2.03-
2.54); risks did not vary significantly among deliveries to women by subtypes of maternal 
hypertensive disorders, with a range of 1.79 to 2.25 (Table 4.21). Among deliveries to 
women with other chronic and pregnancy-associated conditions, the risk of HD 
rehospitalization within six weeks was significantly increased compared to deliveries to 
women without any conditions, ranging from 1.20 to 1.59. 
Within the first year, the adjusted risk of HD rehospitalization remained elevated 
for deliveries to women with SMM (aRR: 1.95; 95% CI: 1.80-2.11) and for both 
superimposed preeclampsia and chronic hypertension (Table 4.22). The risk estimate was 
reduced among deliveries to women with other types of maternal hypertension (severe 
and mild preeclampsia and gestational hypertension) compared to the risk within six 
weeks. Among other chronic and pregnancy-associated conditions, risks were 
comparable to risks within six weeks for: pre-existing diabetes, gestational diabetes, 
asthma, depression, and autoimmune conditions. The risk of HD rehospitalization within 
one year among deliveries to women with substance use disorders was higher than within 
six weeks (aRR: 1.89 vs. 1.40). 
 
Table 4.21 Unadjusted and Adjusted Risk of Hospital Discharge Rehospitalization 
within 6 weeks, Deliveries to MA Women 2002-2011 




SMM25 4.00 (3.61-4.44) 2.27 (2.03-2.54) 
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Superimposed preeclampsia 4.23 (2.51-5.10) 2.25 (1.85-2.73) 
Severe preeclampsia 3.38 (3.00-3.80) 1.79 (1.58-2.04) 
Mild preeclampsia 2.87 (2.62-3.16) 2.01 (1.82-2.22) 
Chronic hypertension 2.47 (2.21-2.77) 1.81 (1.61-2.04) 
Gestational hypertension 2.16 (1.20-2.35) 1.87 (1.72-2.03) 
Pre-existing diabetes 2.36 (2.08-2.68) 1.45 (1.27-1.66) 
Gestational diabetes 1.42 (1.31-1.54) 1.20 (1.11-1.30) 
Asthma 1.55 (1.42-1.70) 1.23 (1.12-1.36) 
Substance use disorder 1.89 (1.67-2.15) 1.40 (1.22-1.61) 
Depression 1.59 (1.44-1.76) 1.29 (1.16-1.43) 
Autoimmune disorders 1.87 (1.55-2.25) 1.59 (1.32-1.91) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




Table 4.22 Unadjusted and Adjusted Risk of Hospital Discharge Rehospitalization 
within 1 year, Deliveries to MA Women 2002-2011 
Characteristic RR (95% CI) aRR
1
 (95% CI) 
SMM25 2.87 (2.67-3.09) 1.95 (1.80-2.11) 
Superimposed preeclampsia 2.93 (2.55-3.36) 1.82 (1.58-2.09) 
Severe preeclampsia 2.18 (2.00-2.39) 1.43 (1.30-1.57) 
Mild preeclampsia 1.87 (1.75-2.01) 1.50 (1.39-1.61) 
Chronic hypertension 2.03 (1.88-2.19) 1.62 (1.50-1.75) 
Gestational hypertension 1.55 (1.46-1.64) 1.44 (1.36-1.53) 
Pre-existing diabetes 2.27 (2.09-2.47) 1.66 (1.52-1.80) 
Gestational diabetes 1.30 (1.23-1.37) 1.20 (1.14-1.27) 
Asthma 1.75 (1.65-1.85) 1.34 (1.26-1.42) 
Substance use disorder 3.17 (2.97-3.38) 1.89 (1.76-2.03) 
Depression 2.03 (1.92-2.15) 1.49 (1.40-1.58) 
Autoimmune disorders 2.31 (2.08-2.56) 2.11 (1.90-2.34) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 
during pregnancy 
 
Observational Stay Rehospitalization 
 
The adjusted risk of OS rehospitalization in the first six weeks postpartum was 
more than double among deliveries to women with SMM at delivery compared to those 
without (aRR: 2.24; 95% CI: 1.79-2.79) (Table 4.23). Deliveries to women with subtypes 
of hypertensive disorders also had a more than two-fold risk of OS rehospitalization 
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within six weeks. Deliveries to women with pre-existing diabetes, substance use 
disorders, and autoimmune conditions were not significantly associated with OS 
rehospitalization within six weeks. Deliveries to women with gestational diabetes, 
asthma, and depression were at increased risk but these point estimates were less in 
magnitude than the risk found for deliveries to women with SMM. 
The one-year postpartum risk of OS rehospitalization was still increased for 
deliveries to women with SMM at delivery (aRR: 1.59; 95% CI: 1.37-1.86) (Table 4.24). 
Compared to six weeks, risk estimates for rehospitalization within one year were 
decreased among deliveries to women with mild preeclampsia (aRR: 2.50 vs. 1.73) and 
with gestational hypertension (2.11 vs. 1.65). Risk estimates for rehospitalization among 
deliveries to women with other types of chronic and pregnancy-associated conditions 
were all significant at one year, ranging from 1.33 to 1.98, with the highest risks seen for 
deliveries to women with chronic hypertension and superimposed preeclampsia. 
 
Table 4.23 Unadjusted and Adjusted Risk of Observational Stay Rehospitalization 
within 6 weeks, Deliveries to MA Women 2002-2011 
Characteristic RR (95% CI) aRR
1
 (95% CI) 
SMM25 3.42 (2.79-4.19) 2.24 (1.79-2.79) 
Superimposed preeclampsia 3.94 (2.74-5.65) 2.56 (1.75-3.74) 
Severe preeclampsia 3.03 (2.41-3.80) 2.06 (1.61-2.65) 
Mild preeclampsia 3.01 (2.55-3.57) 2.50 (2.10-2.98) 
Chronic hypertension 3.13 (2.60-3.77) 2.54 (2.10-3.08) 
Gestational hypertension 2.34 (2.03-2.70) 2.11 (1.82-2.44) 
Pre-existing diabetes 1.70 (1.30-2.23) 1.09 (0.82-1.44) 
Gestational diabetes 1.45 (1.25-1.68) 1.25 (1.08-1.45) 
Asthma 1.70 (1.44-2.00) 1.43 (1.21-1.70) 
Substance use disorder 1.68 (1.31-2.15) 1.30 (0.99-1.72) 
Depression 1.83 (1.54-2.17) 1.54 (1.28-1.84) 




Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 





Table 4.24 Unadjusted and Adjusted Risk of Observational Stay Rehospitalization 
within 1 year, Deliveries to MA Women 2002-2011 
Characteristic RR (95% CI) aRR
1
 (95% CI) 
SMM25 2.23 (1.94-2.57) 1.59 (1.37-1.86) 
Superimposed preeclampsia 2.84 (2.25-3.60) 1.94 (1.53-2.47) 
Severe preeclampsia 2.04 (1.75-2.37) 1.49 (1.26-1.75) 
Mild preeclampsia 2.00 (1.79-2.25) 1.73 (1.54-1.94) 
Chronic hypertension 2.44 (2.17-2.74) 1.98 (1.76-2.24) 
Gestational hypertension 1.75 (1.60-1.92) 1.65 (1.50-1.81) 
Pre-existing diabetes 2.20 (1.92-2.53) 1.58 (1.37-1.83) 
Gestational diabetes 1.48 (1.36-1.61) 1.38 (1.27-1.51) 
Asthma 1.87 (1.71-2.04) 1.48 (1.35-1.62) 
Substance use disorder 1.99 (1.74-2.27) 1.33 (1.15-1.54) 
Depression 1.90 (1.72-2.09) 1.48 (1.34-1.64) 
Autoimmune disorders 1.94 (1.60-2.34) 1.71 (1.41-2.08) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




Emergency Department Admission 
 
 The risk of ED admission within six weeks was increased for deliveries to women 
with SMM (aRR: 1.45; 95% CI: 1.33-1.57) (Table 4.25); it was significantly less than the 
risk estimate for HD (aRR: 2.27; 95% CI: 2.03-2.54) or OS (aRR: 2.24; 95% CI: 1.79-
2.79) rehospitalization within six weeks. For maternal hypertensive disorders, the risk of 
ED admission ranged from 1.14 to 1.27, with the highest point estimates for deliveries to 
women with superimposed preeclampsia and chronic hypertension. Women with other 
chronic and pregnancy-associated conditions also had increased risk of ED admission 
within six weeks, with the highest risk seen among deliveries to women with substance 
use disorders (aRR: 1.43; 95% CI: 1.35-1.52). 
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 The risk of ED admission within one year was still increased among deliveries to 
women with SMM (aRR: 1.16; 95% CI: 1.12-1.21), although it was attenuated from the 
risk within six weeks (aRR: 1.45; 95% CI: 1.33-1.57) (Table 4.26). The risk of admission 
among deliveries to women with all hypertensive disorder subtypes also remained 
significant within one year postpartum (aRR range: 1.08-1.22). For other chronic and 
pregnancy-associated conditions, risks within one year postpartum were similar to those 
seen within six weeks, with the exception of substance use disorders, which was 
decreased within one year postpartum compared to six weeks (1.27 vs. 1.43). 
 
Table 4.25 Unadjusted and Adjusted Risk of Emergency Department 
Rehospitalization within 6 weeks, Deliveries to MA Women 2002-2011 
Characteristic RR (95% CI) aRR
1
 (95% CI) 
SMM25 1.79 (1.65-1.95) 1.45 (1.33-1.57) 
Superimposed preeclampsia 1.43 (1.21-1.69) 1.27 (1.07-1.50) 
Severe preeclampsia 1.49 (1.36-1.63) 1.23 (1.12-1.35) 
Mild preeclampsia 1.30 (1.22-1.40) 1.17 (1.09-1.26) 
Chronic hypertension 1.26 (1.16-1.36) 1.27 (1.17-1.38) 
Gestational hypertension 1.16 (1.10-1.23) 1.14 (1.08-1.21) 
Pre-existing diabetes 1.22 (1.11-1.34) 1.16 (1.05-1.28) 
Gestational diabetes 1.13 (1.08-1.19) 1.15 (1.10-1.21) 
Asthma 1.64 (1.56-1.72) 1.34 (1.27-1.41) 
Substance use disorder 2.90 (2.74-3.07) 1.43 (1.35-1.52) 
Depression 1.78 (1.69-1.87) 1.34 (1.27-1.41) 
Autoimmune disorders 1.16 (1.02-1.31) 1.28 (1.13-1.45) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




Table 4.26 Unadjusted and Adjusted Risk of Emergency Department 
Rehospitalization within 1 year, Deliveries to MA Women 2002-2011 
Characteristic RR (95% CI) aRR
1
 (95% CI) 
SMM25 1.31 (1.26-1.36) 1.16 (1.12-1.21) 
Superimposed preeclampsia 1.27 (1.18-1.37) 1.20 (1.11-1.29) 
Severe preeclampsia 1.19 (1.14-1.24) 1.08 (1.03-1.12) 
Mild preeclampsia 1.16 (1.12-1.20) 1.10 (1.07-1.14) 
Chronic hypertension 1.15 (1.11-1.20) 1.22 (1.17-1.26) 
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Gestational hypertension 1.07 (1.05-1.10) 1.09 (1.07-1.12) 
Pre-existing diabetes 1.19 (1.14-1.24) 1.20 (1.15-1.25) 
Gestational diabetes 1.03 (1.01-1.05) 1.12 (1.10-1.15) 
Asthma 1.58 (1.55-1.62) 1.30 (1.27-1.33) 
Substance use disorder 2.25 (2.20-2.31) 1.25 (1.22-1.28) 
Depression 1.59 (1.55-1.62) 1.27 (1.24-1.29) 
Autoimmune disorders 1.15 (1.09-1.21) 1.30 (1.24-1.38) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




 Other covariates in the main regression models were also evaluated and results are 
presented in Appendix A. There were differences in the risks of rehospitalization by 
hospital type similar to those noted in Aim 2 analyses.  
Moderation Effect Results 
 
SMM was assessed as a moderator in the relation between maternal hypertensive 
disorders and rehospitalization outcomes. First, interaction terms between SMM and 
maternal hypertensive disorder subtypes were assessed in each of the six main models of 
rehospitalization. There were five significant interactions found across all outcomes. For 
hospital discharge rehospitalization: within one year, there was a significant interaction 
between superimposed preeclampsia and SMM (p=0.02); within six weeks, there were 
significant interactions between SMM and severe preeclampsia (p=0.004) as well as 
SMM and superimposed preeclampsia (p=0.003). For observational stay 
rehospitalization: there was a significant interaction between severe preeclampsia and 
SMM within one year (p=0.005) and within six weeks (p=0.02). There were no 
significant interaction terms between maternal hypertensive disorder subtypes noted for 
in the risk of emergency department admission.  
To further evaluate the potential differential effect of SMM on the relation 
between subtypes of hypertensive disorders and rehospitalization, stratified analyses were 
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conducted among deliveries to women with (n=7,815) and without SMM (n=727,761) for 
hospital discharge (Table 4.27) and observational stay outcomes. Superimposed 
preeclampsia and severe preeclampsia were combined into one category. Due to non-
convergence of observational stay outcomes in the stratified analyses, observational stay 
and hospital discharge outcomes were combined (Table 4.28).  
Table 4.27 Stratified Analysis of Hospital Discharge Rehospitalization by Severe 
Maternal Morbidity, Deliveries to MA Women 2002-2011 
Type of 
Rehospitalization 
Exposure No SMM Sample 
aRR (95% CI) 
SMM Sample 
aRR (95% CI) 
HD 1 year SIPE AND SPE 1.57 (1.44-1.71) 1.21 (0.95-1.55) 
 Mild Preeclampsia 1.51 (1.40-1.62) 1.35 (1.01-1.81) 
 Chronic HTN 1.61 (1.49-1.75) 1.70 (1.23-2.36) 
 Gestational HTN 1.44 (1.36-1.53) 1.37 (1.02-1.86) 
 Pre-existing diabetes 1.68 (1.54-1.83) 1.44 (1.05-2.00) 
 Gestational diabetes 1.20 (1.14-1.27) 1.15 (0.86-1.53) 
 Asthma 1.34 (1.27-1.43) 1.24 (0.94-1.63) 
 Substance Use  1.91 (1.77-2.05) 1.46 (1.02-2.10) 
 Depression 1.51 (1.42-1.60) 0.97 (0.70-1.36) 
 Autoimmune 2.15 (1.94-2.39) 1.47 (0.92-2.29) 
HD 6 weeks SIPE and SPE 1.99 (1.77-2.24) 1.45 (1.06-1.99) 
 Mild Preeclampsia 2.03 (1.84-2.25) 1.67 (1.15-2.43) 
 Chronic HTN 1.79 (1.59-2.03) 1.93 (1.21-3.09) 
 Gestational HTN 1.89 (1.74-2.05) 1.47 (0.98-2.21) 
 Pre-existing diabetes 1.51 (1.32-1.73) 0.99 (0.57-1.72) 
 Gestational diabetes 1.21 (1.11-1.31) 1.09 (0.72-1.63) 
 Asthma 1.24 (1.12-1.36) 1.21 (0.80-1.83) 
 Substance Use 1.37 (1.19-1.59) 1.81 (1.07-3.05) 
 Depression 1.33 (1.20-1.48) 0.56 (0.30-1.05) 
 Autoimmune 1.68 (1.39-2.03) 0.70 (0.30-1.67) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




Table 4.28 Stratified Analysis of Hospital Discharge/Observational Stay 




Exposure No SMM Sample 
aRR (95% CI) 
SMM Sample 
aRR (95% CI) 
HD/OS 1 year SIPE AND SPE 1.57 (1.46-1.70) 1.20 (0.96-1.50) 
 Mild Preeclampsia 1.55 (1.45-1.65) 1.43 (1.11-1.84) 
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 Chronic HTN 1.71 (1.59-1.83) 1.85 (1.40-2.46) 
 Gestational HTN 1.50 (1.42-1.58) 1.36 (1.04-1.79) 
 Pre-existing diabetes 1.65 (1.53-1.77) 1.31 (0.97-1.77) 
 Gestational diabetes 1.25 (1.19-1.31) 1.20 (0.93-1.55) 
 Asthma 1.37 (1.30-1.85) 1.22 (0.94-1.57) 
 Substance Use 1.73 (1.62-1.85) 1.24 (0.87-1.75) 
 Depression 1.49 (1.41-1.57) 1.03 (0.77-1.39) 
 Autoimmune 2.00 (1.82-2.20) 1.36 (0.90-2.07) 
HD/OS 6 weeks SIPE and SPE 2.07 (1.87-2.30) 1.41 (1.06-1.88) 
 Mild Preeclampsia 2.11 (1.93-2.31) 1.69 (1.22-2.35) 
 Chronic HTN 1.96 (1.76-2.18) 2.08 (1.38-3.13) 
 Gestational HTN 1.95 (1.81-2.10) 1.43 (0.99-2.06) 
 Pre-existing diabetes 1.42 (1.26-1.61) 0.86 (0.51-1.45) 
 Gestational diabetes 1.23 (1.14-1.32) 1.13 (0.79-1.60) 
 Asthma 1.29 (1.18-1.40) 1.23 (0.85-1.78) 
 Substance Use 1.36 (1.19-1.55) 1.27 (0.75-2.15) 
 Depression 1.37 (1.25-1.50) 0.78 (0.48-1.27) 
 Autoimmune 1.49 (1.25-1.78) 0.92 (0.47-1.82) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




To aid in interpreting the relation between chronic and pregnancy-associated 
conditions, SMM at delivery, and rehospitalization, mutually exclusive categories of 
chronic conditions and SMM at delivery were constructed. First, to understand the 
relation between hypertensive disorders and SMM, a variable was created for mutually 
exclusive combinations of severe forms of maternal hypertensive disorders 
(superimposed preeclampsia and severe preeclampsia), other forms of maternal 
hypertensive disorders (mild preeclampsia, chronic hypertension, and gestational 
hypertension), and SMM at delivery, Table 4.29 shows the result of the analysis of this 
variable. Compared to deliveries to women without hypertensive disorders and without 
SMM at delivery, deliveries to women with only SMM indicated at delivery had an 
increased risk of HD rehospitalization compared to deliveries to women with only 
subtypes of hypertensive disorders both within six weeks and one year; their confidence 
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intervals did not overlap. Point estimates for rehospitalization risk were generally greater 
when both hypertensive disorders and SMM were indicated; within six weeks there was a 
greater than 3-fold risk in HD rehospitalization among deliveries to women with SMM 
and hypertensive compared to those without either; only the estimate for SMM and other 
HTN differed from the estimates for SMM alone of the HTN groups with no SMM. 
Table 4.29 Adjusted Risk of Rehospitalization by both Maternal Hypertensive 
Disorders and Severe Maternal Morbidity, Deliveries to MA Women 2002-2011 
New Variable Categorization: 
Severe Hypertension, Other 
Hypertension, and SMM 
Hospital Discharge 6 week 
aRR
1
 (95% CI) 
Hospital Discharge 1 year 
aRR
1
 (95% CI) 
No HTN and No SMM REF REF 
SMM, No HTN 2.60 (2.28-2.98) 2.06 (1.87-2.26) 
Severe HTN, No SMM 2.03 (1.80-2.27) 1.58 (1.45-1.72) 
Other HTN, No SMM 1.92 (1.81-2.05) 1.50 (1.44-1.57) 
SMM and Severe HTN 3.09 (2.34-4.10) 2.34 (1.89-2.91) 
SMM and Other HTN 3.88 (3.10-4.86) 2.87 (2.42-3.39) 
 Observational Stay 6 week 
aRR
1
 (95% CI) 
Observational Stay 1 year 
aRR
1
 (95% CI) 
No HTN and No SMM REF REF 
SMM, No HTN 2.78 (2.15-3.60) 1.69 (1.41-2.03) 
Severe HTN, No SMM 2.40 (1.93-2.99) 1.66 (1.44-1.92) 
Other HTN, No SMM 2.35 (2.11-2.62) 1.75 (1.63-1.87) 
SMM and Severe HTN 2.43 (1.21-4.90) 1.90 (1.23-2.94) 
SMM and Other HTN 4.43 (2.84-6.92) 2.80 (2.06-3.82) 




 (95% CI) 




 (95% CI) 
0 No HTN and No SMM REF REF 
1 SMM, No HTN 1.51 (1.37-1.66) 1.18 (1.13-1.23) 
2 Severe HTN, No SMM 1.27 (1.16-1.38) 1.11 (1.07-1.16) 
3 Other HTN, No SMM 1.18 (1.13-1.23) 1.12 (1.10-1.14) 
4 SMM and Severe HTN 1.46 (1.12-1.90) 1.21 (1.07-1.37) 
5 SMM and Other HTN 1.61 (1.30-1.98) 1.27 (1.16-1.40) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 
during pregnancy, autoimmune conditions, asthma, pre-existing and gestational diabetes, substance use 
disorder, depression 
 
Another categorization examined the role of pre-existing chronic medical 
conditions (chronic hypertension, superimposed preeclampsia, autoimmune conditions, 
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asthma, and pre-existing diabetes) (PECMC), pregnancy-associated conditions (mild and 
severe preeclampsia, gestational hypertension and gestational diabetes) (PAC), and SMM 
at delivery (Table 4.30). Compared to deliveries to women without SMM, PAC and 
PECMC, the risk of HD rehospitalization within six weeks was greater for those with just 
SMM at delivery compared to women with just PAC or just PECMC. The addition of 
PAC or PECMC, or both to SMM did not increase the risk for six-week rehospitalization 
compared to deliveries to women with just SMM. For one-year rehospitalization, the risk 
estimate was decreased compared to the risk at six weeks for deliveries to women with 
just SMM (2.73 to 2.10) or just PAC (1.72 to1.40); however, the risk stayed constant for 
those with PECMC. The risk of 1 year HD rehospitalization was greater for deliveries to 
women with just SMM compared to deliveries to women with just PAC or just PECMC. 
Deliveries to women with both SMM with PECMC had a greater risk of one-year HD 
rehospitalization than with just SMM or just PECMC.  
Table 4.30 Adjusted Risk of Rehospitalization by Pre-Existing Chronic Medical 
Conditions, Pregnancy-Associated Conditions and Severe Maternal Morbidity, 
Deliveries to MA Women 
Variable categorization: SMM, PAC, PECMC
1 
6 week HD aRR
2 
 (95% CI) 




No SMM, no PAC, no PECMC REF REF 
SMM, no PAC, no PECMC 2.73 (2.37-3.16) 2.10 (1.89-2.33) 
No SMM, PAC, no PECMC 1.72 (1.62-1.82) 1.40 (1.35-1.46)  
No SMM, no PAC, PECMC 1.64 (1.52-1.77) 1.67 (1.60-1.75) 
SMM, PAC, no PECMC 3.45 (2.82-4.22) 2.61 (2.23-3.04) 
SMM, no PAC, PECMC 3.20 (2.37-4.30) 3.30 (2.74-3.96) 
No SMM, PAC, PECMC 2.27 (1.98-2.60) 2.08 (1.90-2.27) 
SMM, PAC, PECMC 3.41 (2.11-5.49) 2.83 (2.01-3.98) 
 6 week OS aRR 
(95% CI) 
1 year OS aRR 
 (95% CI) 
No SMM, no PAC, no PECMC REF REF 
SMM, no PAC, no PECMC 2.82 (2.13-3.73) 1.85 (1.52-2.25) 
No SMM, PAC, no PECMC 2.00 (1.80-2.21) 1.64 (1.54-1.75) 
No SMM, no PAC, PECMC 1.87 (1.64-2.13) 1.82 (1.69-1.96) 
SMM, PAC, no PECMC 3.40 (2.22-5.21) 1.98 (1.43-2.74) 
SMM, no PAC, PECMC 3.43 (1.88-6.24) 2.90 (2.02-4.16) 
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No SMM, PAC, PECMC 2.42 (1.87-3.14) 2.34 (2.02-2.71) 
SMM, PAC, PECMC 4.76 (1.98-11.49) 3.22 (1.74-5.94) 
 6 week ED aRR 
 (95% CI) 
1 year ED aRR  
(95% CI) 
No SMM, no PAC, no PECMC REF REF 
SMM, no PAC, no PECMC 1.50 (1.35-1.66) 1.18 (1.12-1.24) 
No SMM, PAC, no PECMC 1.17 (1.13-1.21) 1.12 (1.10-1.13) 
No SMM, no PAC, PECMC 1.33 (1.27-1.39) 1.30 (1.28-1.33) 
SMM, PAC, no PECMC 1.68 (1.41-2.00) 1.31 (1.20-1.42) 
SMM, no PAC, PECMC 2.04 (1.63-2.55) 1.51 (1.36-1.67) 
No SMM, PAC, PECMC 1.56 (1.42-1.70) 1.40 (1.35-1.46) 
SMM, PAC, PECMC 1.15 (0.69-1.93) 1.30 (1.06-1.59) 
1
SMM: Severe maternal morbidity at delivery; PAC: Pregnancy-associated conditions; PECMC: Pre-
existing chronic medical conditions 
2
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 
during pregnancy, depression, substance use disorder 
 
 Additional categorizations for depression and substance use disorder with SMM 
at delivery can be found in Appendix B. 
Sensitivity Analyses 
Severe Maternal Morbidity without Blood Transfusion 
 
 SMM was also analyzed in all multivariable regressions without the blood 
transfusion indicator. The risk of HD rehospitalization within six weeks was decreased 
among deliveries to women with SMM without transfusion (aRR: 1.75; 95% CI: 1.52-
2.02) compared to SMM with transfusion (aRR: 2.27; 95% CI: 2.03-2.54) (Table 4.31). 
For all other types of rehospitalization outcomes, the risk did not did not differ by the 
inclusion or exclusion of the blood transfusion indicator in the SMM measure. 
Table 4.31 Aim 3 Sensitivity Analysis: Severe Maternal Morbidity with and without 
Blood Transfusion 































































HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
Bold: p<0.05 
Number of Severe Maternal Morbidity Indicators 
 
 In this analysis, we also examined SMM by the number of SMM indicators a 
woman had at delivery hospitalization; 1.11% (n=8,135) of women had only one SMM 
indicator at delivery hospitalization and 0.19% (n=1,426) of women with two or more 
SMM indicators. There was no difference in the risk of rehospitalization with increasing 
number of SMM indicators (Table 4.32). 
Table 4.32 Aim 3 Sensitivity Analysis: Number of Severe Maternal Morbidity 
Indicators 
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HD: Hospital Discharge; OS: Observational Stay; ED: Emergency Department 
1
 Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 
during pregnancy, chronic and pregnancy-associated conditions (maternal hypertensive disorders, pre-
existing and gestational diabetes, asthma, substance use disorder, depression, autoimmune disorders) 
Bold: p<0.05 
 
Severe Maternal Morbidity as a Mediator 
 
The analysis assessed if SMM moderated the relation between chronic and 
pregnancy-associated conditions and rehospitalization. To examine an alternate 
hypothesis that SMM mediated the relation between chronic and pregnancy-associated 
conditions and rehospitalization within the first year postpartum, analyses were 
conducted in accordance with the methodology proposed by Baron and Kenney. First, a 
model estimated the relation between SMM and each of the six rehospitalization 
outcomes, as performed in Aim 2. Second, a model estimated the relation between 
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chronic and pregnancy-associated conditions and rehospitalization outcomes. The third 
and final model estimated the risk of rehospitalization with both chronic and pregnancy-
associated conditions and SMM, as seen above in the Aim 3 main multivariable results. 
Results of the mediation analysis are shown in Appendix C. There was no evidence of 
SMM mediation in any of the rehospitalization outcomes as the coefficients for chronic 
and pregnancy-associated conditions did not change between Models 2 and 3.  
In summary, between 2000-2012, maternal hypertensive disorders were 
documented in 8.7% of deliveries and the SMM rate was 101.9 per 10,000 deliveries in 
Massachusetts. From 2002-2011, 5.2% of all deliveries to women had a least one 
rehospitalization within six weeks and 19.9% within one year postpartum. Hypertensive 
disorders and other chronic conditions increased the odds of SMM at delivery and the 
risk of rehospitalization up to one year postpartum. Rehospitalization risk varied by type 
of admission and hypertensive subtype. SMM at delivery independently increased 
rehospitalization risk within the first six weeks and year postpartum and slightly 








































 This chapter discusses the results of the three aims of the research reported in this 
dissertation. The aims were to: 1) evaluate the relation between maternal hypertensive 
disorders and other chronic and pregnancy-associated conditions in pregnancy with 
severe maternal morbidity at delivery; 2) evaluate the relation between severe maternal 
morbidity at delivery and postpartum maternal rehospitalization in the year following 
delivery among deliveries to women without chronic medical diseases; and 3) evaluate 
the relation between maternal hypertensive disorders and other chronic and pregnancy-
associated conditions in pregnancy with postpartum maternal rehospitalization in the year 
following delivery independent of severe maternal morbidity at delivery. The chapter 
begins with a brief overview of the study methods, a discussion of the main findings for 
each aim, followed by a discussion of strengths and limitations, public health 
implications and conclusions of the research. 
Study Overview  
 
Aim 1 evaluated the relation between maternal hypertensive disorders, pre-
existing and gestational diabetes, asthma, depression, substance use disorders and 
autoimmune conditions and severe maternal morbidity (SMM) at the delivery 
hospitalization. The study population was identified as deliveries to resident women in 
Massachusetts over a 13-year period. Birth certificates and fetal death records (BCFD) 
were linked to delivery-related hospital discharge (HDD) records in Massachusetts from 
2000-2012, using the Pregnancy to Early Life Longitudinal (PELL) data system 
(n=960,982). SMM was defined using the CDC classification system of 25 ICD-9-CM 
diagnoses and procedures codes on HDD records, adjusted for severity-based on length 
137 
 
of stay for method of delivery; it was examined with and without blood transfusion. 
Bivariate comparisons were assessed with Wald χ
2
 tests and trends over time were 
assessed with Cochran-Armitage tests. Multivariate logistic regression using generalized 
estimating equations examined the odds of SMM with and without blood transfusion at 
delivery hospitalization. Main covariates included: maternal age, race/ethnicity, insurance 
status, and hospital level.  
Aim 2 evaluated the association between SMM at delivery hospitalization and 
hospital utilization in the first six weeks and one year postpartum. Non-injury non-
antenatal emergency department (ED), observational stay (OS) and non-delivery hospital 
discharge (HD) records in the first year postpartum were linked to corresponding BCFD 
and HDD deliveries from 2002-2011. Aim 2 was based on data for a subset of deliveries 
to women without chronic medical conditions (superimposed preeclampsia, chronic 
hypertension, diabetes, asthma, and autoimmune conditions) (n=685,228). Analyses 
described types of hospital encounters in the first six weeks and year postpartum by 
timing and frequency. Wald χ
2
 test statistics were used to assess differences in 
postpartum hospital encounters between deliveries with and without SMM. Multivariate 
log-binomial regression with generalized estimating equations modeled the relative risk 
of hospital encounters within six weeks and one year postpartum, adjusting for key 
confounding variables including year, hospital level, maternal age, race/ethnicity, 
insurance payer, pregnancy-specific conditions, method of delivery, and length of stay at 
delivery.  
 Aim 3 evaluated the association between maternal hypertensive disorders, other 
chronic and pregnancy-associated conditions, SMM and postpartum maternal 
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rehospitalization in the year following delivery. We also evaluated whether SMM at 
delivery moderated the relation between maternal hypertensive disorders and 
rehospitalization. Non-injury non-antenatal ED, OS and HD records in the first year 
postpartum were linked to all corresponding BCFD and HDD Massachusetts deliveries 
from 2002-2011, using the PELL data system (n=735,576). Multivariate Poisson 
regression models used a generalized estimating equations approach to estimate the risk 
of each type of rehospitalization within six weeks and one year postpartum. Effect 
modification was examined through interaction terms in multivariate models between 
hypertensive disorder subtypes and SMM at delivery, with significance assessed at 
p<0.05.  
Aim 1 Discussion 
 
Aim 1: Evaluate the relation between maternal hypertensive disorders and other chronic 
and pregnancy-associated conditions in pregnancy with severe maternal morbidity 
outcomes at delivery. 
Maternal hypertensive disorders were documented in 8.7% of delivery 
hospitalizations; the most common subtype was gestational hypertension (3.7%). The 
SMM rate was 101.9 per 10,000 deliveries. Our study results showed increased odds of 
SMM at delivery among all subtypes of maternal hypertensive disorders in pregnancy 
and some chronic conditions. Analyses of trends in hypertensive disorders among 
deliveries between 2000 and 2012 are consistent with previous findings of recent 
increasing rates of maternal hypertensive disorders, with the exception of mild 
preeclampsia (1-5). The increase in the SMM rate over the study period also is consistent 
with previous research, although we report more recent data, inclusive of 2012, showing 
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a continuation of increasing SMM rates (6). A further recalculation of the SMM rate 
without blood transfusion also showed increases over the study period; this rate showed a 
somewhat lower increase over time.  
SMM was more frequent among deliveries to women with all hypertensive 
subtypes when compared to deliveries for women without a hypertension diagnosis. 
Deliveries to women with the most severe maternal hypertensive disorders had the 
greatest odds of SMM after adjustment for social and biological confounders. Compared 
to women without hypertension, the odds of SMM were 4.08 (95% CI: 3.71-4.48) for 
women with severe preeclampsia, 2.65 (95% CI: 2.23-3.15) for superimposed 
preeclampsia, 2.30 (95% CI: 2.09-2.53) for mild preeclampsia, 1.60 (95% CI: 1.46-1.75) 
for gestational hypertension and 1.50 (95% CI: 1.32-1.70) for chronic hypertension. 
When blood transfusion was excluded, there were no considerable changes in the odds of 
SMM by hypertensive disorder type.  
Previous research examining hypertensive disorders and obstetric complications 
showed the highest risk to be among deliveries to women with severe preeclampsia and 
the lowest among those with gestational hypertension (3), although superimposed 
preeclampsia was not considered. A recent study of 15 California hospitals found 8.8% of 
deliveries to women with acute severe intrapartum hypertension (systolic blood pressure 
>160mm Hg or diastolic blood pressure >105 mm Hg) had SMM at delivery compared to 
2.3% without this complication (7). 
The observed association between severe preeclampsia and SMM at delivery is 
biologically plausible. Some conditions in the SMM classification system including 
cardiac arrest, acute myocardial infarction and heart failure, may represent complications 
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of hypertensive disorders (8, 9). Severe preeclampsia may also lead to increased risk of 
hemorrhage requiring transfusion, a qualifying procedure of SMM, due to decreased 
blood flow to organs other than the placenta (10). Another indicator in the measure of 
SMM is amniotic fluid embolism, which is hypothesized to be related to placental 
structural or physiologic abnormalities, also a leading theory of preeclampsia (11). These 
explanations may apply to superimposed and mild preeclampsia, as well. 
A cardiac-related SMM code was created to further understand potential pathways 
from hypertensive disorders to SMM. Deliveries to women with severe preeclampsia had 
increased odds of cardiac-related SMM. The odds of cardiac-related SMM were similar 
to those of overall SMM for superimposed preeclampsia and chronic hypertension but 
were attenuated for severe and mild preeclampsia; the odds of cardiac-related SMM were 
not significant for gestational hypertension. As the definition of severe maternal 
morbidity is broad, conditions and procedures in this classification system related to 
cardiovascular illness represent a plausible pathway of the manifestation of hypertensive 
disorders due to damage to the endothelium (8, 9), as suggested by the results for severe 
preeclampsia in particular.  
Asthma, pre-existing diabetes, and autoimmune conditions were also associated 
with SMM, both with and without blood transfusion. Although we could not account for 
disease severity or the extent of medication management, previous research shows 
adverse perinatal outcomes for women with these conditions. A previous review and 
meta-analysis indicated that pregnant women with asthma have altered placental function 
as well as an increased risk of hemorrhage, placental abruption, and premature rupture of 
the membranes (12). Pre-existing diabetes also has been shown to be associated with 
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increased risk of preterm delivery and cesarean delivery (13). Types of autoimmune 
conditions have been associated with poor obstetric outcomes; lupus is associated with 
cesarean delivery and preterm birth and rheumatoid arthritis is associated with increased 
risk of cesarean delivery; however, there have been mixed findings regarding adverse 
outcomes with multiple sclerosis (14).   
Both substance use disorders and depression showed increased adjusted odds of 
SMM overall; however, when sensitivity analyses examined SMM without blood 
transfusion, both were no longer statistically significant. Opioid use and dependency in 
pregnancy has been associated with increased odds of transfusion (15), which may 
explain why substance use disorders were no longer statistically significant when 
transfusion was omitted. In a study of Medicaid data in the US, antidepressant use late in 
pregnancy was associated with increased risk of postpartum hemorrhage. While our study 
did not account for medication use, the lack of a relation between depression and SMM 
when transfusion was excluded (aOR of SMM with transfusion reduced from 1.24 (95% 
CI: 1.11-1.38) to 1.12 (95% CI: 0.95-1.32) without transfusion) may be due to the 
relation of antidepressant medication in depressed women with transfusion (16). 
Gestational diabetes was not associated with increased odds of any type of SMM. 
The unadjusted odds of gestational diabetes was 1.15 (95% CI: 1.06-1.24); the relation 
between gestational diabetes and SMM was no longer significant when maternal 
characteristics, including age, race/ethnicity, parity, education, and year were added to 
the model. While gestational diabetes is a risk factor for some perinatal complications, 
including macrosomia and cesarean delivery, it does not appear to be associated with 
SMM (17). It is not generally associated with preterm birth or low birthweight. 
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Similar to other studies, social and biological variables associated with increased 
risk of SMM included: maternal age greater than 35 years, non-white race, multiple 
gestations, cesarean or VBAC delivery, public insurance, no prenatal care, and low birth 
weight delivery (18, 19). Variables associated with decreased risk of SMM included post-
graduate education and smoking during pregnancy; this protective association between 
smoking and SMM has also been reported for smoking and preeclampsia (20). Obesity 
was another variable of interest; however, accurate information could not be ascertained 
across the study period and therefore was not included in the analysis. In a previous study 
of SMM in New York City from 2011-2013, deliveries to women with overweight and 
obese pre-pregnancy body mass indices were not at increased odds of SMM compared to 
deliveries to women at normal weight (21). 
Aim 2 and Aim 3 Discussion 
 
Aim 2:  Evaluate the relation between severe maternal morbidity at delivery and 
postpartum maternal rehospitalization in the year following delivery among women 
without chronic medical diseases. 
Aim 3: Evaluate the relation between maternal hypertensive disorders and other chronic 
and pregnancy-associated conditions in pregnancy with postpartum maternal 
rehospitalization in the year following delivery independent of severe maternal morbidity 
at delivery. 
 
Aim 2 was evaluated using the population of deliveries to women without chronic 
medical conditions. Findings included an increased risk of rehospitalization within six 
weeks and one year postpartum among deliveries to women with SMM, independent of 
social and biological confounders in this population. When expanded to include all 
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women with deliveries in Massachusetts, Aim 3 results showed that deliveries to women 
with maternal hypertensive disorders and to women with SMM at delivery had increased 
risk of all types rehospitalization; deliveries to women with chronic medical and 
pregnancy-associated conditions also had increased risk of rehospitalization within one 
year. In adjusted analyses, there was some evidence that SMM moderated the relation 
between maternal hypertensive disorders and types of rehospitalization but this evidence 
was not strong. Also, SMM did not appear to mediate the relation between maternal 
hypertensive disorders and types of rehospitalization. When considered together, SMM at 
delivery appeared to show a stronger effect on HD rehospitalization than maternal 
hypertensive disorders, as determined by the risk ratios when considered together.  
 
Maternal rehospitalization 
Maternal rehospitalization is an indicator of maternal morbidity. The rate of HD 
non-injury non-antenatal rehospitalization among all postpartum women in the first 42 
days in our study (1.2%) was comparable to other studies. Belfort et al. (2010) found 
1.2% readmission within 42 days among a system of 114 hospitals in 21 states in the US 
(22). Liu et al. (2005) found 1.8% of Canadian women with singleton births were 
rehospitalized within 60 days after initial discharge (23) and Lydon-Rochelle et al. (2000) 
found an overall readmission rate within 60 days of 1.2% in Washington State (24). In 
addition to measuring HD rehospitalizations, our study also analyzed OS 
rehospitalization and ED admission rates to provide a wider range of maternal morbidity 
in the postpartum period; in the first six weeks, 0.4% of women had at least one OS 
rehospitalization and 4.0% had at least one ED admission.  
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Rehospitalization in the first year postpartum was examined to mirror current 
definitions of pregnancy-related mortality in the US. Approximately one in five women 
had at least one ED, OS, or HD rehospitalization within the first year postpartum; 17.9% 
had an ED admission, 1.1% had an OS rehospitalization, and 3.0% had an HD 
rehospitalization. There was also a trend of increasing HD and ED admissions within the 
first year postpartum. One Maryland study of reproductive age women aged 15-44 years 
also found an increasing rate of ED admissions from 2.8 per 100 women in 1999 to 4.2 in 
2005 (25). 
Severe maternal morbidity and rehospitalization 
In our analysis, the risk of at least one rehospitalization within six weeks 
postpartum was higher among deliveries to women with SMM at delivery hospitalization. 
Almost three in ten women with SMM at delivery (28.3%) had at least one 
rehospitalization within the first year postpartum compared to two in ten (19.2%) without 
SMM. 
Most studies of delivery events and rehospitalization focused on the impact of 
method of delivery. Lyndon et al. (2012) (19) as well as the results for Aim 1 showed an 
association between cesarean delivery and SMM at delivery. Among primiparous women 
without chronic medical conditions delivering singleton infants in Washington State, 
researchers found an 80% increased risk of rehospitalization within 60 days for women 
with cesarean delivery and 30% increased risk for women with assisted vaginal delivery 
(24). In a population of women with no prior cesarean and no prenatal risk identified on 
the birth certificate, DeClercq et al. (2007) found a greater than two-fold risk of 
rehospitalization in the first 30 days postpartum for women with planned cesarean births 
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compared to those with planned vaginal births (26). In a case control study, Sharvit et al. 
(2014) found increased risk of rehospitalization within 14 days associated with 
emergency cesarean delivery (27). Aim 2 results showed that primary and repeat cesarean 
deliveries were associated with only a 10-30% increase in HD and ED rehospitalization 
compared to vaginal deliveries, less than previous studies. In addition to the method of 
delivery, SMM at delivery was associated with a greater than two-fold increase risk of 
both HD (aRR 2.48; 95% CI: 2.20-2.80) and OS (aRR 2.47; 95% CI: 1.94-3.14) 
rehospitalization and approximately a 50% increased risk (aRR: 1.47; 95% CI: 1.34-1.61) 
in ED admission within the first six weeks postpartum.  
The findings also showed a sustained increased risk for rehospitalization for 
deliveries to women with SMM at delivery up to one year postpartum. Within one year, 
the risk of HD rehospitalization for deliveries to women with SMM was greater than two-
fold compared to women without SMM (aRR: 2.04; 95% CI: 1.87-2.23). Few studies 
have examined rehospitalization up to one year postpartum. The adjusted odds of 
rehospitalization between 181-365 days was 1.77 (95% CI: 1.32-2.38) among women 
with cesarean births with no labor and no complications compared to vaginal births with 
labor in a study by DeClercq et al. (2007) using linked hospital discharge and vital 
records data from 1998-2003 (26). The analyses in Aims 2 and 3 looked beyond method 
of delivery to consider whether or not severe events at delivery adversely impact 
maternal health in the first year postpartum. 
The association between SMM and OS and ED admissions within the first year 
was less clear. Although OS regression models showed increased risk for SMM within 
the first year (aRR: 1.57; 95% CI: 1.21-2.03), it is likely due to relation for OS 
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admissions in the first six weeks. SMM was not significant in adjusted relative risk 
models for OS admissions between 42-364 days postpartum. For ED admissions within 
one year, deliveries to women with SMM had a 16% greater risk than those to women 
without SMM (aRR: 1.16; 95% CI: 1.11-1.21); between 42-365 days, the increased risk 
of ED admission was only 8% and was not significant when SMM was considered 
without transfusion.  
The observed association of SMM with increased risk of rehospitalizations in this 
study is consistent with previous studies of readmission associated with certain SMM 
indicators. A 2010 study by Belfort et al. examined causes of hospital readmission within 
42 days postpartum and found the following SMM indicators as reasons for readmission: 
hemorrhage, sepsis, cardiomyopathy, deep vein thrombosis, and infection (22). Sutton et 
al. (2010), using data from the Healthcare Cost and Utilization Project (HCUP) State 
Inpatient Databases (SID) in seven states, found increased hospital readmission within 
thirty days among patients with a principal or secondary initial diagnosis of septicemia, a 
SMM indicator (28). Pelvic infections were also found to be the most common type of 
infection after hysterectomy, another indicator for SMM (29). Callaghan et al. reported a 
rate of postpartum SMM, 29 per 10,000 deliveries in 2008-2009, based on hospital 
discharge coding of postpartum hospitalizations in the Nationwide Inpatient Sample; 
however, these data were not linked to delivery events (6). 
Sensitivity analyses were conducted to examine SMM with and without blood 
transfusion in relation to rehospitalization. Risk estimates were not significantly different 
when SMM excluded blood transfusion for all postpartum outcomes; however, there was 
a lower risk of 42-364 day HD readmission among deliveries to women with SMM at 
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delivery when compared to <42 days HD admission when transfusion was included. This 
result may be due to greater power to detect differences because of the larger numerator 
when SMM included transfusion. An additional sensitivity analysis excluded women who 
died within the first year postpartum, which also showed no difference in risk estimates.  
Maternal hypertensive disorders and rehospitalization 
The findings from Aim 3 indicated an increased risk of all types of 
rehospitalization among women with maternal hypertensive disorders and other chronic 
and pregnancy-associated conditions. Risk, however, varied by type of rehospitalization 
and by hypertensive subtype. The adjusted risk of HD rehospitalization among deliveries 
to women with hypertensive disorders ranged from 1.81-2.25 within six weeks and 1.44-
1.82 within one year, with the greatest risk seen for superimposed preeclampsia. While 
no other studies have examined all types of maternal hypertensive disorders, one New 
York population-based study showed increased odds of cardiovascular disease and 
stroke-related hospitalizations in the first year postpartum among women with 
pregnancy-induced hypertension (30). Findings from a study of high-risk women 
indicated that 17% of women were rehospitalized within one year, with the highest risks 
of rehospitalization for chronic hypertensives and gestational diabetics (31). In another 
study, hypertension was one of the most common indications for readmission within six 
weeks among both vaginal (16.4 per 10,000) and cesarean (23.9 per 10,000) deliveries 
(22). In our study, risks were similar for HD and OS rehospitalizations within six weeks 
and one year: both superimposed preeclampsia and chronic hypertension, the two types 
of pre-pregnancy hypertension, showed the strongest associations with rehospitalizations, 
emphasizing the role of chronic disease in the postpartum period. All forms of 
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hypertensive disorders, including those diagnosed during pregnancy, still were associated 
with increased risk of HD rehospitalizations, indicating a continuation of risk through one 
year postpartum. 
The study results also showed increased risk of ED admissions among deliveries 
to women with hypertensive disorders, with the highest risk estimates at both six weeks 
and one year among those with superimposed preeclampsia and chronic hypertension. 
The risks ranged from 1.14-1.27 within six weeks and 1.08-1.22 within one year and 
were significantly lower than the risk estimates for HD and OS rehospitalization within 
six weeks and HD rehospitalization within one year. While other studies have not 
examined the role of specific hypertensive disorders, a study of Maryland women on 
Medicaid found the presence of any preconception medical comorbidities (including type 
2 diabetes, chronic hypertension, obesity, asthma, mental health, and substance abuse 
diagnoses) to be associated with increased postpartum ER use in the first six months 
postpartum (OR 1.61: 95% CI: 1.51-1.73) (32). Although the magnitude of the risk of ED 
admission is low in comparison to other types of rehospitalization, the adverse effects of 
maternal hypertensive disorders were still significant up to one year postpartum. 
Other chronic and pregnancy-associated conditions and rehospitalization 
Pre-existing diabetes, gestational diabetes, asthma, substance use disorders, 
depression and autoimmune conditions were all associated with an increased risk of HD 
rehospitalization and ED admission at both time points; some also were associated with 
increased risk of OS rehospitalization. 
Diabetes: Pre-existing diabetes and gestational diabetes were, in general, associated with 
increased risk of all types rehospitalization with risk estimates ranging between 1.12 and 
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2.11; the risk was greater for deliveries to women with pre-existing diabetes across all 
outcomes. Roughly half of women with a history of gestational diabetes will develop 
Type 2 diabetes within ten years (33). Researchers have found increased odds of Type 1 
and Type 2 diabetes hospitalizations in the year after delivery among women with 
gestational diabetes (30). There is mixed evidence of an association between gestational 
diabetes and cardiovascular disease (30, 34).  
Asthma: A continuation of increased risk of all types of rehospitalization was noted for 
asthma through one year postpartum, with risks ranging from 1.23 to 1.48. Women with 
asthma in pregnancy have altered placental function (35); Aim 1 results showed an 
increased risk of SMM at delivery. In a previous meta-analysis, women with asthma were 
at increased risk of other maternal and placental complications, including postpartum 
hemorrhage (RR: 1.29; 95% CI: 1.18-1.41) (12), which could be a cause of 
rehospitalization.  
Autoimmune conditions: Deliveries to women with autoimmune disorders were at 
increased risk of all types of rehospitalization within one year, ranging from 1.30 to 2.11; 
point estimates increased between 6 weeks and one year postpartum. Previous studies 
suggest that some autoimmune disorders, including multiple sclerosis and rheumatoid 
arthritis, remit during pregnancy but exacerbate in the postpartum period (36-38). 
Substance use disorders: Deliveries to women with substance use disorders had 1.89 
times the risk of HD rehospitalization within the first year postpartum, significantly 
higher than the risk at six weeks (aRR: 1.40; 95% CI: 1.22-1.61). Previous studies 
suggest postpartum substance users (illicit drugs, cigarettes, and alcohol) relapse after 
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increased rates of abstention during the pregnancy (39), which could lead to increased 
rehospitalization in the postpartum period. 
Depression: Deliveries to women with depression were at increased risk for all types of 
rehospitalization one year postpartum, with risk estimates ranging from 1.27-1.54. 
Investigators in Scotland found psychiatric admissions fell during pregnancy and 
increased in the early postpartum period, particularly during the first two weeks 
postpartum; they remained elevated up to two years after delivery compared to pre-
pregnancy rates (40). A New York State study found increasing rates of hospitalizations 
for depression in the first year after delivery from 1995-2004 (41). In a meta-analysis, the 
strongest predictors for postpartum depression included depression during pregnancy and 
a previous history of depression (42). 
Maternal hypertensive disorders, severe maternal morbidity and rehospitalization   
Both hypertensive disorders and SMM at delivery increased the risk of 
rehospitalization within the first year postpartum. In our analysis, 1.0% of women 
without SMM at delivery and without maternal hypertensive disorders had an HD 
rehospitalization in the first year; rehospitalization ranged for women with either a 
maternal hypertensive disorder or SMM at delivery between 2.2 and 8.9% in the first 
year.  
When assessed together, the independent association of SMM on rehospitalization 
appeared greater than that of maternal hypertensive disorders. Compared to deliveries to 
women without SMM and without any hypertensive disorders, the risk of HD 
rehospitalization within six weeks and one year was greater for deliveries to women with 
SMM than those with hypertensive disorders. Having both SMM and any type of 
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hypertensive disorder increased the risk of HD rehospitalization to more than 3-fold 
within six weeks and more than 2-fold within one year. When aggregated by pre-existing 
chronic medical conditions, conditions occurring in pregnancy, and SMM at delivery, the 
risk of HD rehospitalization was not attenuated for deliveries to women with pre-existing 
conditions up to one year postpartum, highlighting the continued adverse effects of these 
conditions.  
Our research aligns with the conceptual framework that integrates the life course 
perspective in health outcomes and incorporates both critical and sensitive periods and a 
cumulative pathways model over time (43). Both hypertensive disorders and SMM at 
delivery together increased the risk of HD rehospitalization above the presence of any 
hypertensive disorder alone. However, the number of SMM indicators did not increase 
rehospitalization risk; rather, the presence of at least one SMM indicator at delivery was a 
critical factor in increased rehospitalization risk. 
Previous studies on postpartum rehospitalization have seldom included both pre-
existing conditions and delivery events. Liu et al. (2005) observed an almost doubling of 
odds of 60 day rehospitalization among Canadian women with cesarean compared to 
spontaneous vaginal delivery (23). In Aim 3, the risk of HD rehospitalization within six 
weeks was 30% greater in women with cesarean delivery compared to vaginal delivery, 
significantly less than the risk of SMM at delivery or any type of maternal hypertensive 
disorder. While method of delivery may have been a proxy for severe events at delivery 
in previous studies, the current study adds greater specificity to understanding the impact 
of hypertensive disorders and severe events at delivery on postpartum maternal health.  
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Our study results also are consistent with research about intermediate and longer-
term adverse outcomes in women, adding to our understanding of chronic disease across 
the life course. In a Dutch case control study, markers of future maternal cardiovascular 
disease a median of 7.1 years after delivery were significantly higher among women with 
a history of preeclampsia than those without; these markers included fasting glucose 
levels, larger waist circumferences, and hypertension (44). In a study of Kentucky 
women 50 years and older, women with one or more pregnancy complication (preterm 
labor, preeclampsia, gestational diabetes, and third trimester bleeding) had increased odds 
of cardiovascular disease (including: angina, heart attack, heart failure, arrhythmia) 
compared to women who were never pregnant; women who were pregnant with no 
pregnancy complications had similar risks of cardiovascular disease compared to women 
who were never pregnant (45). The current study identified adverse outcomes among 
postpartum women with hypertensive disorders and severe events at delivery, although 
for a shorter term. 
SMM appeared to slightly moderate the relation between some types hypertensive 
disorders and rehospitalization, although the effect was not strong. In particular, SMM 
appeared to moderate the impact of more severe types of hypertension, including 
superimposed and severe preeclampsia, on HD and OS rehospitalizations as evaluated by 
significant interaction terms. When SMM was not present, there was an increased risk of 
HD and OS rehospitalization for deliveries to women with superimposed and severe 
preeclampsia compared to those to women without hypertensive disorders versus when 
SMM was present. SMM did not appear to mediate the relation between hypertensive 
disorders and any type of rehospitalization. Previous researchers have suggested 
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pregnancy complications may predict later chronic disease, including cardiovascular 
disease (46). The results from Aim 3 support strong independent effects of both SMM at 
delivery and hypertensive disorders on rehospitalization risk in the first six weeks and 
year postpartum.  
Study Strengths 
 
The linkage of vital records with hospital discharge data in our study allowed for 
fuller investigation of variables to study the relation of chronic and pregnancy-associated 
conditions, SMM at delivery and rehospitalization. This linkage enabled better 
ascertainment of key variables including chronic and gestational hypertension as well as 
pre-existing and gestational diabetes, compared to each data source alone (47, 48). In 
addition, other potential confounding social and biological variables from the birth 
certificate and fetal death record were included in the analyses, reducing potential 
residual confounding. 
Another strength was that multiple deliveries across the same women were 
included during the study period, using a generalized estimating equations approach; this 
approach provided better error estimates of the parameters of association. 
Our population-level approach in Aims 1 and 3 was representative of deliveries to all 
resident women in MA hospitals, and may be generalizable of deliveries to women in the 
US with similar characteristics to MA. The more than half a million delivery records 
provided increased statistical power to differentiate maternal hypertensive disorders, 
specifically superimposed preeclampsia.  
Another strength of our study was our ability to use linked data to examine 
maternal morbidity at delivery and into the postpartum period in Aims 2 and 3. This 
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approach limited temporal ambiguity as the exposure and outcome variables were 
obtained from different sources at different points in time.  
Study Limitations 
 
The use of hospital discharge data enabled a population-level approach but also 
had several limitations. The hospital discharge database is primarily an administrative 
database with the main purpose of billing; these data may more accurately reflect 
conditions that affect reimbursement. Obstetric diagnoses usually do not impact 
reimbursement, and may not be abstracted as carefully as medical-surgical conditions 
(49). There is a potential for underestimation of maternal comorbidities in hospital 
discharge data since coding standards only require coding of conditions that affect the 
current condition (50). With a high specificity and lowered sensitivity (2), this 
underestimation more likely influenced ascertainment of preexisting conditions that are 
not also documented on the birth certificate. The birth certificate also has noted low 
sensitivities on pre-existing maternal conditions; however, when these data are combined 
with the hospital discharge data, ascertainment more closely reflects data from the 
medical record (48). 
We did not have access to outpatient data, and relied on rehospitalization 
information as a way to understand maternal morbidity in the postpartum period. There is 
the potential that sick women may be seen in outpatient rather than hospital settings, 
particularly ED admissions, although the sickest, who were captured in our study, were 
still likely to be seen in the hospital.    
Previous studies have suggested that the association of hypertensive disorders 
with cardiovascular risk may be largely due to shared pre-pregnancy risk factors, such as 
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obesity and blood pressure (51). While we focused on many pre-pregnancy conditions, 
our study had limited obesity information from the hospital discharge at delivery and 
only post-2011 obesity data on the birth certificate; this information could not be used in 
the analysis. There were other unmeasured variables that are common risk factors that 
were not be included in the study, such as the family history of disease. 
Public Health Implications  
 
Overall, this research furthers our knowledge of the continuum of maternal health 
in the US from pre-pregnancy through the first year postpartum. Our research suggests 
that women with both maternal hypertensive disorders and SMM at delivery are at 
increased risk of adverse events that extend beyond the delivery hospitalization into both 
the first six weeks and one year postpartum. The need to draw attention to this small, but 
perhaps growing number of women, at the time of postpartum discharge is highlighted by 
our findings. Public health implications of this research include primary and secondary 
prevention of hypertensive disorders, prevention of SMM, as well as mitigation of the 
consequences of both hypertensive disorders and SMM postpartum.  
Prevention strategies for hypertensive disorders during pregnancy may be focused 
on more distal determinants of maternal health, including the physical and social 
environment, and women’s underlying health before pregnancy (52). More proximate 
primary strategies, such as the supplementation of calcium and vitamins C and E have not 
been shown to be effective in randomized controlled trials (53, 54), while other strategies 
for prevention of preeclampsia have been implemented in recent years. For example, the 
United States Preventive Task Force (USPTF) updated clinical guidelines in 2014 to 
prescribe low dose aspirin (81mg/d) after 12 weeks gestation to asymptomatic pregnant 
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women at high risk for preeclampsia; here, the USPTF defined high risk as either: a 
history of preeclampsia, multifetal gestation, chronic hypertension, type 1 or 2 diabetes, 
or renal disease and autoimmune disease.  
Further, there are antihypertensive medication recommendations for pregnant 
women. Randomized controlled trials have shown the benefit of magnesium sulfate 
prophylaxsis to prevent seizures in preeclamptic women (55-57). In a systematic review 
of 15 trials, magnesium sulfate was shown to more than halve the risk of eclampsia and 
potentially reduce maternal death with limited side effects (58). A focus of the subtypes 
of hypertensive disorders in pregnancy at a population-based level in this research has the 
potential to inform these prevention and management strategies. 
At the state level, Perinatal Quality Collaboratives (PQCs) are one mechanism to 
address hypertensive disorders, SMM and postpartum maternal health. According to the 
CDC, state PQCs are “networks of perinatal care providers and public health 
professionals working to improve pregnancy outcomes for women and newborns by 
advancing evidence-based clinical practices and processes through continuous quality 
improvement (CQI)” (59). Successful PQC projects in California and New York have 
been found to decrease the percentage of non-medically indicated deliveries between 37 
and 38 weeks gestation through a variety of interventions including: improving patient 
and provider education, encouraging use of optimal gestational dating criteria, and 
improving communication (59). The use of PQCs to successfully reduce hypertension 
and severe maternal morbidity at delivery is still unclear. 
At the both the state and facility level, one strategy for prevention of SMM is 
implementing Quality Improvement projects created by the National Partnership for 
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Maternal Safety, a national initiative for every birthing center in the US to have a safety 
program in place for the most common preventable causes of maternal morbidity and 
death (60). In 2012, the National Partnership for Maternal Safety identified the need for 
development of three maternal safety bundles for 1) obstetric hemorrhage, 2) severe 
hypertension, and 3) venous thromboembolism. A safety bundle includes a set of 
evidence-based practices that have been shown to improve patient outcomes covering the 
domains of readiness, recognition and prevention, response, and reporting/systems 
learning. The hypertension safety bundle was developed in May 2015 (61). 
Also at the facility level, the CDC and the American College of Obstetricians and 
Gynecologists (ACOG) have recently called for a facility-based identification of women 
with severe maternal morbidity (62, 63). Although there is not complete consensus 
among systems and professional organizations about the conditions that represent severe 
maternal morbidity, they recommend operational criteria for surveillance and review to 
include 1) women who receive transfusion greater than or equal to 4 units of blood or 2) 
are admitted to the Intensive Care Unit. The goal of the reviews is to focus on the 
prevention of morbidity and identify whether there were opportunities to alter the 
outcome (strong, possible, none). If there were strong or possible opportunities to do so, 
the review committee makes specific recommendations. 
Geller et al. (2004) proposed that preventability of severe morbidity and death 
occurs at three levels: the overall system (communication, policies and procedures, and 
care process), overall provider (failure to identify high-risk status, incomplete or 
inappropriate management, or no referral to a tertiary care facility), and overall patient 
(non-adherence) levels (64). Researchers examined cases of pregnant or recently 
158 
 
postpartum women admitted to the Intensive Care Unit in New Zealand who experienced 
severe acute maternal morbidity and found that more than one third of cases were 
potentially preventable (65). Among preventable factors, clinician-related factors 
included a failure to diagnosis or recognize high-risk status and a delay in treatment or 
inappropriate treatment; the most common causes of preventable severe morbidity were 
blood loss and septicemia (65). Specific to cardiovascular morbidity, researchers suggest 
the importance of the obstetrician to identify risk factors during pregnancy to enhance 
prevention efforts, as pregnancy provides a critical time to influence risk factors (66).  
Mitigating the consequences of SMM after delivery may involve more 
comprehensive discharge planning at delivery hospitalization. The number of women 
with SMM is relatively small, indicating that attention to the needs of these women 
would be highly feasible. The best strategies for addressing the needs of these women, 
however, remain unclear. Research findings evaluating discharge readiness, which 
addressed a more individualized approach through taking into consideration the opinions 
of the mother, pediatrician and obstetrician for the timing of discharge, noted increased 
health care use and poorer health outcomes 2-4 weeks post-delivery among mother-infant 
dyads when there was discordance in opinions about discharge readiness (67). A 
systematic review of randomized controlled trials of universal postpartum home visits by 
trained individuals or health care professionals did not show significant improvements in 
outcomes of: maternal knowledge, attitudes, parenting skills, mental health, quality of 
life, or physical health (68, 69); however, home visits may improve maternal satisfaction 
with postpartum support and reduce postpartum depression scores among women at high 
risk for family dysfunction or postpartum depression. 
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The prevention, early diagnosis, and management of maternal hypertensive 
disorders may benefit not only the mother but the infant as well. Poor infant outcomes are 
directly related to preeclampsia as well as to prematurity that results from appropriate 
induction of delivery of women with preeclampsia. Preeclampsia is estimated to account 
for 15% of preterm births in the United States and almost one quarter of medically 
indicated preterm births are indicated for preeclampsia (70, 71). Early onset preeclampsia 
was associated with almost a six-fold increase in odds of fetal death and sixteen fold 
increase in odds of perinatal death or severe neonatal morbidity; late onset preeclampsia 
was associated with a two-fold increase in odds of perinatal death or severe neonatal 
morbidity among women with singleton births in Washington State between 2000 and 
2008 (72). In a recent retrospective cohort study of all deliveries in 16 California 
hospitals, Kilpatrick et al. (2016) found 43% of women with severe maternal morbidity 
delivered preterm with 8% delivering <32 weeks (73). The importance of addressing 
maternal hypertensive disorders and severe maternal morbidity is critical for maternal 
health but also extends beyond it. 
Conclusions 
 
This research addressed a key gap in maternal health research and added to the 
literature on the continuum of maternal health before, during and after delivery. 
Hypertensive disorders and other chronic and pregnancy-associated conditions increased 
the odds of severe maternal morbidity at delivery and the risk of rehospitalization in the 
first six weeks and one year postpartum. The study results also showed severe events at 
delivery independently increased the risk of rehospitalization within the first year 
postpartum. Although the number of women with severe events at delivery is small, it is a 
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growing population warranting additional research. Our study highlights the need for 
efforts to prevent and manage hypertensive disorders and other chronic and pregnancy-
associated conditions before, during, and after pregnancy as well as the need to address 
preventable severe maternal morbidity and mitigate its impacts after delivery through the 
first year postpartum. These latter findings on rehospitalization warrant additional 
research to determine if they prevail in other populations or settings. 
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Appendix A  
Adjusted Relative Risk of Rehospitalization by Social and Biological 
Characteristics, Deliveries to MA Women 2002-2011 
 
Aim 3 Multivariate Models 
Adjusted Relative Risk of 6 weeks Hospital Rehospitalizations by Social and 
Biological Characteristics, Deliveries to MA Women 2002-2011 
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Appendix B  
Risk of Rehospitalization by Severe Maternal Morbidity at Delivery and 
Mental Health Indicators, Deliveries to MA Women 2002-2011 
 
Depression and SMM Variables 
Hospital Discharge: 




1 year HD aRR
1 
 (95% CI) 
No SMM, no Depression REF REF 
SMM, no Depression 2.36 (2.11-2.64) 2.02 (1.86-2.19) 
No SMM, Depression 1.33 (1.20-1.48) 1.51 (1.43-1.61) 
SMM, Depression 1.28 (0.69-2.35) 1.78 (1.29-4.46) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 








1 year OS aRR
1 
 (95% CI) 
No SMM, no Depression REF REF 
SMM, no Depression 2.23 (1.77-2.80) 1.63 (1.40-1.91) 
No SMM, Depression 1.53 (1.27-1.84) 1.50 (1.35-1.66) 
SMM, Depression 3.60 (1.71-7.56) 1.69 (0.91-3.10) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 












No SMM, no Depression REF REF 
SMM, no Depression 1.44 (1.31-1.57) 1.17 (1.12-1.22) 
No SMM, Depression 1.34 (1.27-1.41) 1.27 (1.24-1.29) 
SMM, Depression 2.09 (1.58-2.75) 1.42 (1.24-1.63) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 
during pregnancy, other chronic conditions 
Bold: p<0.05 
 
Substance Abuse and SMM Variables 
 
Hospital Discharge: 




1 year HD aRR
1 
 (95% CI) 
No SMM, no Substance Abuse REF REF 
SMM, no Substance Abuse 2.26 (2.02-2.53) 1.98 (1.83-2.15) 
No SMM, Substance Abuse 1.43 (1.24-1.65) 2.01 (1.87-2.16) 




Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 
during pregnancy, other chronic conditions 
Bold: p<0.05 
 
Observational Stay/Hospital Discharge: 
 










No SMM, no Substance Abuse REF REF 
SMM, no Substance Abuse 2.26 (2.04-2.50) 1.85 (1.72-1.99) 
No SMM, Substance Abuse 1.41 (1.24-1.61) 1.82 (1.70-1.94) 
SMM, Substance Abuse 3.15 (1.93-5.15) 2.39 (1.73-3.29) 
1
OS model on its own did not converge for OS 6 weeks
 
2
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 









1 year ED aRR
1 
 (95% CI) 
No SMM, no Substance Abuse REF REF 
SMM, no Substance Abuse 1.45 (1.33-1.58) 1.17 (1.13-1.22) 
No SMM, Substance Abuse 1.47 (1.39-1.57) 1.28 (1.25-1.32) 
SMM, Substance Abuse 2.16 (1.57-2.97) 1.37 (1.18-1.59) 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
at delivery hospitalization, prenatal care, year, hospital level, parity, marital status, cigarette smoking 
























Mediation of Chronic and Pregnancy-Associated Conditions and 
Rehospitalization by Severe Maternal Morbidity at Delivery, Deliveries to 
MA Women 2002-2011 
 
Aim 3 Mediation Models 
Hospital Discharge 6 weeks: 




 (95% CI) 
Model 2: No SMM 
aRR
1
 (95% CI) 
Model 3: SMM 
aRR
1





SMM25 2.24 (2.02-2.49) -- 2.27 (2.03-2.54)  
Superimposed PE -- 2.32 (1.92-2.82) 2.25 (1.85-2.73) 3.0% 
Severe preeclampsia -- 1.90 (1.67-2.16) 1.79 (1.58-2.04) 5.8% 
Mild preeclampsia -- 2.03 (1.84-2.24) 2.01 (1.82-2.22) 1.0% 
Chronic hypertension -- 1.82 (1.62-2.05) 1.81 (1.61-2.04) 0.5% 
Gestational 
hypertension 
-- 1.88 (1.83-2.04) 1.87 (1.72-2.03) 0.5% 
Pre-existing diabetes -- 1.47 (1.29-1.68) 1.45 (1.27-1.66) 1.4% 
Gestational diabetes -- 1.20 (1.10-1.30) 1.20 (1.11-1.30) 0% 
Asthma -- 1.24 (1.12-1.36) 1.23 (1.12-1.36) 0.8% 
Substance abuse -- 1.40 (1.22-1.61) 1.40 (1.22-1.61) 0% 
Depression -- 1.29 (1.16-1.43) 1.29 (1.16-1.43) 0% 
Autoimmune disorders -- 1.63 (1.35-1.96) 1.59 (1.32-1.91) 2.5% 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 











Model 2: No SMM 
aRR
1
 (95% CI) 
Model 3: SMM 
aRR
1





SMM25 1.94 (1.80-2.09) -- 1.95 (1.80-2.11)  
Superimposed PE -- 1.86 (1.62-2.14) 1.82 (1.58-2.09) 2.2% 
Severe preeclampsia -- 1.48 (1.35-1.63) 1.43 (1.30-1.57) 3.4% 
Mild preeclampsia -- 1.51 (1.40-1.62) 1.50 (1.39-1.61) 0.7% 
Chronic hypertension -- 1.63 (1.50-1.76) 1.62 (1.50-1.75) 0.6% 
Gestational 
hypertension 
-- 1.44 (1.36-1.53) 1.44 (1.36-1.53) 0% 
Pre-existing diabetes -- 1.67 (1.53-1.81) 1.66 (1.52-1.80) 0.6% 
Gestational diabetes -- 1.20 (1.13-1.26) 1.20 (1.14-2.27) 0% 
Asthma -- 1.34 (1.27-1.42) 1.34 (1.26-1.42) 0% 
Substance abuse -- 1.89 (1.76-2.03) 1.89 (1.76-2.03) 0% 
Depression -- 1.49 (1.40-1.58) 1.49 (1.40-1.58) 0% 
Autoimmune disorders -- 2.14 (1.93-2.37) 2.11 (1.90-2.34) 1.4% 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 







Observational Stay 6 weeks: 






Model 2: No SMM 
aRR
1
 (95% CI) 
Model 3: SMM 
aRR
1





SMM25 2.39 (1.95-2.92) -- 2.24 (1.79-2.79)  
Superimposed PE -- 2.62 (1.79-3.84) 2.56 (1.75-3.74) 2.3% 
Severe preeclampsia -- 2.17 (1.70-2.78) 2.06 (1.61-2.65) 5.1% 
Mild preeclampsia -- 2.52 (2.11-3.01) 2.50 (2.10-2.98) 0.8% 
Chronic hypertension -- 2.55 (2.11-3.10) 2.54 (2.10-3.08) 0.4% 
Gestational 
hypertension 
-- 2.11 (1.82-2.44) 2.11 (1.82-2.44) 0% 
Pre-existing diabetes -- 1.10 (0.83-1.45) 1.09 (0.82-1.44) 0.9% 
Gestational diabetes -- 1.25 (1.07-1.45) 1.25 (1.08-1.45) 0% 
Asthma -- 1.44 (1.22-1.70) 1.43 (1.21-1.70) 0.7% 
Substance abuse -- 1.31 (0.99-1.72) 1.30 (0.99-1.72) 0.8% 
Depression -- 1.54 (1.29-1.84) 1.54 (1.28-1.84) 0% 
Autoimmune disorders -- 1.07 (0.72-1.61) 1.05 (0.70-1.57) 1.9% 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




Observational Stay 1 year: 






Model 2: No SMM 
aRR
1
 (95% CI) 
Model 3: SMM 
aRR
1





SMM25 1.69 (1.47-1.94) -- 1.59 (1.37-1.86)  
Superimposed PE -- 1.97 (1.55-2.51) 1.94 (1.53-2.47) 1.5% 
Severe preeclampsia -- 1.53 (1.30-1.80) 1.49 (1.26-1.75) 2.6% 
Mild preeclampsia -- 1.74 (1.54-1.95) 1.73 (1.54-1.94) 0.6% 
Chronic hypertension -- 1.99 (1.76-2.25) 1.98 (1.76-2.24) 0.5% 
Gestational 
hypertension 
-- 1.65 (1.50-1.81) 1.65 (1.50-1.81) 0% 
Pre-existing diabetes -- 1.59 (1.37-1.83) 1.58 (1.37-1.83) 0.6% 
Gestational diabetes -- 1.38 (1.27-1.50) 1.38 (1.27-1.51) 0% 
Asthma -- 1.48 (1.35-1.63) 1.48 (1.35-1.62) 0% 
Substance abuse -- 1.33 (1.15-1.54) 1.33 (1.15-1.54) 0% 
Depression -- 1.49 (1.34-1.65) 1.48 (1.34-1.64) 0.7% 
Autoimmune disorders -- 1.73 (1.43-2.10) 1.71 (1.41-2.08) 1.2% 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




Emergency Department 6 weeks: 










 (95% CI) 
Model 3: SMM 
aRR
1





SMM25 1.42 (1.31-1.53) -- 1.45 (1.33-1.57)  
Superimposed PE -- 1.28 (1.08-1.52) 1.27 (1.07-1.50) 0.8% 
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Severe preeclampsia -- 1.26 (1.14-1.38) 1.23 (1.12-1.35) 2.4% 
Mild preeclampsia -- 1.18 (1.10-1.26) 1.17 (1.09-1.26) 0.8% 
Chronic hypertension -- 1.28 (1.17-1.39) 1.27 (1.17-1.38) 0.8% 
Gestational 
hypertension 
-- 1.14 (1.08-1.21) 1.14 (1.08-1.21) 0% 
Pre-existing diabetes -- 1.16 (1.06-1.28) 1.16 (1.05-1.28) 0% 
Gestational diabetes -- 1.15 (1.10-1.21 1.15 (1.10-1.21) 0% 
Asthma -- 1.34 (1.28-1.41) 1.34 (1.27-1.41) 0% 
Substance abuse -- 1.43 (1.35-1.52) 1.43 (1.35-1.52) 0% 
Depression -- 1.34 (1.27-1.42) 1.34 (1.27-1.41) 0% 
Autoimmune disorders -- 1.29 (1.14-1.46) 1.28 (1.13-1.45) 0.8% 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 




Emergency Department 1 year: 




Model 2: No 
SMM (aRR 95% 
CI) 
Model 3: SMM 





SMM25 1.17 (1.13-1.21) -- 1.16 (1.12-1.21)  
Superimposed PE -- 1.21 (1.12-1.30) 1.20 (1.11-1.29) 0.8% 
Severe preeclampsia -- 1.09 (1.04-1.13) 1.08 (1.03-1.12) 0.9% 
Mild preeclampsia -- 1.10 (1.07-1.14) 1.10 (1.07-1.14) 0% 
Chronic hypertension -- 1.22 (1.17-1.26) 1.22 (1.17-1.26) 0% 
Gestational hypertension -- 1.09 (1.07-1.12) 1.09 (1.07-1.12) 0% 
Pre-existing diabetes -- 1.20 (1.15-1.25) 1.20 (1.15-1.25) 0% 
Gestational diabetes -- 1.12 (1.10-1.15) 1.12 (1.10-1.15) 0% 
Asthma -- 1.30 (1.27-1.33) 1.30 (1.27-1.33) 0% 
Substance abuse -- 1.25 (1.22-1.28) 1.25 (1.22-1.28) 0% 
Depression -- 1.27 (1.24-1.29) 1.27 (1.24-1.29) 0% 
Autoimmune disorders -- 1.31 (1.24-1.38) 1.30 (1.24-1.38) 0.8% 
1
Adjusted for: age, race/ethnicity, education, method of delivery, insurance payer, plurality, length of stay 
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